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Abbreviations 
 
Ad5   Human adenovirus type 5 
Ang1   Angiopoietin 1 
Ang2   Angiopoietin 2 
APS   Ammonium Persulphate 
bp   Base pairs 
CD   Cluster of differentiation 
CIP   Calf intestinal phosphatase 
CEPs   Circulating endothelial precursor cells 
DCs   Dendritic cells 
DNA   Deoxyribonucleic acid 
DTT   Dithiothreitol 
ECM   Extracellular matrix 
ELISA   Enzyme linked immunoabsorbent assay 
EDTA   Ethylenediaminotetraacetic acid  
FCS   Fetal calf serum 
FGF   Fibroblast growth factor 
HC-Ad vector  High capacity adenoviral vector 
HRP   Horse radish peroxidase 
HSCs   Haematopoietic stem cells 
HUVECs  Human umbilical venous endothelial cells 
i.u   Infectious Units 
IL-12   Interleukin 12 
kD   Kilo Dalton 
LLC   Lewis lung carcinoma 
MAb   Monoclonal antibody 
Mwt   Molecular weight 
moi   Multiplicity of infection 
NK cells  Natural killer cells 
dNTPs   Deoxribonucleotides 
OD   Optical density 
PAGE    Polyacrylamide gel electrophoresis 
pfu   Plaque forming units 
PCR   Polymerase chain reaction 
sflt1   Soluble fetal liver kinase 1/VEGFR1 
stie2   Soluble Tie2 receptor 
SDS   Sodium dodecyl sulphate  
TBS   Tris Buffered Saline 
TEMED  N, N, N`, N`, -tetramethyl-ethylendiamine 
TGF   Transforming growth factor 
Tris    Tris-(hydroxylmethyl) aminomethane 
TTRB   Transthyretin 
VEGFR1  Vascular endothelial growth factor receptor 1 
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I Introduction 
 
Cancer is an umbrella term covering a plethora of conditions characterized by unscheduled and 
uncontrolled cellular proliferation [1]. More than 200 types of cancer are known. The dominant 
five types of cancer, which account for more than 50% of all cancers, originate from lung, colon, 
breast, stomach and prostate [1]. Cancer is second only to cardiovascular diseases as the leading 
cause of death in the developed world, with about 2.6 million new cases diagnosed each year in 
Europe and USA. Despite advances in screening, education, and early diagnosis, cancer is 
predicted to be the most common cause of death in the 21st century [2]. New treatments are 
therefore urgently needed to supplement conventional methods of cancer treatment such as 
chemotherapy, radiotherapy, and surgery [2]. Basic research in the past few decades has aided in a 
greater understanding of the molecular basis of cancer, thereby providing new targets for cancer 
therapy. The spectrum of discoveries ranges from identification of oncogenes, tumor suppressor 
genes, apoptosis, angiogenesis and development of novel detection techniques [3-5]. New insights 
in the field of signal transduction, cell cycle regulation and DNA repair mechanisms have now 
made it possible to appreciate the complexity of the disease [1, 3, 6]. This is reflected in the 
definition of new targets for drug design and development. As a result, biological therapy is 
considered as a viable supplement to conventional cancer therapy [7]. Biological therapy aims at 
the activation of the immune system to eradicate tumors. Commonly used strategies in biological 
therapy encompass cancer vaccines, monoclonal antibodies (MAbs), cytokines, dendritic cells or 
activated lymphocytes. Apart from biological therapy, blocking of tumor angiogenesis has recently 
attracted interest [8]. As a result, new regimens are designed to combine biological therapy and/or 
antiangiogenic therapy with conventional cancer treatment methods [9]. In addition, advances in 
virology have made it possible to develop viral vectors for introducing nucleic acids into cells. 
Vectors based on adenovirus can transfer large fragments of DNA, have shown long-term 
expression with minimal toxicity and even may allow to regulate gene expression [10-12]. Thus it 
is now possible to combine advances in the fields of immunology, angiogenesis and vector 
development to generate novel arsenals for the treatment of cancer.  
 
I.1 Concepts in tumor growth and intervention  
 
I.1.1 Origin and development of tumors  
 
Malignant tumors result from uncontrolled proliferation of cells and their migration to sites distant 
from their origin. Tumors originate from a single cell clone, which acquires a series of growth 
enhancing mutations, promoting its survival [1]. Numerous agents and factors such as chemicals, 
radiation, and chronic infection cause mutations [2, 13]. Malignancy often takes years before 
diagnosis because of the multistep nature of its development. In general, proliferation of cells 
within tissues is controlled by the interplay of factors such as cell-cell contact, extracellular matrix, 
growth factors and receptors, integrins, hormones and by the cells of immune system [14]. Thus, 
the tumor cells have to overcome these preventive mechanisms to attain malignancy. Irrespective 
of the functional complexity of tumors, all tumors types must acquire traits such as self-sufficiency 
in growth signals, resistance to antigrowth signals, limitless replicative potential and resistance to 
apoptosis for survival and growth [14, 15]. 
Normal cells require the presence of growth factors secreted by neighboring cells for their growth 
and survival. Many tumors secrete growth factors, which stimulate their own growth thereby 
creating a positive feedback autoloop. As a result, tumor cells are no longer dependent of 
neighboring cells for survival. For example, many breast tumors secrete VEGF and FGF to 
promote their survival [16]. Similarly, certain types of sarcomas and glioblastoma secrete TGF-β 
and PDGFA respectively [17, 18]. Another common mechanism utilized by the tumors involves 
the upregulation of growth factor receptors thereby making the cells hypersusceptible to ambient 
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levels of growth factors. Growth factor receptors such as EGF-R are commonly upregulated in 
tumors. This results in cell activation even in the presence of a low amount of growth factor [14]. 
An alternative strategy commonly observed in tumors is the presence of ligand independent 
signalling, which may occur through structural alteration of receptors such as through absence of 
the cytoplasmic region of the EGF receptor [14]. Along with the changes in growth factor receptor 
expression, integrin mediated signalling is often altered. Integrins are heterodimeric molecules 
found on the cell surface. They transmit signals between matrix and the cell in both directions. 
Integrins control numerous processes including cell proliferation, apoptosis, migration, formation 
of extracellular matrix etc. Cells modulate the expression of integrins in accordance with the 
surroundings [19]. For instance, endothelial cells often up regulate αvβ3 and αvβ5 during 
proliferation and α2β1 to prevent apoptosis. Interestingly, cancer cells often modulate the 
expression of integrins by expressing those, which promote their survival [20, 21]. Alternatively, in 
many tumor types downstream mediators of integrins are often mutated or unregulated. For 
example, Ras is upregulated or mutated in 25% of all tumors. 
Cancer cells often have mutations in genes, which control cell cycle and apoptosis [22]. Many 
tumor types often have mutations of pRB or its related molecules, which play a central role in the 
entry of cells into the cycle [6, 23]. Also as a preventive mechanism, terminally differentiated cells 
lose their capacity to divide. Cancer cells circumvent this hurdle by expression of oncogenes such 
as myc protein or its related members, which inhibit differentiation. Thus, the indefinite 
proliferation of cells is often associated with changes in levels, mutation and types of transcription 
factors. Nevertheless, the capacity to divide indefinitely does not entail the cells to become 
malignant because of balance of death by apoptosis [1, 22, 24]. Cancer cells have mutations in 
genes such as p53, which control apoptosis. p53 is an important sensor, which activates the 
apoptosis cascade in response to DNA damage, hypoxia or activation of oncogenes. p53 tumor 
suppressor protein or downstream molecules are mutated in 50% of tumors [4]. Another major 
hurdle, which a cancer cell needs to overcome, is its ability to replicate its chromosomes 
indefinitely. Most cells have a finite replicative potential owing to the shortening of telomeres 
following each replication. Cancer cells circumvent this hurdle by over-expressing telomerase 
enzyme, which adds hexanucleotide repeats onto the ends of telomeric DNA [25].  
Cancer cells initially are often restricted in size to few mm3 [26]. These avascular tumors, due to 
absence of sufficient oxygen and nutrients, are hypoxic. At this critical stage, the progression of 
cancer cells rests on its ability to form new blood vessels, a process called angiogenesis. 
Angiogenesis is an important rate-limiting step during progression to malignancy. Endothelial cells 
line the inner surface of blood vessels and are quiescent in adult vasculature [27]. Angiogenesis in 
adult life is tightly regulated and occurs as brief bursts of capillary blood vessel growth that usually 
lasts only days or a week [28]. This is due to a balance between anti- and proangiogenic factors in 
the form of cytokines, matrix, hormones, and growth factors. Tumors cleverly tilt the balance in a 
process called angiogenic switch towards angiogenesis by secretion of growth factors such as 
VEGF, b-FGF, Ang2, EGF, IGF-1 and others. Additionally, proteolytic enzymes secreted by the 
tumors liberate growth factors arrested in the matrix [29]. Furthermore, tumors induce the secretion 
of chemokines and cytokines by immune cells promoting angiogenesis [30]. Conversely, this 
remodeling process also releases endogenous inhibitors such as angiostatin, endostatin, tumistatin, 
thromospondin, which inhibit angiogenesis [31, 32]. Tumor angiogenesis is further influenced by 
the presence of immune cells, which can influence angiogenesis in both directions. In total, only a 
net increase in the proangiogenic factors activates the normally quiescent endothelial cells in the 
tumor microenvironment. Activated endothelial cells upregulate integrins such as αvβ3 and αvβ5 
and migrate towards the tumors mass [33]. Migrating endothelial cells proliferate and form cords, 
which later mature, into vessels acting as a conduit for blood flow. Angiogenesis is preceded by 
loosening of pericytes or smooth muscle cells, which form the outer covering of blood vessels. 
Once the new blood vessels are formed, pericytes cover the new vasculature again and secrete 
matrix and growth factors, which stabilize the vasculature [34]. Thus, tumor-induced blood vessel 
formation provides the hypoxic tumor with much needed oxygen and nutrients resulting in an 
explosive increase in size. Nevertheless, tumor induced formation of blood vessels leads to 
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irregular and leaky vessels that do not contain typical arteriole and venule differentiation 
representing a potential target for therapy [35, 36].  
Angiogenesis is followed by the invasion and disruption of normal tissue architecture by tumor 
cells, a process summarized as metastasis [37]. Metastatic tumors are often aggressive and 
refractory to all forms of therapy and are the major cause of cancer death [2]. Metastasis is again a 
complex process involving an interplay of numerous factors such as integrins, proteases, growth 
factors and numerous cytokines. Cancer cells display remarkable alteration in cell adhesion 
molecules, which are responsible for maintenance of the tissue integrity. Notably members of 
calcium dependent cadherin and immunoglobulin superfamily exhibit decreased expression and 
binding in cancer cells [20, 38]. In addition to these changes, cancer cells secrete proteases or 
induce their release by recruited cells such as stromal cells and cells of the immune system [37]. 
Proteases belonging to matrix metalloproteases or to the serine kinase family have been often 
shown to be upregualted in numerous tumors. The secreted proteases bring about a breakdown in 
the matrix in an orchestrated manner, and are guided by altered integrins on the neighboring cell 
types. In addition, proteases act in a redundant manner making the absence of one member being 
compensated by others [27, 39]. Thus, the concerted action of proteases, cytokines and modulation 
in surface receptor expression culminate in the invasion of tumor cells into the neighborhood and 
remote areas. 
During transformation tumor cells constantly subvert the immune system by direct interaction with 
immune cells or by secretion of cytokines [40, 41]. Cells of the immune system such as 
macrophages, dendritic cells, and T cells have been demonstrated to influence tumor progression. 
Tumor associated macrophages (TAMs) at later stages of tumor progression have been shown to 
display a phenotype which favors tumor growth by secretion of proangiogenic molecules and 
remodeling enzymes [42]. Dendritic cells (DCs) present in the tumor vicinity have been 
demonstrated to be immature due to the presence of an immunosuppressive microenvironment and 
therefore cannot effectively present antigens [43, 44]. Therefore, strategies such as vaccination or 
ex vivo stimulation of DCs with different means are currently in clinical trials. NK cells, another 
important constituent of the immune system, have been shown to lack efficient trafficking to the 
tumor tissue due to the loss of adhesion or costimulatory molecules and probably due to an 
immunosuppressive tumor microenvironment [45]. T cells, the major regulators of the immune 
reaction, have been shown to be anergic to tumor growth due to the lack of costimulatory 
molecules exhibited by APCs and by the presence of certain cytokines, shifting the immune 
response towards the Th2 type [46]. In addition, some tumor cells express Fas ligand, which 
induces apoptosis in CD8 cells. Also a new subset of CD4+ CD25+ cells has been identified which 
amongst other functions may be responsible for suppression of immune response against the tumor 
[47]. Apart form direct contact, tumor cells and immune cells communicate via cytokines. 
Cytokines are soluble extracellular proteins or glycoproteins affecting inflammatory host defenses, 
cell growth, differentiation, cell death, angiogenesis, development and repair processes. Cytokines 
are very potent and act at concentrations of 10-9 to 10-15 M, are produced by virtually every 
nucleated cell type in response to injurious stimuli and act on cells expressing complementary 
receptors. Cytokines play an important role in tumor initiation, progression and therapy [48]. 
Cytokine-induced inflammation during H.Pylori and Hepatitis C virus infection has been shown to 
cause gastric and hepatic carcinoma, respectively [13]. Mice constitutively expressing IL-15 
succumbed to NKT cell leukaemia [49]. The role of cytokines as protective agents against cancer 
formation has been shown using knockout mouse models. Mice deficient in IFNγ or IFNγ receptor 
are susceptible for polycyclic hydrocarbon methyl cholanthrene induced tumors [50]. In addition, 
cytokines have also been postulated to be responsible for immunosupression, which causes tumor 
anergy in cancer patients. In this regard, elevated levels of immunosuppressive cytokines like 
TGFß and IL-10 have been observed in the serum of cancer patients [51]. Conversely, tumor 
mediated immune suppression may be mediated by down-regulation of IL-2 or its receptors. 
Cytokines have also been used to inhibit tumor growth in clinical settings. For example, IL-2 and 
IFNα have been already approved by the FDA for the treatment of renal cell carcinoma (RCC) and 
melanoma [52]. IL-2 is a specific T cell growth factor and can increase NK cell counts. IL-2 when 
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given locally enhances tumor rejection through a coordinated host reaction composed of 
neutrophils, eosinophils, macrophages, NK cells and lymphocytes. Apart from IL-2 and IFNα, IL-
12 has shown striking anticancer effects in mouse models. Thus, the growth of tumors requires 
concerted deregulation of multiple pathways, alteration of surface receptor expression, and 
secretion of proteases and recruitment of cells in the vicinity. Numerous targets, which are 
currently being investigated for tumor intervention is shown in Figure I.1. An in-depth 
understanding of these factors shall aid in the design of new adjuvant therapies for cancer 
treatment. The physiological function of VEGF, angiopoietins and IL-12 and strategies for their 
blockade, the subject of this thesis, is discussed in the next Chapter.  
 
Figure I.1: Potential target molecules for antiangiogenic therapy of tumors. The picture was taken from the article 
“Tumor angiogenesis-new drugs on the block” published in the journal, Nature Biotechnology Vol 17 October 1999. 
.
 
I.1.2 Physiology of angiopoietins, VEGF, and IL-12 
 
Cancer occurs because of breakdown of several regulatory circuits as discussed earlier. Despite this 
complexity, cancer growth intervention can be achieved by selectively blocking growth factors or 
by the presence of cytokines. Among the growth factors, sequestration of members of VEGF and 
angiopoietins is currently being pursued in different animal models and clinical trials. Similarly, 
among the cytokines, IL-12 has repeatedly demonstrated tumor inhibition in different mouse 
models of cancer. Therefore, in this chapter the physiology of members of the VEGF and the 
angiopoietin growth factor families and of the cytokine IL-12 is discussed. 
Proliferation of endothelial cells in adulthood occurs mainly during wound healing, muscle 
building and during the menstrual cycle. As discussed earlier tumor growth beyond few mm3 
requires proliferation of endothelial cells. Although numerous growth factors such as FGFs, IL-8, 
IFN,TNF etc [26] promote endothelial proliferation, members of the VEGF and angiopoietin 
growth factor and receptor families are relatively specific for endothelial cells. They have been 
shown to be upregulated in numerous tumor types apart from physiological angiogenesis [51, 53]. 
Members of the angiopoietin family of growth factors and members of their cognate receptor 
family namely Tie1 and Tie2 play an important role during embryonic, adult and pathological 
angiogenesis [54]. Unlike VEGF, which stimulates the growth of endothelial cells, angiopoietins 
are important for the modeling of the vasculature. On the basis of sequence homology four 
different angiopoietins (Ang1-4) have been discovered all binding to the tie2 receptor [54]. A 
ligand for the tie1 receptor has not been yet discovered. Ang1 is a 70 kD glycoprotein and binds to 
the tie2 receptor with a Kd of 3.7 nM. Ang1 plays an important role in the adult female 
reproductive system, haematopoiesis, and the maintenance of endothelial integrity in the adult 
vasculature [55]. Targeted inactivation of Ang1 in mice causes embryonic lethality (E12.5) as a 
result of defective modeling of the vascular plexus, lack of perivascular cells, a phenotype 
resembling tie2 knock out mice [56]. These results indicate that Ang1 recruits and sustains 
pericytes and is needed for the maturation of blood vessels during embryonic development. Over-
expression of Ang1 results in blood vessels that are resistant to leakage induced by VEGF or 
inflammatory cytokines [57]. The role of Ang2 is not yet completely understood. Mice deficient in 
Ang2 are born relatively normal, but develop ascites and edema, have remodeling defects in the 
retina and die by day 14 [58]. Ang2 has been shown to be abundantly expressed in the tumor 
vasculature during earlier and later stages of vascular activation [54]. It has been proposed that the 
level of Ang1 remains constant during the vascular remodeling process but an increased ratio of 
Ang1/Ang2 favors vessel stabilization whereas a decreased ratio results in vessel regression [54]. 
All of the discovered angiopoietins mediate their action by signalling via the tie2 receptor. Tie2 
knockout mice have a phenotype similar to Ang1 knockout mice [59]. High levels of tie2 
expression are observed in the vasculature of endothelial cells in tumor cells as well as in healing 
skin wounds. Unlike Tie2, the role of the Tie1 receptor is not yet clearly understood. Mice 
deficient in Tie1 undergo embryonic death between E13.5 and E18.5, depending on their genetic 
background. It has been suggested that Tie1 might mediate its action by forming heterodimers with 
Tie2 [59, 60]. Absence of the identification of the Tiel ligand has hampered an understanding of its 
role in angiogenesis. Recently, Ang3 and Ang4 were discovered based on sequence homology 
[61]. Ang3 appears to act as an antagonist, whereas Ang4 appears to function as an agonist. Further 
characterization of these molecules with respect to tumor development is eagerly awaited. In 
summary, the angiopoietins play a pivotal role in vascular remodeling and its selective inhibition 
might offer an opportunity to inhibit tumor growth. 
VEGF A, the dominant VEGF is a specific mitogen and motogen for endothelial cells and is 
produced by a wide variety of cell types [62]. VEGF A has a molecular mass of 34-45 kD 
exhibiting multiple and diverse functions that are important under physiological and pathological 
situations [63]. VEGF A binds to three different receptor tyrosine kinases, VEGFR1 (Flt1) and 
VEGFR2 (flk1) and VEGFR3 (flt4). VEGF A displays chemotactic effects on endothelial cells and 
promotes their survival in adult vasculature. Over-expression of VEGF A in pathological situations 
 12
 13
such as during tumor growth causes vasodilatation, increased expression of proteolytic enzymes 
from endothelial cells, upregulation of integrins, remodeling of matrix and migration of endothelial 
cells [64]. VEGF also inhibits the maturation of antigen presenting dendritic cells in adult mice 
[65]. A dramatic effect of VEGF A is observed in mice that lack one VEGF allele. VEGF +/- mice 
die around day 10 of embryonic development because of cardiovascular defects [66, 67]. The 
human gene for VEGF A on chromosome 6p21.3 is organized in eight exons. Five isoforms of 
hVEGF A are generated as a result of alternative splicing of the single VEGF A gene (VEGF 121, 
VEGF 145, VEGF 165, VEGF 189, and VEGF 206). The mouse isoforms are one amino acid 
shorter than the corresponding human ones. All VEGF A isoforms are secreted as covalently 
linked homo-dimers and they differ in their ability to bind to heparan sulphate and extracellular 
matrix [68]. VEGF 206 binds most strongly to heparin in contrast to VEGF 121, which is the most 
diffusible isoform. The abundant isoform VEGF 165 displays intermediate diffusion 
characteristics. It is speculated that combinatorial expression of heparin binding and soluble VEGF 
results in a gradient that peaks at the site of its secretion and elicits a chemotactic response for 
endothelial cells [69]. Many growth factors and cytokines upregulate VEGF mRNA or induce 
release of VEGF. These include PDGF, TNF-α. TGF-β, FGF-4, keratinocyte growth factor (KGF), 
epidermal growth factor (EGF), IL-1α, IL-β, IL-6 and insulin like growth factor 1 (IGF-1). VEGF 
A is highly upregulated by hypoxia and is believed to be the main mediator of hypoxia-induced 
angiogenesis in tumor growth [70, 71]. Recently, novel VEGF A related proteins were identified 
and characterized based on sequence homology. The identified proteins are placental growth factor 
(PIGF), VEGF B, C, D and E. Three isoforms of PIGF have been discovered their expression being 
restricted to placenta [70]. PIGF isoforms form heterodimers with VEGF, which have a weak 
mitogenic activity. VEGF-B has a wide distribution but is particularly abundant in the heart and 
skeletal muscle. Two isoforms of VEGF-B exist, which bind to VEGFR-1 and neuropilin-1 
receptor. VEGF C and VEGF D proteins bind to VEGFR-3 and VEGFR-2. VEGF B and VEGF D 
play an important role in the development and maintenance of lymphatic vessels [72, 73]. VEGF-E 
is a collective term for a group of proteins encoded by strains of orf virus [74].  
Three tyrosine kinase receptors binding to the VEGF family of growth factors namely VEGFR 1 
(Flt1), VEGFR 2 (KDR), and VEGFR 3 have been identified. They are characterized by seven 
extracellular immunoglobulin (Ig)-like domains followed by a membrane-spanning region and a 
conserved intracellular tyrosine kinase domain interrupted by a kinase insert sequence [75]. In 
adult mice, Flt1 is expressed in endothelial cells, osteoclasts, moncytes, haematopoietic stem cells 
and leydig cells. Flt1 has a MW of 180 kDa and has the highest affinity for VEGF A (Kd 10-30 
pM) [53]. Flt1 also binds to PIGF and VEGF-B. During embryonic development Flt1-/- mice die at 
embryonic day 8.5, but mice deficient in the intracellular domain of flt1 develop normally [76, 77]. 
It is speculated that the main role of VEGFR1 is to act as a decoy receptor for VEGF. A soluble 
form of flt1 (sflt1) is found at high concentration in the placenta and is believed to sequester excess 
VEGF [78]. VEGFR 2 is expressed in endothelial cells, haematopoietic stem cells, circulating 
endothelial precursors (CEPs) and in umbilical stroma. VEGFR2 has a molecular weight of 200-
230 kDa and is bound by VEGFA (Kd = 75-125 pM) [53]. The VEGFR2 receptor also binds to 
VEGF C, VEGF D and VEGF E. Mice deficient in VEGFR2-/- undergo embryonic death due to 
severe vascular deformities [79]. VEGFR 2 seems to mediate almost all of the observed endothelial 
cell responses to VEGF A. VEGFR 3 is primarily expressed in lymphatic endothelial cells and is a 
high affinity receptor for VEGF C and VEGF D [80]. In summary, members of the VEGF and 
angiopoietin family of growth factors and receptors play an important role in the development of 
blood vessels during physiological and pathological angiogenesis. Sequestration of these growth 
factors or interfering with their receptor signalling offers a new therapeutic intervention for cancer.  
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Among the cytokines, IL-12 is a principal mediator of the early innate immune response to 
intracellular microbes and is a key inducer of cell mediated immunity [81]. IL-12 was identified as 
a product of Epstein-Barr Virus (EBV) transformed human B-cell lines that can activate NK cells, 
generate lymphokine-activated killer cells (LAKs) and induce IFNγ production and T cell 
proliferation [82]. In vivo IL-12 is mainly produced by dendritic cells and mononuclear 
phagocytes. Stimuli for the production of IL-12 are LPS and infection by intracellular bacteria or 
viruses. IL-12 is secreted by antigen presenting cells (APCs) in response to infection and it initiates 
several physiological changes such as production of IFNγ by NK cells and T lymphocytes, and the 
cytolytic function of activated NK cells and CD8 T lymphocytes. Since IL-12 is produced by APCs 
in response to infection, it links innate and adaptive immunity responses [83]. Large amounts of 
IL-12 are produced in response to gram-negative sepsis, which stimulate macrophages to produce 
TNF, the principal mediator of septic shock. 
Structurally, IL-12 is a heterodimer formed by a 35 kDa light chain (known as p35 or IL-12A) and 
a 40-kDa heavy chain (known as p40 or IL-12B). p35 is homologous to other single chain 
cytokines, where as p40 is homologous to the extracellular domain of members of the 
haematopoietic cytokine receptor family. It has been proposed that the unusual structure of IL-12 
might have evolved from a primordial cytokine of the IL-6 family and one of its receptors [81]. IL-
12 p40 is produced in large excess over the IL-12 heterodimer and homodimers of p40 are 
observed in mice. Knock out mice lacking the p40 component of IL-12 are defective in IFN 
production, TH1 responses and NK cell function. The IL-12 receptor is composed of two chains 
IL-12 β1 and IL-12 β2 and is expressed on activated Th1 cells, NK cells and on other cell types, 
such as DCs and B-cell lines [84]. Human subjects with mutations in the IL-12 receptor are highly 
susceptible to infection with salmonella and atypical mycobacteria. 
The antitumor and antimetastatic effects of IL-12 have been demonstrated in many studies using 
murine models of cancer [81]. The mechanism of IL-12 mediated anti-tumor action is complex and 
may utilize effector mechanisms of both innate resistance and adaptive immunity to mediate 
antitumor resistance. It has been shown that dose and route of IL-12 and the cell environment 
played a major role in its antitumor activity. IL-12 has been shown to directly activate NK, NKT, 
CD4 and CD8 cells [81]. Other activated cell types include endothelial cells, dendritic cells, and 
macrophages. Activation of neutrophils by IL-12 has been proposed to cause microhemorrhage and 
thrombosis associated with its antitumor activity [85]. In most experimental models, antitumor 
activity of IL-12 was shown to require IFNγ. In addition to augmentation of cellular responses, IL-
12, by inducing Th1 responses, also augments the production of opsonizing antibodies, also having 
antitumor activity. It has been demonstrated that the antiangiogenic effect of IL-12 is mediated by 
activating the downstream effectors of IFNγ such as IP-10 and MIG. However, in spite of its 
antitumor effect, IL-12 is toxic and has resulted in the death of patients during phase II clinical 
trials. Numerous protocols and methods have been proposed to allow for safe and effective 
application of this potent cytokine. If successfully applied to humans, IL-12 could be a powerful 
therapeutic agent against cancer.  
I.2 Gene transfer methods and adenoviral vector systems  
 
I.2.1 Vectors and cancer gene therapy 
 
Vectors are vehicles for the introduction of nucleic acids into cells. They are either viral or nonviral 
in nature. Viral vectors used routinely for gene transfer belong to the family of retrovirus, adeno- 
associated virus (AAV), adenovirus and herpes simplex virus (HSV). Retrovirus is a RNA virus 
containing genes namely gag, pol and env that encodes for viral proteins, reverse 
transcriptase/integrase and viral envelope glycoprotein respectively [86]. Retroviral vectors are 
used extensively for introducing genes into dividing cells, such as tumor cells and hematopoietic 
cells. Retroviral vectors are constructed by providing the genes gag/pol and env in trans separately 
in packaging cells. The vector RNA, which has the packaging signal alone, is packaged and the 
vector is released from the cell by budding. Retroviruses have been extensively modified which 
includes modification of envelopes to improve its infectivity and generation of transcriptionally 
controlled vectors such as self-inactivating vectors in which all the viral promoter activity is lost 
upon integration and the transcription of the transgene is under the control of a heterologous 
promoter. The main limitation of retroviral vectors has been their inability to infect non-dividing 
cells and loss of transgene expression in transduced cells upon transplantation. The use of retroviral 
vectors has leaded the way to the technological production, storage, and distribution of commercial 
vectors on a scale that is required for the human clinical trials [87]. However, in the recent years 
lentiviral vectors, which also belong to the retroviral family, have been extensively used. Lentiviral 
vectors have the unusual property of transducing non-dividing cells and therefore may have wider 
application. 
Adeno associated virus (AAV) is a small, nonpathogenic, single stranded DNA virus and requires 
the expression of genes from a helper virus such as Ad viruses or HSV for replication [88]. AAV 
contains two genes namely rep and cap. Rep encodes for replication and integration function of the 
virus and cap encodes for the structural components of the virus. The viral DNA also has two 
inverted terminal repeats, which contain the sequences needed for the packaging of the virus. The 
viral vector is produced by replacing the rep and cap gene with the therapeutic gene [89]. The rep 
and cap genes are expressed in trans in a packaging cell line along with the adenoviral genes 
needed for replication of the virus. Long-term expression of AAV vector has been observed in 
tissues such as muscle, liver and brain after transduction. The major limitations of the AAV vector 
are titer and the size of the transgene, which is limited to about 4.5 kb [89].  
Adenoviruses are double stranded DNA viruses that may cause in general mild diseases of 
respiratory tract and gastro intestinal tract depending on the serotypes [90]. Replication defective 
Ad vectors for gene transfer are generated by deleting multiple genes or by complete removal of all 
viral genes. Ad vectors are very desirable for gene transfer because they can be produced in high 
titers, do not integrate in to the host genome, can transfer large DNA sequences, can infect both 
dividing as well as non-dividing cells and have broad tropism. The characteristics of adenovirus 
and its vectors are discussed in detail below. 
Numerous gene transfer strategies have been devised to combat cancer including transfer of tumor 
suppressor genes (TSG) or cell cycle genes, direct attack on tumor cells, activation of the immune 
system and or blocking angiogenesis [91, 92]. The idea to use TSG was based on the observation 
that tumor tissues frequently have mutations in genes regulating cell cycle and apoptosis. Tumor 
suppressor genes which have for example been used are p53 or RB [93]. A second broad approach 
to selectively kill cancer cells is based on the transfer of suicide genes [94]. These suicide genes 
express enzymes, which convert a harmless drug into a potent cytotoxin, which apart from killing 
the tumor cell can also diffuse and kill the neighboring cells, thereby creating a bystander effect. 
Suicide genes that have been employed are for example HSV-thymidine kinase, cytosine 
deaminase or nitroreductase. The cytotoxins generated by these enzymes kill the cancer cell by 
mechanisms such as blocking DNA synthesis, DNA cross linking, or inhibition of topoisomerase 
activity. Thus, the transfer of suicide genes in contrast to transfer of TSG results not only in the 
 15
 16
death of directly transduced neoplastic cells but also the surrounding cells. Another kind of gene 
transfer method involves the transfer of cytokines to activate the immune system or to promote the 
recovery of haematopoietic cells during chemotherapy [95]. A fourth commonly used approach is 
the use of vectors referred to as oncolytic viruses, which selectively replicate in tumor cells. 
Commonly used oncolytic viruses belong to the HSV or adenovirus family [96]. The commercially 
developed oncolytic vector Onyx 15 has a mutation in the E1B 55K gene and was believed to 
replicate selectively in p53 defective tumor cells [97]. 
 
I.2.2 Regulation of gene expression 
 
Another important requirement for the expression of transgenes is the specific promoter. The 
choice of a promoter depends on the application and can be either constitutive or regulatable. In 
general strong constitutive promoters such as hCMV, MCMV and EF-1α are preferred for gene 
transfer experiments [98]. These promoters express transgenes ubiquitously and the expression is 
improved by the use of upstream enhancers and the inclusion of introns. In special applications 
such as cancer gene therapy, the expression of suicide genes or TSGs needs to be restricted to the 
tumor tissue to avoid systemic toxicity. Numerous tumor specific promoters are available which 
have some degree of selective activity in tumor cells. A promoter that is considered relatively 
specific for cancer cells is the telomerase promoter since telomerase is over-expressed in most 
tumors. Promoters of oncofetal origin such as the carcinoembryonic antigen (CEA), the α 
fetoprotein and the ErbB2 promoter have increased activity in breast tumors and in pancreatic 
tumors. Promoters, which are upregulated in the tumor microenvironment such as hypoxia 
responsive promoters, endothelial specific promoters and glucose specific promoters, are also 
currently being tested. Another strategy involves the use of tissue specific promoters for cancer 
gene therapy and is restricted to tissues in which the damage is not critical for the survival of the 
host. Some of the commonly used tissue specific promoters are the albumin promoter for 
hepatoma, tyrosinase promoter for melanoma, and prostate specific antigen (PSA) promoter for 
prostate carcinoma [99].  
Regulation of gene expression is important, when toxic genes are expressed and expression should 
be limited for a short time. Several systems, which depend on the addition of exogenous chemicals 
such as antibiotics (doxcycline) and progesterone analogues (RU 486) have been developed. Apart 
from these methods of regulable/controllable gene expression, systems using promoters responding 
to UV, heavy metal and temperature have been tested. A system based on the progesterone 
analogue RU 486 is versatile and is recognized for its superior expression kinetics and lack of 
expression in the absence of the drug RU 486 [100]. RU 486 based systems consist of two 
expression cassettes. The first expression cassette expresses pSwitch. pSwitch is a fusion protein 
consisting of three domains: a DNA binding region, a RU 486 binding domain and a transcription 
activation domain. The DNA binding domain is derived from the yeast GAL 4 protein. The RU 
486 binding domain is a mutated progesterone receptor and the transcription activation domain is 
derived from p65, a component of the NFkB complex. pSwitch is 86% human in sequence and is 
therefore less immunogenic when compared to an earlier form of regulator proteins, which used 
VP16 derived from HSV as the activation domain. The second cassette consists of a cDNA placed 
downstream of the UAS-TATA box-binding region. The UAS region consists of a tandemly 
arranged 17mer sequence to which the GAL4 DNA binding region of pSwitch binds efficiently in 
the presence of the drug RU 486. In the absence of RU 486, pSwitch resides in the cytosol as an 
inert complex with heat shock protein and other molecular chaperones. Binding of RU 486 triggers 
a conformational change that causes pSwitch to translocate to the nucleus where it initiates 
transcription of the target gene. Apart from RU 486 other progesterone analogues such as 
Org31376, Org 313806, ZK 98,229, ZK98.734 have been used, but detailed dose-response studies 
have not been reported. RU 486 is used as antiprogestin and antiglucorticoid at a dose of 10mg/kg. 
In contrast the doses sufficient to achieve gene induction studies are in the range of 0.1 to 0.8 
mg/kg [101].  
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RU 486 mediated inducible transgene expression has been achieved both in vitro and in vivo using 
viral vectors and plasmids. High levels of erythropoietin in the presence of RU 486 was reported in 
mice upon intramuscular injection of a pGeneswitch plasmid designed to express erythropoietin 
[102]. Similarly, a lentiviral vector based on the pGeneswitch system demonstrated a 50-200 fold 
increase in EGFP expression upon RU 486 induction in vitro [103]. Tail vein injection of a HC-Ad 
vector expressing hGH under the control of the liver specific promoter TTRB followed by 
induction with RU 486 resulted in high level expression of hGH. Apart from gene transfer 
experiments, effective and tissue specific, anitprogestin-dependent regulation of gene expression 
has also been achieved in transgenic mice [104].  
 
I.2.3 Adenovirus structure and characteristics  
 
Adenoviruses are a large group of DNA viruses that infect vertebrates. They constitute the 
Adenoviridae family of viruses, which is divided into four genera, Mastadenovirus, Aviadenvirus, 
Atadenovirus and Siadenovirus [105]. So far more than 50 human adenovirus serotypes have been 
identified based on sequence comparison and neutralization assays. The serotypes are further 
classified into 6 species. Most vectors are based on adenovirus serotype 5 (Ad5) and Ad2. 
Adenoviruses are icosahedral particles with a size of 70-100 nm in diameter. The virion consists of 
a protein capsid surrounding a DNA-containing core. The capsid is composed of 252 subunits 
(capsomeres), of which 240 are hexons and 12 are pentons (241). Each penton consists of a base, 
which forms part of the surface of the capsid, and a projecting fiber whose length varies among 
different serotypes. Additional structural and non-structural include V, VI, VII, VIII, IX, III and 
IVa2 and a virus-encoded protease. The virus genome is a linear double stranded DNA of 36 kb 
with a terminal protein covalently attached to the 5´ termini. The MW of a single particle is 150-
180 x 106. Virions have a buoyant density in CsCl of 1.32-1.35 g cm-3.  
Adenoviral genomes of different serotypes have the same or similar general organization. The viral 
genome consists of five early transcription units (E1A, E1B, E2, E3, and E4), two delayed early 
units (IX and IVa2) and one late unit (major late), which is processed to generate five families of 
late mRNAs (L1 to L5). The replication origins of adenoviruses are present in the first 50 base 
pairs of the about 100 bp inverted terminal repeats (ITRs) located at each end of the viral genome. 
A cis acting sequence required for the packaging is present at the left end and is responsible for the 
polar encapsidation of the viral DNA.  
Proteins generated by the early transcription units are involved in cell transformation, replication 
and transactivation of viral and cellular transcription units and in immunosuppressive functions. 
Adenoviral entry into the cells involves the binding of the fiber to the Coxsackie Adenovirus 
Receptor (CAR) and the interaction of the RGD sequence in the penton base with αv integrins  
[106]. This process is very efficient and rapid and involves the sequential uncoating of the virion 
before the ending up of DNA in the nucleus within 30 minutes to a few hours. After nuclear entry, 
the virus expresses the E1A proteins, which activate other transcription downstream proteins, 
which play a role in induction of apoptosis and bind to numerous cellular protein involved in 
transcriptional regulation [90]. The E2 region unit encodes the viral proteins involved in 
adenovirus DNA replication such as Ad DNA polymerase, pre-terminal protein (pTP) and DNA 
binding protein (DBP). The E3 region encodes multiple proteins that function to inhibit multiple 
pathways of cell death induced by host innate and cellular immune responses to the infected cells.  
Proteins encoded by the E4 region have been shown to play important roles in viral DNA 
replication, viral mRNA transport and splicing, shut off of host cell protein synthesis and 
regulation of apoptosis. Replication of adenoviral DNA occurs after accumulation of replication 
proteins encoded from the E2 region and requires as cis element the origin of replication present 
within the ITR region. Following DNA replication the major late promoter is activated resulting in 
the transcription of the late transcription units and in the production of the virus structural proteins 
followed by capsid formation and DNA encapsidation [90]. The encapsidation process is governed 
by the presence of a packaging signal located at the left end of the virus DNA. An infectious cycle 
is completed in 36-48 hours with the release of about 10,000 virions per permissive cell.  
 
I.2.4 Adenoviral vector systems  
 
First or second generation adenoviral vectors are replication deficient and are characterized by 
deletion of viral sequences. First generation Ad vectors were generated by the deletion of E1 genes, 
allowing introduction of about 8.0 kb of foreign DNA under the control of heterologous promoters. 
Without the E1 function the E2 transcription unit is inactive. Thus proteins necessary for viral 
DNA replication are not expressed. First generation Ad vectors are propagated in a permissive cell 
line such as 293 cells, which provides E1 functions in trans [107]. Numerous systems have been 
developed for the generation of first generation Ad vectors. In general, these systems are based on 
in vivo recombination between shuttle plasmids containing a gene of interest flanked by 
homologous sequences such as Ad E1 or E3 and a second plasmid containing essentially the entire 
Ad genome in a circular form [108]. The shuttle plasmids differ in size and location of the Ad 
deletion, the regulatory sequences present, and unique restriction sites available for the insertion of 
a foreign gene. The generated first generation adenoviral vector is further selected by several 
rounds of plaque purification. In many studies with first generation Ad vectors performed in vivo 
in mice, expression has peaked about one week after vector administration and returned to 
background levels at 2-4 weeks. The transient expression has been attributed to immune response 
against capsid proteins and the expressed transgenes. Also the elimination of E3 proteins from the 
vector may contribute to the elimination of defenses against host responses. Short term transgene 
expression from first generation Ad vectors make this vector type unsuitable for most gene therapy 
applications in which continuous expression of a therapeutic protein is required. However, because 
of their immunostimulatory activity it is likely that this vector will be used in the future in 
vaccination studies. 
Second generation adenoviral vector were generated by further deletion of parts of the E2 region 
and E4 regions, increasing somewhat the capacity for gene transfer. In some cases, the E3 function 
of the vector has been restored to augment prolonged transgene expression. The advantages of 
second generation over first generation adenoviral vector are controversially discussed. 
In an attempt to improve the expression kinetics and the safety profile a new generation of Ad 
vectors called high capacity adenoviral (HC-Ad) vectors has been generated [109]. These vectors 
unlike earlier generation vectors are completely devoid of viral genes. They contain only the ITRs, 
which are required as cis-elements for initiation of replication and packaging. The HC-Ad vectors 
are also referred to by different names such as helper dependent Ad vectors, gutless vectors, gutted 
vectors, and mini adenoviruses [110]. HC-Ad vectors can carry transgenes up to a maximum 
capacity of 37 kb thereby facilitating the transfer of complete genomic fragments. In the case of an 
expression cassette having a smaller size, stuffer DNA is used to bring the total vector genome size 
to at least 27 kb to prevent rearrangement during production [111]. In one system stuffer DNA was 
derived from the non-coding region of the hypoxanthine guanine phosophoribosyl transferase 
(HPRT) locus or from the human cosmid C346 [112]. Stuffer DNA may contain matrix or scaffold 
attachment regions, which are believed to have positive influences on vector and/or expression 
stability in transduced cells. The influence of stuffer sequence on transgene expression was 
demonstrated when a CpG rich stuffer DNA derived from phage lambda was used. These vectors 
showed a significantly shorter hepatic expression of a lac Z transgene when compared to a vector 
containing HPRT stuffer sequences [112].  
Generation of a HC-Ad vector requires three components, a helper virus, a permissive cell line 
expressing Cre-recombinase and a linear plasmid to be rescued as a vector. The helper virus is a 
first generation vector having deletions in the E1/E3 region and two LoxP sites flanking the 
packaging signal. The permissive cell line Cre66 expresses cre recombinase and E1a and E1b 
protein constitutively. Cre recombinase is derived from the bacteriophage P1 and is responsible for 
recombination between the two LoxP sites. The plasmid to be rescued as HC-Ad vectors requires 
free terminal ITRs and a size between 27-36 kb. HC-Ad vector is generated by transfecting the 
linear plasmid and infection with helper virus into Cre66 cells. Replication is initiated by the E1a 
protein expressed in trans by Cre66 cells. Along with the helper virus, the vector DNA also 
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replicates to high numbers. However, in the presence of Cre recombinase, the packaging signal 
from the helper virus genome is excised. In contrast, the vector DNA containing the ITRs is 
packaged efficiently. The HC-Ad vector is released by freeze thawing and the lysates containing 
the HC-Ad vector are serially passaged for about six times to yield high titers. As a result of serial 
passaging, the helper virus contamination is reduced to 1%.  
First and second generation adenoviral vectors have been used extensively for gene transfer in 
different rodent models and in clinical trials. These vectors have shown efficacy in different animal 
models of liver diseases, hemophilia, Duchenne muscular dystrophy (DMD), cystic fibrosis (CF) 
and cancer [113]. In general, the results from these vectors were characterized by short-term 
expression of transgenes due to clearance of transduced cells by infiltrating lymphocytes and by 
ADCC against the transgene [90]. In contrast, HC-Ad vectors administered intravenously show 
improved expression kinetics and significantly less toxicity compared to first generation adenoviral 
vectors. HC-Ad vectors have been also been used in preclinical models of liver diseases, 
hemophilia, and DMD. HC-Ad vectors have also been used in the successful gene transfer to the 
eye and the CNS. An HC-Ad vector containing the complete locus for α-antitrypsin gene expressed 
the protein in immuno-competent mice for more than a year with negligible toxicity [12]. In a 
similar study another HC-Ad vector expressed leptin for a longer time compared to first generation 
vector demonstrating the superiority of the HC-Ad vector [11]. In another example, high levels of 
RU 486 dependent expression of hGH were observed in immunocompetent mice. The expression 
of hGH could be induced over time by repeated RU 486 administration during the 50-days study 
period [10]. HC-Ad vectors have also been used in animal models for hemophilia, which causes 
prolonged bleeding into joints, muscle, and internal organs. An HC-Ad vector expressing the F 
VIII human cDNA under the control of the 12.5 kb AAT promoter showed correction of the 
phenotype in a mice model [114]. However, it was also observed that the levels of F VIII decreased 
which was believed to be due to antibodies generated against the transgenic F VIII protein. 
Adenoviral vectors have also been tested for efficacy in different murine models of cancer. First 
and second generation adenoviral vectors have been constructed to incorporate TSGs, suicide 
genes or cytokine genes. The vectors have been injected either intravenously by tail vein injection 
or by direct injection into the tumor site. Ad vectors incorporating p53 showed efficacy with 
thyroid cancer, malignant gliomas, and breast cancer[115-118]. Adenoviral vectors incorporating 
suicide genes such as thymidine kinase or cytosine deaminase were tested in situ for head and neck 
tumors and phase 1 trials have been completed for malignant mesothelioma and for prostate 
carcinoma [119, 120]. A trimodal therapy involving a double suicide vector of HSV-tk and CD 
combined with radiotherapy has proved very effective in tumor reduction in a cervical carcinoma 
xenograft model [121]. Also, adenoviruses replicating in tumor tissues called oncolytic vectors 
have been developed. The commercially developed vector called Onyx 15 has a mutation in the 
E1B 55K gene and was supposed to replicate selectively in p53 defective tumor cells [97].  
Numerous methods have been shown to improve the kinetics of transgene expression using Ad 
vectors. The methods include retargeting of virus, injection of immunosuppressive agents, use of 
tissue specific promoters, use of alternate serotypes, improvement of stuffer regions and depletion 
of Kupffer cells. Thus the advancement in the development of adenoviral vectors shall aid in the 
delivery of transgenes, which are known to inhibit cancer growth. Also the modification of viral 
tropism may increase the tumor infectivity of adenoviral vectors in the future. Taken together, 
these strategies offer new hope in the treatment of susceptible tumors. 
 
 II Objective 
 
Conventional tumor therapy is frequently unsuccessful in the eradication of distant metastases and 
recurrent tumors. Therefore, new strategies are required to supplement current therapies. Some of 
the recent efforts have been directed to the activation of the immune system and to the suppression 
of tumor angiogenesis. We reasoned that long-term expression of immunomodulatory or anti-
angiogenic molecules at significant levels might represent a promising strategy to control 
malignant tumor growth.  
As vector delivery system we chose HC-Ad vectors since they allow long-term gene expression 
from hepatocytes following systemic administration.  
As therapeutic molecules, we focused on IL-12, sflt1 and stie2, which are well-studied proteins 
with potent immunomodulatory and anti-angiogenic functions, respectively.  
A first aim was the generation of HC-Ad vectors expressing sflt1 and stie2 in a constitutive 
manner. Since constitutive high-level expression of murine IL-12 and sflt1 was expected to have 
toxic side effects, a further safety level was introduced by constructing additional vectors that 
expressed IL-12 and sflt1 in a drug-inducible manner. Because the RU 486-inducible pGeneSwitch 
system has been shown to allow tight transcriptional control in vivo, this system was used as the 
basis for these studies. 
A second aim consisted in the characterization of the generated vectors in vitro and in vivo with 
respect to expression kinetics and functional activity. Since the human IL-12 is not functional (and 
not toxic) in mice, this molecule was used as a reporter to follow expression from a RU486 
inducible and liver-specific vector format in vivo. 
Finally, a third aim was the testing of the different vectors in two different syngenic tumor models 
in mice, the subcutaneous LLC model and the orthotopic MC-38 model. The former is a relatively 
simple model that allows rapid screening of antitumor effects of biologicals. The latter is a 
physiological model of liver metastases, in which tumor cells are implanted directly into the liver 
and anti-tumor effects of proteins expressed in normal hepatocytes in the tumor environment can 
be studied. 
Together, these studies were designed to contribute to an improved understanding of the potential 
of vector-mediated expression of anti-angiogenic and immunomodulatory functions for tumor 
therapy. 
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III Materials and Methods 
 
III.1 Materials and Instruments 
 
III.1.1 Materials 
 
All chemicals, when not specially mentioned, were purchased from the company Applichem 
GmbH (Germany). The solutions were prepared using water obtained from EASY pure instrument 
(Werner water purification system, Germany). The bacterial media and agar was purchased from 
Invitrogen (Germany). The enzymes were purchased from NEB (Germany). Oligonucleotides were 
purchased from Invitrogen (Germany). Cell culture media, when not specially mentioned, were 
purchased from Invitrogen (Germany). All cell culture materials (cell culture dishes, pipettes etc.,) 
were purchased from Renner (Germany). The secondary antibodies used in western blot analysis 
were purchased from Jackson Immunochemicals (USA). The ELISA plates were purchased from 
NUNC (Germany).  
 
III.1.2 Instruments and equipment 
 
Autoclave     Systec (Germany)  
Cell culture hood    Clean Air Technik (Netherlands) 
Cell culture incubator    Forma Scientific, (USA) 
Centrifuges     Biofuge fresco (Germany) 
      Eppendorf 5417C (Germany) 
      Sigma 6K15 (Germany) 
Gel chamber for protein gels   “Mini-protean II Electrophoresis Cell” 
      Bio-Rad Laboratories GmbH (Germany) 
Heating block     VWR (Germany) 
Hitachi Auto analyzer    Roche/Hitachi 904/911: ACN 166 (USA) 
Incubator (Bacterial culture, 
enzyme reactions, pipette sterilization) VWR (Germany) 
Minihybridization oven   Biometra biomedizinische Analytik GmbH   
      (Germany) 
Micro Plate reader     Model 550.Bio-Rad Laboratories GmbH   
      (Germany)  
PCR thermocycler Uno II   Biometra biomedizinische Analytik GmbH   
      (Germany) 
pH-meter pH526    WTW GmbH (Germany) 
Spectrophotometer    Pharmacia Biotech (Germany) 
Ultracentrifuge     Beckman, L7-65 with SW41-Rotor (USA) 
 
III.1.3 Buffers and Solutions 
 
Agarose overlay medium 
0.5%      autoclaved agarose (FMC products, USA) 
1 x      MEM 
0.5%      penicillin/streptomycin 
0.05%      yeast extract 
5%      FCS 
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DNA-loading buffer (6x) 
30%       Glycerin 
60 mM       EDTA 
0.1%      Bromophenol blue 
0.1%       Xylene cyanol  
 
HBS-Buffer (2x) 
50 mM      HEPES 
280 mM     NaCl 
1.5 mM     Na2HPO4 
pH      7.13 
 
Hybridization buffer for slot blot 
2 x      SSC 
10%      Milk powder solution 
0.5 mg/ml     Herring sperm 
10%      Dextran sulfate  
 
Laemmli Buffer with SDS (4x) 
20%       Glycerin 
0.7 M       Mercaptoethanol 
4%      SDS 
0.25 M      Tris-HCl (pH 7.0) 
0.1%      Bromophenol blue 
 
Milk powder solution for slot blot 
5%       Low fat milk powder 
10%      SDS 
 
PCR-Mix 
DNA      Plasmid DNA was used at concentration 
       of 1-10 ng 
       Genomic DNA was used at concentration 
       of 1-2 µg 
Pfu polymerase buffer   1x 
Pfu polymerase    1.25 units (Stratagene, Netherlands) 
dNTP-Mix     40 nmol (Roche, Germany) 
dH20         made up to a volume of 50 µl 
 
Sodium phosphate-buffer  
46.6 ml     1M Na2HPO4 
3.4 ml      1M NaH2PO4 
8.8 gm       NaCl 
500 ml      dH2O 
pH       8.0 
 
Stacking gel for SDS PAGE 
5%      Acrylamide/Bisacrylamide 
125 mM     Tris-HCl, pH 6.8 
0.1%       SDS 
0.1%      APS 
0.1%      TEMED 
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Separation gel for SDS PAGE 
5-10%      Acrylamide/Bisacrylamide 
375 mM     Tris-HCl, pH 8.8 
0.1%       SDS 
0.1%      APS 
0.1%      TEMED 
 
SDS-Running buffer (10x) 
250 mM     Trisbase 
2.5 M      Glycine 
1%      SDS 
 
SSC solution (20x) 
3 M      NaCl (tri-sodium citrate) 
0.3 M      Na3H5C607  (tri-sodium citrate) 
pH       7.0 (adjusted with NaOH) 
 
Substrate solution for ELISA 
0.024 M      C6H807 
0.052 M     Na2HPO4 
pH      5.0 (adjusted with HCl) 
1 tablet TMBD (3,3´, 5,5´-Tetramethyl benzidine) for 10 ml 
2l µl of 30% H202 for 10 ml 
The solution was filtered through a 0.22 µm filter 
 
TAE-Buffer (50x) 
2 M      Tris-Base 
0.05 M      Acetic acid 
0.05 M      EDTA 
 
TBE Buffer 
0.225 M     Tris base  
0.225 M     Boric acid 
0.02 M      EDTA 
 
TBST Buffer for the ELISA 
0.05 M      Tris-HCl, pH 7.5 
0.1 M      NaCl 
0.05%      Tween-20 
 
TBS-Buffer (1x) for resuspension of virus 
137 mM      NaCl 
2.7 mM     KCl 
25 mM      Tris-Base 
pH 7.4 (adjusted with HCl) 
(The solution was sterilized by autoclaving)  
 
TE Buffer (1x) 
10 mM      Tris-HCl, pH 7.5 
1 mM      EDTA 
 
 
 
 23
 24
TELT Buffer 
50 mM      Tris-HCl, pH 8.0 
62.5 mM     EDTA 
2.5 M      LiCl 
0.6%      Triton X-100 
One spatula of Lysozyme 
 
Transfer buffer for Western blot analysis 
25 mM      Tris-Base 
150 mM     Glycine 
20%      Methanol 
 
TTBS for Western blot analysis 
10 mM      Tris-Base 
150 mM     NaCl 
0.1%       Tween-20 
pH      7.6 (adjusted with HCl) 
 
Transfer buffer for Southern blot analysis 
0.1 N      NaOH 
 
III.1.4 Oligodeoxyribonucleotides 
 
The oligodeoxyribonucleotides were purchased from Invitrogen (Germany). The lyophilized 
oligonucleotides were dissolved in 1x TE buffer and were stored at –20 οC. 
Oligodeoxyribonucleotides used for ligation were dissolved in 10 mM Tris buffer. 
 
Actin-s  5´- GACGGCCAGGTCATCACTATTG-3´ 
 
Actin-as  5´-CCACAGGATTCCATACCCAAGA-3´ 
 
Fiber I   5´-ATGAAGCGCGCAAGACCGTCTG-3´ 
   binds to nucleotides 31042-31063 of the Ad 5 sequence 
 
Fiber II  5´-CCAGATATTGGAGCCAAACTGCC-3´. 
   binds to nucleotides 32368-32390 of the Ad 5 sequence 
 
ITR I   5´- AACGCCAACTTTGACCCGGAACGCGG- 3´ 
   binds to nucleotides 438-413 of the Ad 5 sequence 
 
ITR II   5´- CATCATCAATAATATACCTTATTTTG-3´ 
    binds to nucleotides 1-26 of the Ad 5 sequence 
 
GLp65F   5´-AGCCAGATCTGAAGCTAC-3´ 
   binds to nucleotides 3476-3493 of plasmid pRS 17 
 
GLp65R  5´-TGCTTGATATATCTCGTCGA-3´ 
   binds to nucleotides 4562-4579 of plasmid pRS 17 
 
17merf2  5´-GGGACCGATCCAGCCTCCGCG-3´ 
   binds to nucleotides 2452-2464 of plasmid pRS 17 
 
 
BGHPA1  5´-GCAACTAGAAGGCACAGTCGA-3´ 
   binds to nucleotides 2681-2702 of plasmid pRS 17 
 
BGHPA2  5´-GCCCTCGACCTGCAGCCCAAGCTT-3´ 
   binds to nucleotides 2971-2995 of plasmid pRS 17 
 
MCMV1  5´-ATCGATGCGGCCGCTACGTAAGGCCTCTCGAG-3´ 
   was generated to insert a Not I and SnaB I site into plasmid pRS 34 
 
MCMV2  5´-CTCGAGAGGCCTTACGTAGCGGCCGCATCGAT-3´ 
   was generated to insert a Not I and SnaB I site into plasmid pRS 34 
 
Oligo 78  was generated by annealing complementary oligos V01 and V02 
 
Oligo V01  5´-ATTTAAATATCGAT-3´ 
   Contains a Swa I and ClaI site  
 
Oligo V02  5´-ATCGATATTTAAAT-3´ 
   contains a Swa I and Cla I site  
 
Oligo 79  was generated by annealing oligos V03 and V04 
 
Oligo V03  5´TATGTCGCGGCCGC TCGCC-3´ 
   Contains a Not I site 
 
Oligo V04  5´GGCGAGCGGCCGCGACATA-3´ 
   Contains a Not I site 
 
SG TTRB  5´-GGCTTCTGAGGCGGAAAGAAC-3´ 
   binds to nucleotides 2908-2927 of plasmid pRS 17 
 
SG PSwitch  5´-GCGGACATGGACTTCTCAGCCC-3´ 
   binds to nucleotides 5339-5361 of plasmid pRS 17 
 
III.1.5 Plasmids 
 
The following plasmids were constructed during the work. The plasmids were constructed 
according to the protocols described in Chapter III.3. The plasmids obtained as a gift are specially 
mentioned. When non-cohesive ends of DNA were ligated, the ends were treated with Klenow 
enzyme to fill up the 5´ends. All the plasmids used, when not specially mentioned, were based on 
pBluescript II KS (Stratagene). pBluescript II KS has an ampicillin resistance gene, Co1E1 and f1 
(+) origin of replication. pBluescript II KS also has a multiple cloning site for the insertion of DNA 
fragments.  
 
a) Construction of plasmid pRS 14 
The plasmid pRS 14 expresses the transactivator GLp65 under the control of transthyretin 
promoter (TTRB). The plasmid pRS 14 was generated from the plasmid pSTK 119 TA End TTRB 
and plasmid pPAP CMV GLp65 SV40. The plasmid pRS 14 was generated by subcloning the Asc 
I/Pac I fragment (expresses the transactivator under the control of TTRB promoter) from the 
plasmid pSTK 119 TA End TTRB GLp65, into the Asc I/Pac I site (by replacing the DNA 
fragment expressing the transactivator GLp65 under the control of CMV promoter) of the plasmid 
pPAP CMV GLp65 SV40. The plasmid pSTK 119 TA End TTRB GLp65 was obtained as a kind 
gift from Dr. Mark Burcin. The plasmid pSTK 119 TA End TTRB GLp65 expresses the transgene 
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endostatin, upon induction with RU 486, in a liver specific manner. The plasmid pPAP CMV 
GLp65 SV40 was obtained as a kind gift from Dr. Mark Burcin. The plasmid pPAP CMV GLp65 
SV40 expresses the transactivator p Switch protein (pGLp65) under the control of the CMV 
promoter. The plasmid pRS 14 was later used in the construction of plasmid pRS 17. The cloning 
scheme for the construction of plasmid pRS 14 is shown in Figure III.1. 
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Figure III.1: Cloning scheme for the generation of plasmid pRS 14. The plasmid pRS 14 was generated by the 
insertion of the expression cassette TTRB GLp65 SV40 from the plasmid pSTK 119 TAEnd TTRB GLp65 SV40 into 
the plasmid pPAP CMV GLp65 SV40. 
 
b) Construction of plasmid pRS 15 
The plasmid pRS 15 has a unique Cla I and Swa I site for cloning the transgene for inducible 
expression, under the control of the TTRB promoter and RU 486. The plasmid pGene V5/His A 
was cleaved with enzymes Hind III and Pme I to release the multiple cloning site. The linear 
plasmid was isolated by agarose gel electrophoresis and was ligated to Oligo 78 containing Swa I 
and Cla I sites. The cloning scheme for the construction of plasmid pRS 15 is shown in Figure 
III.2. 
 
c) Construction of plasmid pRS 16 
The plasmid pRS 16 was generated from the plasmids pRS 15 and pPNA ∆ Sal I/Kpn-CAT (a kind 
gift of Dr. Mark Burcin). The plasmid pRS 15 was digested with Sal I and Pvu II to release the 
insert containing the TATA box, cloning site and bGH poly A. The insert was made blunt by 
Klenowing and after agarose gel extraction the insert was subcloned into the Sal I/Sma I site of the 
plasmid pPNA ∆ Sal I/Kpn-CAT. The plasmid pPNA ∆ Sal I/Kpn-CAT contains the cDNA 
chlorophenicol acetyl transferase enzyme inserted downstream of the 17 mer TATA box. The 
plasmid pPNA ∆ Sal I/Kpn-CAT contains a SV 40 poly A cloned downstream of the transgene. 
The plasmid pRS 16 was later used in the construction of plasmid pRS 17. The cloning scheme for 
the construction of plasmid pRS 16 is shown in Figure III.3. 
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Figure III.2: Generation of plasmid pRS 15. The plasmid pRS 15 was generated by replacing the MCS with the Oligo 
78 containing restriction sites for Cla I and Swa I. 
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Figure III.3: Generation of the plasmid pRS 16. The plasmid pRS 16 was generated by inserting the Pvu II and Sal I 
fragment (Klenowed) derived from the plasmid pRS 15 into the Sal I and Sma I sites of plasmid pPNA del SalI / KpnI-
CAT. 
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d) Construction of plasmid pRS 17 
The plasmid pRS 17 has the two expression cassettes required for inducible expression of 
transgenes. The plasmid pRS 17 was generated from the plasmids pRS 14 and pRS 16. The 
plasmid pRS 17 was generated by insertion of the Pme I/Asc I fragment from plasmid pRS 16 into 
the Pme I/Asc I site of plasmid pRS 14. The oligos used for sequencing the pSwitch protein were 
GLp65F and GLp65R (Chapter III.1.4). The oligo used for sequencing the GAL4 region was 
17merf2 (Chapter III.1.4). The oligos used for sequencing the BGHpA region were BGHPA1 and 
BGHPA2 (Chapter III.1.4). The cloning scheme for the construction of plasmid pRS 17 is shown 
in Figure III.4. 
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Figure III.4: Generation of plasmid pRS 17. The plasmid pRS 17 was generated by inserting the Asc I/Pme I fragment 
from desired plasmid pRS 16 into the Asc I/Pme I site of plasmid pRS 14.  
 
e) Construction of plasmid pRS 20 
The plasmid pRS 20 expresses sflt1 upon induction with RU 486 in a liver specific manner. The 
plasmid pRS 20 was generated from plasmids pRS 17 and pBS SK+flt1 D1-6 (a kind gift of Dr. 
Hubert Weich). The plasmid pRS 20 was generated by the insertion of the sflt1 cDNA, derived 
from the plasmid pBS SK+flt1 D1-6, into the Swa I site of plasmid pRS 17. pBS SK+flt1 D1-6 was 
digested with enzymes Bam HI and Xho I to release the sflt1 cDNA. The cloning scheme for the 
construction of plasmid pRS 20 is shown in Figure III.5. 
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Figure III.5: Generation of plasmid pRS 20. The plasmid pRS 20 was generated by inserting the Bam HI/Xho I 
fragment derived from plasmid pBS SK+flt1D1-6 into the Swa I site of plasmid pRS 17. 
 
f) Construction of plasmid pRS 21 
The plasmid pRS 21 expresses the hIL-12 upon induction with RU 486 in a liver specific manner. 
The plasmid pRS 20 was generated from the plasmids pRS 17 and pBS/hIL-12. The plasmid pRS 
21 was generated by insertion of the hIL-12 cDNA into the Swa I site of plasmid pRS 17. The 
plasmid pBS/hIL-12 was digested with the enzymes Xba I and Spe I to release the hIL-12 cDNA. 
The released cDNA was made blunt by using the Klenow enzyme. The DNA was separated on a 
0.8 % agarose gel, and was purified by using the Qia quick gel extraction kit (Qiagen, Germany). 
The blunt ended cDNA was cloned into the Swa I site of plasmid pRS 17. The cloning scheme for 
the construction of plasmid pRS 21 is shown in Figure III.6. 
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Figure III.6: Generation of plasmid pRS 21. The plasmid pRS 21 was generated by inserting the Spe I/Xho I fragment 
from the plasmid pBS hIL-12 into the Swa I site of plasmid pRS 17.  
 
g) Construction of plasmid pRS 22 
The plasmid pRS 22 expresses mIL-12 upon induction with RU 486 in a liver specific manner. The 
plasmid pRS 22 was generated by insertion of mIL-12 cDNA into the Swa I site of plasmid pRS17.  
The plasmid pBSmIL-12 was initially digested with enzymes Xho I and Spe I to release the mIL-12 
cDNA. The cloning scheme for the construction of plasmid pRS 22 is shown in Figure III.7. 
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Figure III.7: Generation of plasmid pRS 22. The plasmid pRS 22 was generated by inserting the Spe I/Xho I fragment 
from plasmid pBS mIL-12 into the Swa I site of plasmid pRS 17.  
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h) Construction of plasmid pRS 23 
The plasmid pRS 23 expresses the sflt1 upon induction with RU 486 in a liver specific manner. 
The pRS 23 was generated from the plasmids pRS 20 and pSTK 119. The plasmid pRS 23 was 
generated by the insertion of the Not I fragment (expresses sflt1 upon induction in hepatic cells) 
from the plasmid pRS 20 into the Ecl XI site of plasmid pSTK 119. The cloning scheme for the 
construction of plasmid pRS 23 is shown in the Figure III.8. 
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Figure III.8: Generation of plasmid pRS 23. The plasmid pRS 23 was generated by inserting the Not I sequence from 
plasmid pRS 20 into the Ecl X I site of plasmid pSTK 119. 
 
i) Construction of plasmid pRS 24 
The plasmid pRS 24 was constructed to express the hIL-12 upon induction with RU 486 in a liver 
specific manner. Plasmid pRS 24 was generated from the plasmids pRS 21 and pSTK 119. The 
plasmid pRS 24 was generated by the insertion of the Not I fragment (expressing hIL-12 upon 
induction in hepatic cells) from the plasmid pRS 21 into the Ecl XI site of plasmid pSTK 119. The 
cloning scheme for the construction of plasmid pRS 24 is shown in Figure III.9. 
 
j) Construction of plasmid pRS 25 
The plasmid pRS 25 expresses the mIL-12 upon induction with RU 486 in a liver specific manner. 
The plasmid pRS 25 was generated from the plasmids pRS 22 and pSTK 119. The plasmid pRS 24 
was generated by the insertion of the Not I fragment (express mIL-12 upon induction in hepatic 
cells) from the plasmid pRS 22 into the Ecl XI site of the plasmid pSTK 119. The cloning scheme 
for the construction of plasmid pRS 21 is shown in Figure III.10. 
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Figure III.9: Generation of plasmid pRS 24. The plasmid pRS 24 was generated by inserting the Not I sequence from 
plasmid pRS 21 into the Ecl XI site of plasmid pSTK 119. 
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Figure III.10: Generation of plasmid pRS 25. The plasmid pRS 25 was generated by inserting the Not I sequence from 
plasmid pRS 22 into the Ecl XI site of plasmid pSTK 119. 
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k) Construction of plasmids pRS 28 and pRS 29 
The plasmid pRS 28 was used for the generation of plasmid pRS 29. The plasmid pRS 28 was 
generated from plasmid pRS 17. The plasmid pRS 17 was digested with enzymes Asc I/ Spe I (to 
remove the sequence TTRB GLp65 SV40 pA) and was religated to generate the plasmid pRS 28. 
The cloning scheme for the construction of plasmid pRS 28 is shown in Figure III.11. 
 
  
Figure III.11: Generation of plasmid pRS 28. The plasmid pRS 28 was generated by digesting the plasmid pRS 17 
with the enzymes Asc I and Spe I and self-ligating the linear plasmid. 
 
The plasmid pRS 29 was designed to express transgenes under the control of the elongation factor 
1α (EF1α) promoter. It has a bovine growth hormone poly A. The plasmid pRS 29 was constructed 
from plasmids pRS 28 and pEF-BOS. The plasmid pEF-BOS was digested with the enzymes Hind 
III and Xba I to release the EF1α promoter containing fragment. This fragment was inserted into 
the Hind III / Swa I site of plasmid pRS 28 to generate plasmid pRS 29. The generation of plasmid 
pRS 29 is shown in Figure III.12. 
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Figure III.12: Generation of plasmid 29 The plasmid pRS 29 was generated by inserting the Xba I / Hind III fragment 
from plasmid pEF-BOS into the Hind III / Swa I site of the plasmid pRS 28. 
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l) Construction of plasmid pRS 31  
The plasmid pRS 31 was designed to express transgenes under the control of the murine CMV 
(MCMV) promoter. The plasmid pRS 31 was generated from plasmid pPDK6 (a kind gift of 
Dr.J.M.Sallenave) and plasmid pPAP CMV GLp65. 
The plasmid pPDK6 was digested with Bam HI and Xba I to release the DNA fragment containing 
the MCMV promoter. This sequence was cloned into the BamH I and Sal I site of the plasmid 
pPAP CMV GLp65. The cloning scheme for the construction of plasmid pRS 31 is shown in 
Figure III.13.  
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Figure III.13: Generation of plasmid pRS 31. The plasmid pRS 31 was generated by inserting the Xba I / Bam HI 
fragment from the plasmid pPDK6 into the Sal I /Bam HI site of the plasmid pPAP CMV GLp65 SV40pA. 
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m) Construction of plasmid pRS 33  
The plasmid pRS 33 expresses sflt1 under the control of the EF1α promoter. The plasmid pRS 33 
was based on plasmid pRS 29 and plasmid pBSK + flt1 D1-6. The sflt1 cDNA was released from 
plasmid pBSK+ flt1 D1-6 by digesting with the enzymes Bam HI and Xho I. This DNA fragment 
was inserted into the Spe I site of plasmid pRS 29. The cloning scheme for the construction of 
plasmid pRS 33 is shown in Figure III.14. 
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Figure III.14: Generation of plasmid pRS 33. The plasmid pRS 33 was generated by inserting the Xho I/Bam HI 
fragment from plasmid pBS SK+fltD1-6 into the Spe I site of plasmid pRS 29.  
 
n) Construction of plasmids pRS 34 and pRS 42 
The plasmid pRS 34 expresses the murine tie2 under control of the MCMV promoter. The plasmid 
pRS 34 was based on plasmids pRS 31 and pBS II KS Tie2 EC His. The tie2 cDNA was excised 
from plasmid pBS II KS Tie2 EC His using the enzymes Eco RI and Not I. The released cDNA 
was cloned into the Hind III site of plasmid pRS 31. The cloning scheme for the construction of 
plasmid pRS 34 is shown in Figure III.15 
The plasmid pRS 42 expresses stie2 under the control of the MCMV promoter. The plasmid pRS 
42 was based on plasmid pRS 34. The plasmid pRS 34 was digested with the enzyme Asc I. Oligo 
79 containing a Not I site was inserted into the Asc I site of plasmid pRS 34 to generate plasmid 
pRS 42. The cloning scheme for the construction of plasmid pRS 42 is shown in Figure III.15. 
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Figure III.15: Generation of the plasmid pRS 34 and 42. The plasmid pRS 34 was generated by digesting the plasmid 
pBS II KS-Tie2 EC His with the enzymes Eco RI and Not I and inserting the DNA fragment into the Hind III site of 
plasmid pRS 31. The plasmid pRS 42 was generated by inserting oligo 79 into the Asc I site of plasmid pRS 34. 
 
o) Construction of plasmid pRS 44  
The plasmid pRS 44 was based on plasmids pSTK 129 and pRS 33. The plasmid pRS 33 expresses 
the sflt1 protein under the control of the EF1α promoter. The plasmid pRS 33 was digested with 
Not I to release the cassette expressing sflt1 under the control of EF1α promoter. This fragment 
was inserted into the Not I site of plasmid pSTK 129 to generate plasmid pRS 44. The cloning 
scheme for the construction of plasmid pRS 44 is shown in Figure III.16. 
 
p) Construction of plasmid pRS 45 
The plasmid pRS 45 was based on plasmids pSTK 129 and pRS 42. The plasmid pRS 42 expresses 
the stie2 protein under the control of the MCMV promoter. The plasmid pRS 42 was digested with 
Not I to release the cassette expressing stie2 under the control of the MCMV promoter. This 
fragment was inserted into the Not I site of plasmid pSTK 129 to generate plasmid pRS 45. The 
cloning scheme for the construction of plasmid pRS 45 is shown in Figure III.17. 
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Figure III.16: Generation of plasmid pRS 44. The plasmid pRS 44 was generated by inserting the Not I fragment from 
plasmid pRS 33 into the Not I site of plasmid pSTK 129. 
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Figure III.17: Generation of plasmid pRS 45. The plasmid pRS 45 was generated by inserting the Not I fragment from 
plasmid pRS 42 into the Not I site of plasmid pSTK 129. 
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III.2 Bacterial methods 
 
III.2.1 Bacterial culture techniques 
 
Culture of bacteria in Luria Broth Base 
E.coli was cultured in Luria Broth Base in the presence of the antibiotic ampicillin at a 
concentration of 100 µg/ml. For small-scale preparation 1.5 ml Eppendorf tubes with a capacity of 
2.0 ml were used. For large-scale preparation (200 ml), Erlenmeyer flasks with a capacity of 500 
ml were used. The cultures were incubated for 12 hours with shaking at 250-300 rpm at 37οC.  
 
Culture of bacteria in Luria Broth Agar 
E.coli was cultured in 10 cm plates containing 20 ml of Luria Broth Agar (LBA) containing 
ampicillin at a concentration of 100 µg/ml.  
 
III.2.2 Transformation of E. Coli 
 
Transformation with plasmid DNA 
Transformation of E.coli with plasmid DNA was performed by incubating 20 µl of XL-2 blue ultra 
competent bacteria (Stratagene, Germany) with 10-100 ng of plasmid in a 1.5 ml Eppendorf 
reaction tube for 5 minutes in ice. After five minutes incubation in ice, the bacteria were placed in 
a water bath having a temperature of 42οC for 45 seconds. The bacteria were then immediately 
placed in ice for 2 minutes and SOC medium was added. The bacteria were incubated for 1 hour at 
37°C. After 1 hour, the bacteria were transferred to LBA plates containing ampicillin and were 
incubated for 12 to 16 hours. 
 
Transformation with plasmid DNA from ligation 
To transform bacteria using a ligation mix, 50 µl of XL-2 blue ultra competent bacteria 
(Stratagene, Heidelberg) were incubated with 0.5 µl of 2-Mercaptoethanol (1.42 M) for 10 minutes 
on ice. After 10 minutes, 2 µl of ligation mix was added and the bacteria were further incubated for 
30 minutes in ice. The bacteria were placed in a water bath having a temperature of 42οC for 45 
seconds. The bacteria were then immediately placed in ice for 2 minutes and 200 µl of SOC 
medium was added. The bacteria were incubated for 1 hour at 37°C before being transferred to 
LBA plates containing antibiotic and were incubated for 12 to 16 hours. 
 
III.2.3 Isolation of plasmids 
 
Analytical plasmid isolation (“Mini prep”) 
Mini prep of DNA was performed to analyze the integrity of DNA by restriction digestion. Isolated 
bacterial clones picked from Luria Broth Agar plates were grown over night (12-14 hours) in 1.5 
ml of LB shaker culture containing ampicillin at 100 µg /ml. The bacteria were pelleted by 
centrifuging at 5000 RPM for 3 minutes at RT. The bacterial pellet was re-suspended in a volume 
of 200 µl of TELT buffer. The re-suspended bacterial pellet was incubated at 96ºC for 3 minutes 
followed by incubation in ice for 5 minutes. The supernatant containing DNA was collected by 
centrifugation at 14,000 RPM for 10 minutes. The DNA present in the collected supernatant was 
precipitated by mixing the supernatant with an equal volume of isopropanol and centrifuging at 
20000 g for 10 minutes. The precipitated DNA was washed once with 300 µl of 70% ethanol. The 
DNA was finally suspended in a volume of 30 µl of TE and was stored at 4ºC until further use. 3 µl 
of the re-suspended DNA was used for restriction digestion.  
 
Preparative plasmid Isolation (“Maxi prep”) 
Maxi prep of DNA was performed to obtain large quantities of DNA for transfection, cloning etc. 
The DNA was prepared using the Qiagen Maxi Plasmid Kit (Qiagen, Germany). The protocol 
prescribed by the manufacturer was followed. 
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III.3 Molecular Biology Methods 
 
III.3.1 Determination of the concentration of DNA 
 
The concentration of DNA was determined using a spectrophotometer. The concentration of the 
DNA present in the solution was calculated using Lambert Beers Law which states concentration 
of double stranded DNA in mg/ml= A260 x 50 x dilution factor, whereby A is the absorption 
coefficient of DNA at 260 nm. The solution was also measured to determine the absorption at 280 
nm for proteins. DNA samples containing A260/A280 values of 1.7-2.0 were used for experiments. 
 
III.3.2 Storage of DNA 
 
For routine use, plasmid DNA was stored in TE buffer at 4οC. Plasmids having a size of larger than 
8 kb were stored in TE buffer having a pH of 8.5. Plasmids having a size less than 7 kb were stored 
in TE buffer having a pH of 7.5. For long-term storage, plasmid DNA was dissolved in 70% 
ethanol and was stored at –20οC. Oligodeoxynucleotides and vector inserts used for ligation were 
stored in 10 mM Tris buffer.  
 
III.3.3 Precipitation of DNA 
 
Ethanol precipitation 
Ethanol precipitation of solution containing DNA was performed by adding 0.1 volume of sodium 
acetate solution (3 M, pH 5.2) and two volume of 100% ethanol. After mixing, DNA was collected 
by centrifuging at 20,000 g for 30 minutes at 4οC. The supernatant was discarded and the pellet 
was washed with 70% ethanol by centrifuging at 20,000g for 30 minutes at 4οC. The supernatant 
was discarded and the pellet was air dried at RT for 5-10 minutes. The pellet was dissolved in TE 
buffer. Vector inserts and oligodeoxynucleotides were dissolved in 10 mM Tris buffer. 
 
Isopropanol precipitation 
Isopropanol precipitation of solution containing DNA was performed by adding 0.1 volume of 
sodium acetate solution (3 M, pH 5.2) and 0.5 volume of isopropanol. After mixing, the DNA was 
pelleted by centrifugation at 20.000 g for 20 minutes at RT. After discarding the supernatant, the 
pellet was washed with 70% ethanol for 30 minutes at 4οC. The supernatant was discarded and the 
DNA was air dried at RT for 5 minutes before being resuspended in TE buffer. 
 
III.3.4 Phenol chloroform extraction of DNA. 
 
Phenol-chloroform extraction of DNA was performed for purification of DNA from proteins. 200 
µl of DNA containing solution was mixed with an equal volume of TE equilibrated phenol 
(Invitrogen, Germany). After mixing the aqueous and organic phase were separated by 
centrifugation at 20,000 g for 4 minutes at RT and the organic phase was discarded. The aqueous 
phase was mixed with an equal volume of chloroform/isoamyl alcohol (24:1) and the phases were 
separated by centrifuging at 20.000 g for 4 minutes at RT. The DNA present in the aqueous phase 
was finally precipitated with ethanol.  
 
III.3.5 Restriction digestion of DNA and agarose gel electrophoresis  
 
Restriction analysis was performed with 10 µg or 200 ng of DNA for preparative or analytical 
digest respectively. DNA was digested with restriction enzyme (5 IU/µg of DNA) in the prescribed 
buffer for 2 hours. DNA was digested in a total volume of 20 µl or 200 µl. In the case of double 
digestion of DNA with enzymes having different prescribed buffers, the digested DNA was 
precipitated with ethanol and was re-suspended in Tris-HCl (pH 8.5), before being re-digested. The 
digested DNA fragments were dissolved in DNA loading buffer, and were electrophoreticaly 
separated in a 0.8% agarose gel. The agarose gel used for the separation of DNA bands contained 
ethidium bromide for visualizing the DNA. TBE running buffer was used for analytical preparation 
of DNA. TAE running buffer was used in the case of preparative digests of DNA, when a DNA 
fragment was to be isolated from the gel. 
 
III.3.6 Isolation of DNA fragments from agarose gels 
 
Digested DNA for preparative analysis was separated by agarose gel electrophoresis. The separated 
DNA was visualized under UV light. The desired DNA band was cut out using a sharp knife. DNA 
bands having sizes of less than 5 kb were isolated using the QIAEX II Gel extraction kit. DNA 
bands having a size of more than 5 kb were isolated by electroelution using Elu trap electrophoretic 
system (Schleicher & Schuell, Germany). The isolated DNA was precipitated using ethanol and 
was re-suspended in 20 µl of 1x TE buffer. 
 
III.3.7 Filling up of 5´ends (“Klenowing”) 
 
Filling up of 5´ends of DNA fragments was performed when non-compatible ends were to be 
ligated. DNA (50 ng/µl) was incubated with two units of Klenow enzyme for 15 minutes in 
Klenow buffer. After 15 minutes, the Klenow enzyme was inactivated by adding EDTA to a final 
concentration of 5 mM followed by incubation at 75ºC for 10 minutes. The DNA was purified by 
phenol/chloroform extraction and ethanol precipitation. Following centrifugation, the precipitated 
DNA was re-suspended in 20 µl of 10 mM Tris-HCl (pH 8.5).  
 
III.3.8 Dephosphorylation of DNA fragments 
 
Dephosphorylation of digested vector DNA was performed to prevent selfligation. One to two µg 
of DNA were incubated with 1 unit of calf intestinal phosphatase (CIP) at 37ºC for 1 hour. After 1 
hour, CIP was inactivated by adding EDTA to a concentration of 5mM followed by incubation at 
75ºC for 10 minutes. The dephosphorylated DNA was purified by phenol/chloroform extraction 
and ethanol precipitation. Following centrifugation, the precipitated DNA was re-suspended in 20 
µl of 10 mM Tris-HCl (pH 8.5).  
 
III.3.9 Ligation of DNA fragments. 
 
Ligation of DNA fragments and dephosphorylated vector DNA was performed in a volume of 10µl 
in 1x T4 ligase buffer, for 2 hours at room temperature, in the presence of five units of T4 DNA 
ligase. The amount of vector DNA and DNA fragments were in molar ratios of 1:3, 1:6 and 1:12.  
 
III.3.10 Polymerase Chain Reaction 
 
Construction of primers for PCR 
In general, the primers used for PCR had around 18 nucleotides. The melting temperature for the 
oligonucleotide primer used in PCR was determined using the formula  
Tm[C] = ((A+T) x 2)+((G+C) x 4) 
T represents thymine base, G represents guanine base, C represent cytosine base and A represent 
adenine base. 
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Performance of PCR 
Polymerase chain reaction was performed in a total volume of 50 µl. The equipment used for PCR 
was a PCR – Automat Uno II (Biometra, Germany). The dNTPs were used in a concentration of 
200 µM, primers at a concentration of 300 nM and MgCl2 at an end concentration of 1.5 mM.  
When not specially mentioned Taq polymerase (Invitrogen, Germany) was used for preparation of 
probes and pfu polymerase (Stratagene, Germany) was used for sequencing and for cloning 
purposes. Genomic DNA was used at a concentration of 1-2 µg and plasmid DNA was used at a 
concentration of 1-10 ng. The denaturing temperature was set at 95°C for 5 minutes. The annealing 
temperature was set at 5°C below the melting temperature of the primers. In general, 25–30 cycles 
were used for amplification of desired fragments. 
 
Purification of PCR products 
PCR products were purified using a PCR purification kit (Qiagen, Germany). The PCR product 
was analysed using agarose gel electrophoresis.  
 
III.3.11 Generation of DNA probes for slot blot analysis 
 
The probes for slot blot analysis namely the ITR and the fiber probes were prepared using PCR. 
The 438 bp long ITR probe binds to the Ad-ITR (nucleotide 1 to 438). The primers used for the 
generation of the ITR probe were ITR I and II. The 1348 bp long fiber probe binds to the Ad–fiber 
DNA (nucleotide 31042 to 32390). The primers used for the generation of the fiber probe were 
fiber I and fiber II. PCR amplification, was carried out for 2 minutes at 94ºC followed by 20 cycles 
of 1 minute at 94ºC, 1 minute at 55ºC, and 1 minute at 72ºC, followed by a final extension of 10 
minutes at 72ºC. The probes generated by PCR were purified using the QIA quick PCR 
purification Kit (Qiagen, Germany). The probes were stored at –20ºC. The concentration of the 
probes was determined spectroscopically and by agarose gel electrophoresis.  
 
III.3.12 Detection of Ad RS 24 presence in tissues using PCR 
 
PCR was used for the detection of the tissue distribution of the vector Ad RS 24. The primers used 
for the PCR were GLp65F and GLp65R. The size of the PCR product was 1103 bp. Total DNA 
and RNA from the tissues of the animal was isolated using the TRI reagent (Sigma, Germany) 
according to the instruction of the manufacturer. The PCR was performed using 0.5 µg of DNA 
from tissues of mice, in a volume of 25 µl, using 1 unit of Red Taq polymerase (Sigma, Germany). 
The PCR amplification steps were 5 minutes at 94ºC followed by 30 cycles of 30 seconds at 94ºC, 
30 seconds at 48°C and 1 minute at 72ºC, followed by a final extension of 5 minutes at 72ºC. 5µl 
of the amplification product was separated by agarose gel electrophoresis on 2% agarose and the 
product was visualized under UV light. 
 
III.3.13 Detection of GLp65 expression from Ad RS 24 in tissues using RT-PCR 
 
16µg of total RNA from each tissue was treated with 15 units of RNAse-free DNAse (Roche, 
Germany) and 20 units of RNAse inhibitor (Invitrogen, Germany) for 15 minutes at room 
temperature. After extraction with phenol/chloroform and precipitation with ethanol, RNA was 
redissolved in 20 µl of DEPC-treated H20. 1 µg of RNA was subjected to reverse transcription 
using 100 units of M-MLV Reverse Transcriptase (Invitrogen, Germany) in a 12 µl volume for 60 
minutes at 37ºC and followed by 5 minutes at 95ºC. 6 µl of this mixture were used for PCR 
amplification in a 50 µl total volume containing 10 pmol of primers GLp65F and GLp65R and 2 
units of Red Taq DNA polymerase (Sigma, Germany). PCR conditions were the same as described 
in Chapter III. 3.10. 10 µl of PCR products were analyzed by electrophoresis on 2% of agarose gels 
and visualized with ethidium bromide. RT-PCR for mouse ß actin was used as control. The primers 
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used for the amplification of ß actin were Act-s and Act-as. The PCR conditions were the same as 
described in Chapter III. 3.10. The size of the ß actin product is 182 bp.  
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III.4 Cell culture techniques 
 
III.4.1 Cell lines and media 
 
The cell culture media and fetal calf serum (FCS), when not otherwise mentioned, were purchased 
from Invitrogen (Germany). Minimum essential medium (MEM) and α-MEM powder were 
dissolved at room temperature in 4.5 L of water. 11 g of NaHCO3 was added to the prepared media 
and the medium was adjusted to pH 7.1 with 1 N HCl. The media was made up to a volume of 5 L 
and was sterile filtered through a 0.2 µm filter. 
All cell culture and viral techniques were performed in the S2 laboratory facility. The cells were 
harvested by centrifugation at 250g. The cell lines were passaged once or twice per week. For 
passaging of cells plated in 15 cm cell culture dishes, the medium was aspirated, and the cells were 
washed once with 10 ml of PBS. After washing, the PBS was aspirated and the cells were detached 
using 3.0 ml of Trypsin-EDTA solution. After detachment, the trypsin was neutralized with 10 ml 
of medium containing 10% FCS. The cells were centrifuged and were resuspended in new medium 
for passaging. 
 
293 Cre 66: The cell line is based on HEK 293. 293 Cre 66 expresses Cre recombinase 
constitutively. The cell line was used for the amplification of HC-Ad vectors. It was a kind gift 
from our colleague Dr. Gudrun Schiedner. The cell line was cultured in MEM/10% FCS/1x 
penicillin-streptomycin. The cell line was passaged 1:3, twice every week. 
 
A549: The cell is derived from a human lung carcinoma. The cell line was purchased from Cell 
line services, Germany. The cell line was cultured in DMEM/10% FCS/1x penicillin-streptomycin. 
The cell line was passaged 1:5 once every week. 
 
HEK 293: The cell line is derived from embryonic kidney cells [107]. The cell line has been stably 
transformed with the E1 function of Adenovirus type 5. The cell line was used for the production 
of helper virus before being replaced by N52E6. The cell line was a kind gift from Dr. Frank 
Graham, Toronto General Research Institute, Canada. The cell line was cultured in MEM/10% 
FCS/1x penicillin-streptomycin. The cell line was passaged 1:5 twice every week. 
 
HeLa: The cell line is derived from of a human tumor of cervical epithelial origin. The cell line 
was purchased from Cell line services, Heidelberg. The cell line was used for transduction with 
HC-Ad vector to estimate the levels of transgene expression in vitro. The cell line was passaged 
1:5 once every week. 
 
HUVEC: Human umbilical venous endothelial cells (HUVEC) are primary endothelial cells 
derived from human umbilical cord. The cells were purchased form Promocell GmbH (Germany). 
The cells were cultured with Macro vascular media purchased from Promocell GmbH (Germany).  
The cells were passaged 1:3 once every week. Cells were used until passage 5. 
 
HepG2: The hepatic cell line is human in origin. The cell line was a kind gift from Dr. Cheng 
Qian, University of Navarra, Pamplona, Spain. The cell line was used for transduction with HC-Ad 
vectors to estimate the levels of transgene expression. The cell line was cultured in RPMI/10% 
FCS/1x penicillin-streptomycin. The cell line was passaged 1: 8 once every week. 
 
HUH 7: The hepatic cell line was a kind gift of Dr. Cheng Qian. The cell line was used for 
transduction with HC-Ad vectors to estimate the levels of transgene expression. The cell line was 
cultured in MEM/10% FCS/1x penicillin-streptomycin. The cell line was passaged 1:5 once every 
week. 
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PLC/PRF/5: The hepatocarcinoma cell line was a kind gift of Dr. Cheng Qian. The cell line was 
used for transduction with HC-Ad vectors to estimate the levels of transgene expression. The cell 
line was cultured in MEM/10% FCS/1x penicillin-streptomycin. The cell line was passaged 1:8 
once every week. 
 
LLC: The Lewis Lung Carcinoma cell line is a syngenic cell line derived from a lung carcinoma of 
C57BL mice. The cell line was a kind gift from Dr. Cheng Qian. The cell line forms aggressive 
tumors in C57BL mice (LLC tumor model). The LLC tumor model was used for determining the 
anti-cancer properties of the generated HC-Ad vectors. The cell line was cultured in MEM/10% 
FCS/1x penicillin-streptomycin. The cell line was passaged 1:4 twice every week. 
 
MC-38: The colon carcinoma cell line was derived from a colon carcinoma of C57BL mice. The 
cell line was a kind gift from Dr. Cheng Qian. The MC-38 cell line forms aggressive subcutaneous 
tumors or colonic tumor, which is metastatic to liver in C57BL mice. The cell line was cultured in 
MEM/10% FCS/1x penicillin-streptomycin. The cell line was passaged 1:4 twice every week. 
 
N52E6: The cell line is based on human amniocytes [122]. The cell line was stably transformed 
with the E1 function of Ad type 5. The cell line was used for the production of helper virus. The 
cell was a kind gift of our colleague Dr. Gudrun Schiedner. The cell line was cultured in MEM/10 
% FCS/1x penicillin-streptomycin. The cell line was passaged 1:5 once every week. 
 
III.4.2 Freezing of eukaryotic cells 
 
For freezing, early passages of cells were used. The cells were washed twice with PBS and were 
detached using trypsin-EDTA solution. The cells were pelleted and resuspended using freezing 
mix. The freezing mix was aliquoted in 2 ml cryotubes (Nunc, Germany). The cryotubes were 
placed at RT for 15 minutes and were placed in an isopropanol bath, which was frozen at –80ο C 
for overnight. The cryotubes were then placed in a liquid nitrogen container until further use. The 
freezing mix used was 90% FCS, 10% DMSO (Sigma-Aldrich, Germany). 
 
III.4.3 Transfection of eukaryotic cells 
 
The transfection of eukaryotic cells was performed using Fugene transfection reagent (Roche, 
Germany) as described by manufacturer. The cell lines were plated at a density of 50 to 80% 
confluency for 24 hours before transfection. The DNA used for transfection was purified using 
phenol-chloroform extraction method (Chapter III.3.4). For transfecting cells in 6 well plates, 1.5 
µg of DNA was added to transfection solution containing 6 µl of Fugene reagent diluted in 100 µl 
of serum free medium. The transfection solution was incubated at RT for 15 minutes for complex 
formation. The transfection solution was added dropwise to the cells and was swirled to equally 
distribute the DNA complex. The volume of the culture supernatant was increased to 1 ml. The 
medium containing the expressed proteins was collected at 48 hours post transfection.  
 
III.4.4 Matrigel assay 
 
A Matrigel assay was performed to determine the biological activity of sflt1 and stie2. It is a semi-
quantitative assay based on the principle that tube like structures formed on a matrigel by HUVECs 
can be inhibited by anti-angiogenic agents. To perform the assay, the matrigel was thawed 
overnight in ice at 4°C. Culture plate and pipettes were placed at –80οC for four hours before 
usage. The thawed matrigel was coated on cell culture plates and the matrigel was allowed to gel at 
37οC for 1 hour. Early passage HUVECs were mixed with control medium or medium containing 
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the anti-angiogenic principle and were plated on the matrigel for 9 hours. The formation of tubes 
was visualized under a microscope and the number of branch points was counted visually. 
 
III.4.5 Proliferation assay for determination of sflt1 activity 
 
The assay was performed to confirm the biological activity of sflt1 expressed from the vectors Ad 
RS 23 and Ad RS 44. The assay was performed in two steps. In the first step, the sflt1 containing 
supernatant was obtained by infecting HepG2 cells with the vector Ad RS 23 or Ad RS 44 at a moi 
of 100. A control supernatant was obtained by infecting the HepG2 cells with the vector Ad SLS 
14. The levels of sflt1 were estimated by ELISA and were then diluted to a concentration of 100 
ng/ml before the supernatants were used in the experiment. In the second step, the serum-starved 
HUVECs (2% FCS) were stimulated to proliferate by addition of VEGF at a concentration of 10 
ng/ml. The stimulated HUVECs were incubated for further 48 hours with the supernatant from the 
HepG2 cells that had been transduced with the vectors HC-Ad RS 23, HC-Ad RS 44 and HC-Ad 
SLS 14. The serum-starved HUVECs, which had not been stimulated with VEGF, acted as a 
control for VEGF- mediated proliferation. Recombinant sflt1 at concentration of 100 ng/ml was the 
positive control for assaying the inhibition of VEGF mediated proliferation. The extent of 
proliferation was estimated using the WST-1 reagent (Roche, Germany), which measures the 
mitochondrial dehydrogenase enzyme. 
 
III.4.6 Preparation of RU 486 for cell culture  
 
For use in cell culture, a 1mM stock solution of RU 486 (Invitrogen, Germany) was prepared by 
dissolving 4 mg of RU 486 in 9.3 ml of 100% ethanol. The stock solution was stored at –20°C. A 
10 µM working solution of RU 486 was prepared by diluting 100 µl of the RU 486 stock solution 
in 10 ml of 100% ethanol.  
 
III.5 Adenovirus methods 
 
III.5.1 Isolation of plaques 
 
N52E6 or 293 cells were plated at 60-70% confluency in a 6 well plate. 24 hours after seeding, the 
cells were either transfected with a plasmid used for the generation of first generation vector or 
infected with the first generation vector. After 16 hours, the transfected or infected cells were 
overlaid with agarose overlay medium (Chapter III.1) and were incubated at 37ºC in a cell 
incubator containing 5% CO2 for a maximum period of two weeks. The cells were observed for 
two weeks under a light microscope for focal areas of lysed cells called plaques. Individual plaques 
representing single rescue events of vector were picked using sterile Pasteur pipettes. The plaques 
were re-suspended in 1 ml of TBS and were frozen at –80οC. 
 
III.5.2 Generation of high capacity adenoviral (HC-Ad) vectors 
 
Cre 66 cells were used for the generation of HC-Ad vectors. The plasmid used for the generation of 
the HC-Ad vector was digested with Pme I to release the ITRs. For the first amplification, the 
Cre66 cells (2x106 cells in a 6 cm plates) were transfected with the plasmid using effectene reagent 
(Qiagen, Germany). 16 hours after transfection, the cells were infected with 5 moi of helper virus. 
The infected cells showing a CPE at 48 hours were harvested. The harvested Cre 66 cells were re-
suspended in 2 ml of TBS followed by three times freeze thawing to release the vector particles. 
During the second and the third amplification, Cre 66 cells (3x106 cells in 6 cm plate) were 
infected with half the supernatant from the cell lysate of the earlier amplification, and 5 moi of 
helper virus. During the fourth and fifth amplifications, Cre 66 cells, plated at a density of 3x107 
cells in 15 cm plates were infected with half the supernatant (from the cell lysate of the earlier 
amplifications) and 5 moi of helper virus. For a large-scale preparation, 293 Cre 66 (ten 15 cm 
plates having a cell density of 3x107) were infected with the supernatant (containing the vector) 
from the fifth amplification or 10 moi of HC-Ad vector (if the titer had previously been 
determined) and 5 moi of helper virus. The infected cells were harvested at 48 hours and were re-
suspended in TBS containing glycerol. 
 
III.5.3 Purification of adenoviral vectors using CsCl density gradient 
ultracentrifugation 
 
The re-suspended cells were freeze thawed for vector release. The vector containing supernatant 
was collected by centrifugation at 200g to remove the cell debris. The supernatant was made up to 
a volume of 20 ml and CsCl was added at a concentration of 0.5 gm/ml. The virus was centrifuged 
twice at 32,000 RPM at 4ºC for 22 hours in an ultracentrifuge (Ultracentrifuge L7-65 with SW41- 
Rotor, Beckman, USA). The adenoviral vector floats as a band in the CsCl gradient at a density of 
1.34gm/cm3. The virus was aspirated using a 2 ml syringe fitted to a needle. After the second 
gradient, the virus was desalted in PD 10 columns using TBS buffer. Glycerol was added to the 
eluted vector at a concentration of 10%. The virus was stored at -80ºC. 
 
III.5.4 Titration of helper virus or first generation adenoviral vectors 
 
N52E6 cells were used for determining the titer of first generation vectors and helper virus vectors.  
The cells were plated at a density of 2x106 in 6 cm plates. The plated cells were infected with 
different dilutions of the vector. 16 hours after infection the cells were overlaid with 10 ml of 
agarose overlay medium for 15 minutes at room temperature. The cells were incubated at 37ºC in 
cell incubator containing 5% CO2 for 5-14 days. The plates were observed with a light microscope 
for the appearance of plaques. The average number of plaques at a given dilution represents the 
plaque forming units (pfu) of the virus. 
 
III.5.5 Titration of HC-Ad vectors using slot blot analysis 
 
The slot blot method was used to determine the infectious units, total particle, and the helper virus 
contamination titers. A549 cells were used for the determination of infectious units of the HC-Ad 
vectors. The A549 cells were plated for overnight, at a density of 1x105 cells, in a 24 well plate 
before infection with HC-Ad vector. HC-Ad vectors were diluted 1:20 in TBS, and 4 to 20 µl of 
the diluted HC-Ad vector was used to infect A549 cells in duplicates. 16 hours after infection, the 
A549 cells were washed intensively with PBS and were incubated with 200 µl of PBS/5mM EDTA 
for 15 minutes to detach the cells from the plate. The detached cells were incubated with 200 µl of 
0.8 N NaOH for 30 minutes to lyse the cells. The plasmid pGS 46, added to uninfected A549 cells 
at copy numbers ranging from 1x106 to 1x108, acted as the standard. 
The total particle titer of HC-Ad vectors was determined using a cell free system. The HC-Ad 
vector was diluted 1: 400 in TBS buffer. Four to 20 µl of the diluted HC-Ad vector was made up to 
a volume of 200 µl of TBS and was lysed with 200 µl of 0.8 N NaOH for 30 minutes at room 
temperature. The plasmid pGS 46 was used as the standard and was diluted in TBS (to a volume of 
200 µl) to represent copy numbers ranging from 1x106 to 1x108. The diluted standards were mixed 
with 200 µl of 0.8 N NaOH and were incubated for 30 minutes at room temperature.  
The helper virus contamination was determined using a cell free system. The HC-Ad vector was 
diluted 1: 200 in TBS. Four - 20 µl of the diluted virus was made up to a volume of 200 µl of TBS 
and was lysed with 200 µl of 0.8 NaOH for 30 minutes at room temperature. The plasmid pGS 46 
was used as the standard and was diluted in TBS (to a volume of 200 µl) to represent copy 
numbers ranging from 1x106 to 1x108. The diluted standards were mixed with 200 µl of 0.8 N 
NaOH and were incubated for 30 minutes at room temperature. 
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300 µl of cell or particle lysate was transferred to a Bio Dyne nylon membrane, (PALL 
corporation, USA) using a slot blot apparatus (Hoefer PR 648, Bio-Rad laboratories, Germany). 
After transfer, the membrane was washed with 2x SSC buffer followed by backing at 120ºC for 30 
minutes. The baked membrane was pre-hybridized with hybridization buffer for 4 hours at 68ºC. 
The probe used for the determination of infectious units and total particle binds to the left ITR of 
the adenovirus (nucleotide 1- 438). The probe used for the determination of the helper viral particle 
binds to the fiber (nucleotide 31042 to 32390) The PCR probe was radioactively labeled with 50 
µCi 32[P] dCTP (Amersham Pharmacia, Germany) using a DNA Labeling Kit (Amersham 
Pharmacia, Germany). The membrane was hybridized using the radioactive probe for 16 hours at 
68ºC. The membrane was washed at 68ºC with buffer containing 2 x SSC/0.1 % SDS for 15 
minutes followed by a second wash with buffer containing 0.1% SSC / 0.1% SDS for 20 minutes. 
The membrane was transferred to a phosho-imager cassette and the signal was read using Phospho 
imager 445SSI (Molecular Dynamics, USA). The titer of the HC-Ad vector was estimated by 
comparing the signal intensity between the HC-Ad vector and the plasmid standards.  
 
III.5.6 Storage of adenovirus 
 
Adenovirus desalted after double cesium chloride centrifugation with a PD 10 column was eluted 
in TBS and was mixed with 10% glycerol. The virus was stored at –80ºC until further use.  
 
III.6 Biochemical methods 
 
III.6.1 SDS-Polyacrylamide gel electrophoresis (PAGE) 
 
The supernatant, obtained by infecting the cells with viral vector was diluted in 4x Laemmli buffer 
in a total volume of 40 µl and was boiled in a water bath at 95ºC for 5 minutes. The proteins were 
separated using a discontinuous buffer system. The proteins were initially run in a stacking gel 
(5%, pH 6.8) and were separated in a running gel (6 or 8% gel, pH 8.8) at 100V for 2 hours. A 
molecular weight marker (Rainbow marker, BioRad, Germany) was used as a standard.  
 
III.6.2 Western blot analysis 
 
The proteins were initially separated using a discontinuous PAGE. The separated proteins were 
transferred to a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia, Germany) in a 
western blot apparatus (BioRad, Germany). The proteins were transferred to a nitrocellulose 
membrane for 1 hour using 100 V in a cold room (temperature maintained at 4ºC). The 
nitrocellulose membrane was blocked overnight using TBS containing 5% milk powder in a cold 
room with shaking. The blocked membrane was incubated successively with the primary antibody, 
secondary antibody and detection antibody (having a tagged peroxidase enzyme) for 1 hour at 
room temperature respectively. After each incubation step, the membrane was washed thrice with 
TBST for 15 minutes. The final wash of the membrane was extended for further 15 minutes. The 
membrane was finally incubated with 3 ml of peroxidase substrate solution (ECL detection kit, 
Amersham Pharmacia, Germany) for one minute. The bands were visualized using a 
chemiluminescence sensitive film (Biomax ML, Kodak, Germany). 
 
III.6.3 Biochemical analysis of serum parameters 
 
Determination of concentrations of urea, total protein, albumin, creatinine, SGOT, SGPT in serum 
of mice was performed using Hitachi Auto analyzer. (Roche/Hitachi 904/911: ACN 166). 
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III.6.4 Enzyme linked immunosorbent assay (ELISA) for determination of sflt1, 
stie2, hIL-12 and mIL-12  
 
A sandwich ELISA technique was used for detecting hIL-12, mIL-12, sflt1 and tie2 proteins 
present in the cell supernatant or in serum of mice. Kits were used for the detection of sflt1 (Bender 
MedSystems, Austria), mIL-12 (Pharmingen, Germany) and hIL-12 (Pharmingen, Germany). The 
protocol described by the manufacturer was followed. 
 
Detection of hIL-12 by ELISA 
 
Rat monoclonal antibody specific for the human IL-12 p75 heterodimer from p35 and p40 subunits 
was coated on a 96 well plate (Nunc Maxisorp) for overnight at 4ºC using PBS. The plate was 
blocked for 1 hour at room temperature using 10% FCS in PBS for 1 hour. The test fluid or 
standards containing hIL-12 were incubated for 1 hour. The plates were washed five times using 
TBST buffer (Chapter III.1.3). The captured hIL-12 was detected using working detector 
(conjugated detection antibody consisting of avidin and horse radish peroxidase). The plate was 
washed seven times and was developed using substrate solution for ELISA (Chapter III.1.3). The 
plates were read at 450 nm. The ELISA kit was purchased from Pharmingen, Germany.  
 
Detection of mIL-12 by ELISA 
 
Rat monoclonal antibody specific for the murine IL-12 p75 heterodimer from p35 and dp40 
subunits was coated on a 96 well plate (Nunc Maxisorp) for overnight at 4ºC using PBS. The plate 
was blocked for 1 hour at room temperature using 10% FCS in PBS for 1 hour. The test fluid or 
standards containing hIL-12 were incubated for 1 hour. The plates were washed five times using 
TBST buffer (Chapter III.1.3). The captured mhIL-12 was detected using working detector 
(conjugated detection antibody consisting of avidin and horse radish peroxidase). The plate was 
washed seven times and was developed using substrate solution for ELISA (Chapter III.1.3). The 
plates were read at 450 nm. The ELISA kit was purchased from Pharmingen, Germany.  
 
Detection of sflt1 by ELISA 
 
Rat monoclonal antibody specific for human sflt1 was coated on a 96 well plate (Nunc Maxisorp) 
for overnight at 4ºC using PBS. The adsorbed plate was blocked for 1 hour at room temperature 
using blocking buffer (Bender med systems). The test fluid or standards containing hIL-12 and 
biotin conjugate were incubated for 1 hour. The plates were washed five times using TBST buffer 
(Chapter III.1). The captured sflt1 was detected using avidin-horse radish peroxidase. The plate 
was washed five times and was developed using substrate solution for ELISA (Chapter III.1.3). 
The ELISA kit was purchased from Bender Med Systems, Austria. 
 
Detection of stie2 by ELISA 
 
An ELISA for detection of stie2 protein was established. A rat monoclonal antibody specific to 
stie2 was used as a coating antibody (a kind gift from Dr. Urban Deutsch). The stie2 protein was 
purchased from R&D Systems, Germany. 5% albumin solution was used for blocking after 
overnight coating. As secondary antibody a mouse monoclonal antibody was used, specific to 
murine tie2 (Upstate, USA). Protein A-peroxidase conjugate (Sigma, Germany) was used as the 
detection antibody. The plates were developed using substrate solution (Chapter III.1.3). 
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III.7 Animal handling techniques  
 
Female C57BL/6J (5-8 week old) mice were used in all the experiments. The animals were 
supplied by Harlan (Spain). The animals were maintained under pathogen free conditions at the 
animal facility of the University of Navarra. The mice were fed with standard diet (B&K universal) 
and sterilized water. All mice were cared for in compliance with the guidance prescribed by the 
University of Navarra.  
 
III.7.1 Collection of blood from mice 
 
Blood was collected by puncturing the retro-orbital plexus. The collected blood was centrifuged 
twice at 14,000 RPM for 8 minutes to separate serum. The serum was stored at -20ºC. 
 
III.7.2 Preparation of RU 486 for mouse studies 
 
For use in mice, a stock solution of RU 486 (Sigma, Germany) was prepared by dissolving 9 mg 
RU 486 in 18 ml of sesame oil (Sigma, Germany). Mice were injected intraperitonealy with 
RU 486 with a dose of 250 µg/kg of body weight in a total volume of 50 µl. 
 
III.7.3 Injection of clodronate liposomes 
 
Clodronate was a kind gift of Dr. Nico van Rooijen. Injection of clodronate liposomes through the 
tail vein of mice was done to deplete the Kupffer cells in the liver. Transient Depletion of Kupffer 
cells prior to Ad vector administration has been shown to increase and stabilize the transgene 
expression in mice [123-125]. It was suggested that improved expression kinetics upon Kupffer 
cell depletion was attributed to reduced humoral response to the transgenic protein [125].  
Clodronate liposomes were injected at a dose of 20 µl/10 gm bodyweight in a total volume of 200 
µl of PBS. The injection was performed 24 hours prior to the injection of the HC-Ad vectors. In 
this study, unless otherwise stated, Kupffer cells were depleted prior to the injection of sflt1 or 
stie2 expressing vectors. Kupffer cell depletion did not alter the tumor growth or survival time in 
both orthotopic MC-38 and heterotopic LLC mice model of cancer (not shown). 
 
. 
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III.7.4 LLC heterotopic cancer model 
 
C57BL/6J mice were injected first with vector by tail vein injection. In order to increase the 
efficiency of liver transduction, Kupffer cells were depleted by injecting clodronate liposomes 24 
hours prior to vector injection (Chapter III.7.3). One week after injection of the vector, the mice 
were injected with 106 LLC cells subcutaneously. The sizes of the tumors and the levels of 
transgene expression were ascertained at weekly intervals. The volume of the tumor was calculated 
using the formula V= D x d2/2, where V is the volume of the tumor, D is the larger diameter of the 
tumor and d is the smaller diameter of the tumor. The animals were sacrificed when any of the 
diameters (major or minor) of the tumor exceeded 1.5 cm (800-1000 mm3) or when the mouse 
 
became moribund. 
igure III.18: LLC heterotopic cancer model. The scheme displays the design of the LLC heterotopic cancer model. 
Scheme for LLC subcutaneous model
Day 1 
Day 2 
Day 9 
Day 16 
Day 23 
Day 30 
Day 37 
Injection of clodronate
Injection of the vector 
Injection of LLC cells
  Ist Measurement of tumor size + ELISA+ start of 
induction with RU 486* 
 IInd  Measurement of tumor size + ELISA
  
IVth Measurement of tumor size + ELISA
 
 IIIrd  Measurement of tumor size + ELISA
  
* Induction only for Ad RS 23 and Ad RS 25
F
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III.7.5 MC-38 orthotopic cancer model 
 
C57BL/6 mice were injected first with the vector by tail vein injection. Seven days after injection 
of the vector, the mice were implanted with 5x105 MC-38 cells into the liver by laparotomy 
(Figure III.20). Five days after the implantation of the MC-38 cells, the initial size of the tumor 
was ascertained by laparotomy (Figure III.21 B). The animals were induced with RU 486 at a dose 
of 250 µg/kg for 10 days. Five days after the end of induction, the size of the tumor was 
determined by laparotomy. Serum was collected once during the 10-days induction period for 
estimating the levels of transgene expression. After the second laparotomy, mice either were 
induced or were left uninduced with RU 486. In mice not responding to the treatment, the tumor 
spreads and metastasizes to the peritoneum (Figure III.21 C). The volume of the tumor was 
calculated using the formula V= Dx d2/2, where V is the volume of the tumor, D is the larger 
diameter of the tumor and d is the smaller diameter of the tumor. In animals injected with the 
vectors expressing sflt1, clodronate liposomes were injected 24 hours prior to the administration of 
the vector. 
 
Scheme for MC-38 tumor model 
Injection of clodronate Day 0 
Injection of the Vector 
Day 1 
Injection of MC-38 cells 
Day 8 
  Ist Measurement of tumor size + start of Induction 
with RU 486* Day 13 
 E
 
LISA 
Day 15 
IInd Measurement of tumor size  
  
Day 28 
Measure Survival rate of animals 
  
Day 35 
*Induction only for Ad RS 23 and Ad RS 25 
 
 
Figure III.19: MC-38 orthotopic cancer model. The scheme displays the design of MC-38 heterotopic cancer model. 
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A B 
c 
Figure III.20: Picture A shows the liver exposed for injection of MC-38 cells. Figure B shows the injection of MC-38 
cells directly into the liver. Figure C shows the completion of laparotomy. 
 
 
      
Figure III.21: Figure A shows the liver 
development of tumor five days after th
prominent MC-38 tumor. 
 Aof the animal before the injection o
e injection of MC-38 cells. Figure
53BC 
f the MC-38 cells. Figure B shows the 
 C shows the liver of a mouse with a 
 54
 
III.8 Statistical analysis 
 
When indicated, the statistical differences were calculated by using a nonparametric test (Mann-
Whitney U test, 2-tailed) for unpaired samples. P values smaller than 0.05 were considered 
significant.   
 
III.9 Summary of the generated HC-Ad vectors 
 
All HC-Ad vectors contain the left terminus of Ad5 (nucleotides 1 to 440; ITR), the right terminus 
(nucleotides 35818 to 35935; ITR), and the packaging signal from Ad5 (Ψ). pSTK 129 is a shuttle 
plasmid that can be used to generate high-capacity adenoviral vectors. pSTK 129 consists of the 
left terminus of the adenovirus type 5 (nucleotide [nt] 1-440), and the right terminus of adenovirus 
type 5 (nt 35818-35935) a 20-kb DNA fragment derived from the human HPRT locus 18 
HUMHPRTB (gene map positions, 1777-21729), a 6.5-kb human fragment of C346 (locus, 
HUMDXS455A; cosmid map positions, 10205-16750). pSTK 119 is a shuttle plasmid that can be 
used to generate high-capacity adenoviral vectors. pSTK 119 consists of the left terminus of the 
adenovirus type 5 (nucleotide [nt] 1-440), and the right terminus of adenovirus type 5 (nt 35818-
35935) a 16-kb DNA fragment derived from the human HPRT locus 18 HUMHPRTB (gene map 
positions, 1777-17777), a 6.5-kb human fragment of C346 (locus, HUMDXS455A; cosmid map 
positions, 10205-16750). The HC-Ad vectors generated during this study and the transgenes 
expressed by the vectors are shown in the Table 1. 
 
Table 1: HC-Ad vectors generated during the work. The HC-Ad vectors, the expressed transgene, and the shuttle 
plasmid are shown above. 
 
 
Name of the HC-Ad 
vector 
Name of the expressed 
transgene 
Mode of expression Based on 
plasmid  
Ad RS 23 sflt1 Inducible pSTK 119 
Ad RS 24 hIL-12 Inducible pSTK 119 
Ad RS 25 mIL-12 Inducible pSTK 119 
Ad RS 44 sflt1 Constitutive pSTK 129 
Ad RS 44 stie2 Constitutive pSTK 129 
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IV Results 
 
IV.1 Construction and characterization of hIL-12 expressing 
plasmids and vector  
 
IV.1.1 Construction of pRS 21, pRS 24 and Ad RS 24  
 
In certain human tumors hIL-12 has anti-metastatic effects [48, 81]. However, serious side effects 
have been regularly observed, when hIL-12 was given systematically. Therefore, we aimed to 
establish a system that enabled tissue specific and controlled release of hIL-12 following gene 
transfer. Since hIL-12 is inactive and nontoxic in mice, we used this human version of IL-12 as a 
reporter to study the in vivo pharmacokinetics of the RU 486 gene switch system.  
To obtain inducible liver specific transgene expression, a primary plasmid pRS 17 based on Gene 
Switch was constructed (Figure III.4). Subsequently, hIL-12 cDNA was inserted into pRS 17 to 
generate reporter plasmid pRS 21 (Figure III.6). After confirming the integrity of pRS 21, it was 
used to construct pRS 24. pRS 24 was used to generate the HC-Ad vector Ad RS 24. Ad RS 24 
consists of two expression cassettes (Figure IV.1). The first cassette consists of hIL-12 placed 
downstream of the GAL4 E1b TATA region and upstream of BGHpA. The second cassette consist 
of GLp65 placed downstream of the liver specific promoter TTRB and upstream of SV40pA. Ad 
RS 24 apart from the ITRs has two stuffer regions namely C346 and HPRT. 
 
Figure IV.1: The vector Ad RS 24. Ad RS 24 expresses hIL-12 upon induction with RU 486 in a liver specific 
manner. The vector contains two expression cassettes. The first cassette expresses the regulator GLp65 under the 
control of the liver specific TTRB promoter and enhancer. GLp65 in the presence of RU 486 binds to the GAL4 region 
present in the second expression cassette and hIL-12 is transcribed. Ad RS 24 contains the left terminus, the right 
terminus of Ad5 and the packaging signal Ψ. In addition Ad RS 24 also contain C346 and HPRT stuffer sequences. 
 
IV.1.2 hIL-12 is inducibly expressed upon transfection of pRS 21 in vitro  
 
To investigate the liver specific regulable expression of hIL-12, pRS 21 was transfected into 
HepG2, PLC/PRF/5 and HeLa cell lines using Fugene reagent (Chapter III.4.3). The cell lines were 
seeded at a density of 3x105 in six well plates and were cultured for 24 hours before transfection. 
pCMV hIL-12 expressing hIL-12 constitutively served as a control. 24 hours later, the cells 
transfected with pRS 21 were induced with 10-8 M of RU 486 or were left uninduced (Chapter 
III.4.6). The supernatants were collected at 48 hours post induction and were analyzed for the 
expression of hIL-12 using ELISA (Chapter III.6.4). As shown in Figure IV.2 high levels of hIL-
12 expression and induction in hepatic cell lines were observed, when compared with the non-
hepatic cell line HeLa. Having confirmed the functional integrity of the plasmid pRS 21, the two 
expression cassettes were sub-cloned into the plasmid pSTK 119 to generate the plasmid pRS 24 
(Figure III.9).  
  
ITR Ψ GAL4 hIL- 12 BGHpA         TTRB GLp65 SV40pA              ITR
C346                                    HPRT   
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Figure IV.2: Inducible expression of hIL-12 from pRS 21 in vitro. 3x105 cells of PLC/PRF/5, HeLa and of HepG2 
were cultured in 6 well plates for 24 hours before transfection. Transfection of cell lines with pRS 21 was performed 
using Fugene reagent. 24 hours later, the pRS 21 transfected cells were induced with 10-8 M of RU 486 or were left 
uninduced. pCMVhIL-12 expressing hIL-12 constitutively served as a control. The supernatants were collected 48 
hours later, and the levels of hIL-12 were determined using ELISA. The legend - RU 486 and + RU 486 indicates the 
absence and presence of the drug RU 486. The legend CMV hIL-12 represents the plasmid expressing hIL-12 under 
the control of the hCMV promoter.  
 
IV.1.3 hIL-12 is inducibly expressed upon infection of liver cell lines with Ad RS 
24 in vitro  
 
Ad RS 24 was tested for the expression of hIL-12 in vitro before being used in vivo. To test for 
dose dependent and liver specific expression of hIL-12, Ad RS 24 was tested on the cell lines 
HepG2, PLC/PRF/5, A549, and HeLa (Chapter III.4.1). The cells were seeded at densities of 5x 
105 in six well plates and were cultured for 24 hours before infection. The cells were infected with 
Ad RS 24 at a moi of 100 and were either induced or left uninduced with 10-8 M of RU 486 at 3 
hours post infection. The first generation adenoviral vector Ad CMV hIL-12 expressing hIL-12 
under the control of the hCMV promoter served as a control. The amount of hIL-12 present in the 
supernatants was determined using ELISA (Chapter III.6.4). As shown in Figure IV.3, HepG2 cells 
and PLC/PRF/5 cells in the presence of RU 486 expressed hIL-12 after transduction with 100 moi 
of Ad RS 24. The levels of hIL-12 were low or undetectable in the absence of RU 486. 
Interestingly, the levels of hIL-12 secreted by HepG2 cells upon infection with Ad RS 24 and 
induction with RU 486 were comparable to the expression levels obtained after transduction with  
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Figure IV.3: Inducible expression of hIL-12 from Ad RS 24 in vitro. 5x105 cells of PLC/PRF/5, A549, HeLa and 
HepG2 cells were seeded in 6 well plates. 24 hours later, the cells were infected with Ad RS 24 or Ad CMV hIL-12 at 
mois of 100. 3 hours after infection, Ad RS 24 infected cells were either induced with 10-8 of RU 486 or were left 
uninduced. The cell supernatants were collected after 48 hours and were assayed for hIL-12 expression. The legend -
RU 486 and +RU 486 indicates the absence or presence of RU 486. The legend Ad CMV hIL-12 represents the virus 
Ad CMV hIL-12 expressing hIL-12 under the control of the hCMV promoter.  
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Ad CMV hIL-12. HeLa cells and A549 cells expressed low or undetectable levels of hIL-12 upon 
induction. In conclusion, inducible and liver cell specific hIL-12 expression from the vector Ad RS 
24 was observed in cell lines HepG2 and PLC/PRF/5. In addition, the levels of hIL-12 were 
minimal or below the detection limit in the absence of RU 486. 
 
IV.1.4 RU 486 induces hIL-12 expression in a dose dependent manner in vitro  
 
Ad RS 24 expresses hIL-12 upon induction with RU 486 in a liver cell specific manner (Figure 
IV.3). To determine the effect of increasing concentrations of RU 486 on hIL-12 expression, 
HepG2 cells were infected with 100 moi of Ad RS 24 and were induced with increasing 
concentrations of RU 486. The supernatants from the infected HepG2 cells were collected at 48 
hours post induction and the levels of hIL-12 were determined using ELISA. As shown in Figure 
IV.4, a RU 486 dose dependent (10–10 mol/L to 10–7 mol/L) increase in the expression of hIL-12 
was observed. This experiment clearly demonstrates that varying the dosages of RU 486 can 
modulate the levels of hIL-12 expression in vitro. 
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Figure IV.4: RU 486 dose dependent expression of hIL-12 in vitro. 1x105 cells of HepG2 cells were cultured in 24 
well plates for 24 hours before infection. The HepG2 cells were infected with Ad RS 24 at a moi of 100 with Ad RS 
24. 3 hours post infection, RU 486 was added to the culture medium at different concentrations. The supernatants were 
collected at 48 hours post induction and were assayed for the expression of hIL-12 by ELISA.  
 
IV.1.5 hIL-12 is inducibly expressed upon injection with Ad RS 24 in vivo  
 
The vector Ad RS 24 expresses hIL-12 upon induction with RU 486 in a liver specific manner in 
vitro (Chapter IV.1.3). To characterize the kinetics of hIL-12 expression in vivo, C57BL/6J mice 
were injected into the tail vein with the vector Ad RS 24 at a dose of 3x109 i.u (n=8). Two weeks 
post injection, hIL-12 expression was induced by a single intra-peritoneal injection of RU 486 
(Chapter III.7.2) in Ad RS 24 injected mice (n=5). The control mice (n=3) were injected with 
sesame oil not containing RU 486. Blood samples were collected at 4, 10, 24 and 48 hours post 
induction for the determination of serum hIL-12. As shown in Figure IV.5, in the absence of 
RU 486, hIL-12 expression was not detected in the serum. Measurable expression of hIL-12 was 
observed at 4 hours post induction. High levels of hIL-12 expression were observed at 10 hours 
post induction. The expression of hIL-12 decreased sharply at 24 hours and dropped below the 
detection limit at 48 hours. This experiment demonstrated that inducible expression of hIL-12 from 
Ad RS 24 was achieved with administration of RU 486 in vivo.  
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Figure IV.5: Inducible expression of hIL-12 from Ad RS 24 in vivo. C57BL/6 mice were injected with Ad RS 24 at a 
dose of 3x109 i.u and were induced once with RU 486 at a dose of 250 µg/kg. Serum was taken at regular intervals. + 
and - RU 486 indicates presence or absence of drug . 
0
2000
4000
6000
0 4 10 24 48 72 120
Hours
hI
L-
12
 le
ve
l (
pg
/m
l)
 -RU486  +RU486
 
IV.1.6 RU 486 and Ad RS 24 increases hIL-12 expression in a dose dependent 
manner 
 
Modulation of hIL-12 expression in vivo is important to obtain hIL-12 levels within the therapeutic 
window. Increasing the dosages of RU 486 in vitro could modulate the levels of hIL-12 (Figure 
IV.4). To investigate the dose dependence of hIL-12 expression on RU 486 in vivo, C57BL/6J 
mice were injected with Ad RS 24 at doses of 1x109 i.u (n=4) or 3x109 i.u (n=4). Two weeks post 
injection, RU 486 was injected at 125, 250 and 500 µg per kg body weight. Ten hours after 
induction, serum was collected and hIL-12 was measured. As shown in Figure IV.6, a RU 486 dose 
dependent increase in the levels of hIL-12 was observed. In addition, mice injected with the vector 
Ad RS 24 at the higher dose of 3x109 i.u showed RU 486 dose dependent increase of hIL-12. This 
experiment demonstrated that increasing the doses of both vector and RU 486 increased the levels 
of hIL-12 expression in vivo.  
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Figure IV. 6: Modulation of hIL-12 expression by Ad RS 24 and RU 486 doses in vivo. C57BL/6J mice (n=4) were 
injected with  Ad RS 24 at a dose of 1x109 i.u and 3x109 i.u represented by Figure A and Figure B respectively. The 
mice were injected with increasing doses of RU 486 and the levels of hIL-12 expression were determined by ELISA. 
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IV.1.7 hIL-12 expression kinetics is dependent on intervals of RU 486 injection 
in vivo  
 
For clinical application and in order to avoid toxic and potential lethal effects, it would be 
important to control IL-12 levels both qualitatively and quantitatively. The vector Ad RS 24 
expresses hIL-12 only upon induction (Figure IV.5). To determine the optimal time intervals of RU 
486 injection for maintaining a sustained level of hIL-12, C57BL/6J mice (n=8) were injected with 
Ad RS 24 at a dose of 3x109 i.u followed by induction (n=5) with RU 486 for six days either 12, 24 
or 48 hour time interval respectively. Control mice were injected with sesame oil not containing 
RU 486. 
 
Induction by injection of RU 486 every 12 hours  
 
In week 9 post vector injection, RU 486 was given for six days every 12 hours. Serum was 
collected every 24 hours and 10 hours after the last induction. As shown in Fig IV.7, the levels of 
hIL-12 values were between 5000-7000 pg/ml in the first two days of induction and were at around 
3000 pg/ml during the remaining four days. The levels of hIL-12 in the controls were below the 
Figure IV.7: Induc
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vector Ad RS 24 at a dose of 3x109 i.u were injected (n=5) with RU 486 at time interval of 12 hours, for six days. The 
control mice (n=3) were injected with sesame oil. The serum was analyzed daily for levels of hIL-12. +RU 486 and –
RU 486 indicates the presence and absence of RU 486 induction. 
 
I
 
In
by injection every 48 hours for six days. Serum was collected every 24 hours and 10 hours after the 
last induction. As shown in Figure IV.8, the hIL-12 levels showed a saw like pattern with peak 
levels of hIL-12 of about 6000 pg/ml on the day of induction alternating with 6-8 fold lower values 
on the following day. The levels of hIL-12 in the controls were below the detection limit. 
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Figure IV.8: Inducible expression of hIL-12 by injection of RU 486 every 48 hours. C57BL/6J mice (n=8) injected 
with the vector Ad RS 24 at a dose of 3x109 i.u were injected (n=5) with RU 486 at time intervals of 48 hours, for six 
days. The control mice were injected with sesame oil. The serum was analyzed daily for levels of hIL-12. +RU 486 
and –RU 486 in the legend indicates the presence and absence of induction with RU 486. 
 
Induction by injection of RU 486 every 24 hours 
 
At week 14 post vector injection, the same group of mice was injected again with RU 486, now at 
time intervals of 24 hours for a period of 6 days. As shows in Figure IV.9, the levels of hIL-12 
were 5000-6000 pg/ml for the first two days and followed by a relatively sustained level of 
approximately 3000 pg/ml for the remaining four days. Together these experiments indicated that 
hIL-12 expression could be sustained in mice by injecting RU 486 every 12 or 24 hours. Treatment 
for cancer varies depending on the type of tumor and sometimes prolonged expression of hIL-12 
might be necessary. To investigate whether it was possible to sustain hIL-12 expression by 
repeated induction for a longer period of time Ad RS 24 injected C57BL/6J mice (n=4) were 
induced with the drug RU 486 every 24 hours for 21 days. Control mice (n=3) were injected with 
sesame oil without RU 486. As shown in Figure IV.10, the serum level of hIL-12 was kept 
constant at around 3000 pg/ml until the 9th day of induction and decreased moderately thereafter 
but was still above 1500 pg/ml on day 21. Thus, this experiment demonstrated that it was possible 
to sustain hIL-12 expression by repeated induction every 24 hours. 
 
Figure IV.9: Inducible expression of hIL-12 by induction with RU 486 every 24 hours. C57BL/6J mice (n=8) were 
injected with Ad RS 24 at a dose of 3x109 i.u followed by induction with RU 486 (n=5) at time intervals of 24 hours 
for six days. +RU 486 and –RU 486 in the legend indicates the presence and absence of induction with RU 486. 
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Figure IV.10: Inducible expression of hIL-12 for 21 days. C57BL/6J mice were injected with Ad RS 24 at a dose of 
3x109 i.u followed by daily induction with RU 486 for 21 days. Serum was collected at 10 hours post induction and the 
levels of hIL-12 were measured by ELISA. +RU 486 and –RU 486 in the legend indicates the presence and absence of 
induction with RU 486. 
 
IV.1.8 hIL-12 is inducibly expressed for a long-term in vivo  
 
The ability to induce hIL-12 expression at different time points might be essential for the treatment 
of recurrent tumors or for the eradication of residual tumors. To investigate whether long-term 
repeat induction in vivo of hIL-12 was possible for 48 weeks, RU 486 was injected at weeks 2, 9, 
11, 14, 19, 28, 33 and 48 weeks. At these time points, hIL-12 was measured in serum before and 
10 hours after RU 486 administration. In all cases, hIL-12 was undetectable in serum before 
induction and increased to values around 2000 pg/ml after induction, indicating that the system 
remained operative for at least 48 weeks. As shown in Figure IV.11, hIL-12 expression at week 28 
was similar to that observed at week 2. At week 48, although the induction was quite significant, 
the levels obtained were about 43% of those of at week 2. This experiment demonstrated that 
inducible expression of hIL-12 could be observed for at least 48 weeks.  
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Figure IV.11: Long-term inducible expression of hIL-12 in vivo. C57BL/6J mice injected with Ad RS 24 at a dose of 
3x109 i.u were induced with RU 486 at different time points over a period of 48 weeks. Serum was collected at 10 
hours post induction and the levels of hIL-12 were determined by ELISA.  
 61
 62
IV.1.9 Ad RS 24 is widely distributed but expresses pGLp65 only in liver in vivo  
 
 
Figure IV.12: Distribution of Ad RS 24 and tissue RNA expression of the transactivator GLp65 in vivo. M, L, S, Lu, 
K refers to molecular weight marker, liver, spleen, lung and kidney. A) Total DNA was extracted from the organs to 
determine distribution of viral vector by PCR. B) Total RNA was extracted from the organs to determine tissue 
distribution of viral vector by RT-PCR. C) RT-PCR for amplification of the house keeping gene β actin was used for 
internal control of RNA. 
 
The vector Ad RS 24 expresses hIL-12 upon induction in a liver specific manner. It is well known 
that the majority of Ad vector particles administered by tail vein injection will locate to the liver.  
To determine tissue distribution and expression of the transactivator GLp65 in vivo, mice were 
injected with Ad RS 24 at a dose of 3x109 i.u. The mice were sacrificed at weeks 2 (n=2), 28 (n=2) 
and 48 (n=1) post vector injection. Liver (L), lung (Lu), spleen (S) and kidney (K) were obtained 
from these 5 mice and 2 controls. Total DNA and RNA were extracted from the organs to 
determine vector distribution and RNA expression of the transactivator GLp65. (Chapter III.3.12 
and III.3.13).  
As shown in Figure IV.12 A, the presence of vector DNA was observed in all the organs, the signal 
being more intense in the liver, indicating vector DNA persisted in all tissues for a long period.  
To demonstrate RNA expression from the vector, RT-PCR was performed to detect the expression 
of GLp65 in different tissues (Chapter III.3.13). As shown in Figure IV.12 B, GLp65 specific 
signals were detected in the liver even 48 weeks after vector administration. In control mice no 
PCR signals of the transactivator was found in any of the organs analyzed. This data indicated that 
the promoter and enhancer controlling GLp65 transcription allowed liver specific transgene 
expression for a long time. ß actin was used as internal control for the RT-PCR and is shown in 
Figure IV.12 C. 
A
B
C 
2 weeks                       28 weeks          48 weeks         not injected 
M  L   S   Lu   K    L    S  Lu   K  L   S  Lu  K   L  S  Lu  K  L    S   Lu   K  L    S   Lu   K 
 63
IV.2 Construction and characterization of mIL-12 expressing 
plasmids and vector  
 
IV.2.1 Construction of pRS 22, pRS 25 and Ad RS 25 
 
mIL-12 has been shown to have a profound anti-tumoral effect in different murine models of 
cancer [81]. However, sustained expression of mIL-12 for a long time is toxic in mice and human 
subjects [81, 126]. Therefore, the vector Ad RS 25 was designed to express mIL-12 upon induction 
with RU 486 in a liver specific manner. In order to generate Ad RS 25 the plasmids pRS 22 and 
pRS 25 were initially constructed. pRS 22 was generated by the insertion of the mIL-12 cDNA into 
the plasmid pRS 17 (Figure III.7). After confirming the integrity, pRS 22 was used to construct 
pRS 25 (Figure III.10). pRS 25 was used to generate Ad RS 25. A schematic diagram of Ad RS 25 
is shown in Figure IV.13.  
Figure IV.13: Vector Ad RS 25. The vector consists of two expression cassettes. The first cassette expresses the 
regulator GLp65 under the control of the liver specific TTRB promoter and enhancer. GLp65 in the presence of RU 
486 binds to the GAL4 region present in the second expression cassette and mIl-12 is expressed. Ad RS 25 also 
contains the left terminus of Ad5, the right terminus of Ad 5, and the packaging signal from Ad5 (Ψ). In addition Ad 
RS 25 also contain C346 and HPRT stuffer sequences. 
 
IV.2.2 mIL-12 is inducibly expressed in vitro upon transfection with pRS 22  
 
pRS 22 was tested for liver specific and regulable expression of mIL-12 in vitro, before it was used 
for the generation of the vector Ad RS 25. To investigate the regulable liver specific expression of 
IL-12, pRS 22 was transfected into HepG2, PLC/PRF/5 and HeLa cell lines (Chapter III.4.1) using 
Fugene reagent. 24 hours post transfection the cells were induced with 10-8 M of RU 486 (III.4.6). 
The supernatants were analyzed 48 hours post induction for the expression of mIL–12 by ELISA 
(Chapter III.6.4). As shown in Figure IV.14, mIL-12 expression and induction in the hepatic cell 
lines was observed. However, expressions of mIL-12 was also observed in cell lines transfected 
with pRS22, but were left uninduced. The reason for background expression might be due to high 
GLp65 levels attained due to transfection of pRS 22, which results in spontaneous dimerization, 
and subsequent expression of the transgene downstream of the 17mer. 
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Figure IV.14: Inducible expression of mIL-12 following transfection of pRS 22 in vitro. 5x105 cells of PLC/PRF/5, 
HUH 7 and HepG2 were cultured in 6 well plates for 24 hours before transfection. Transfection of cells with plasmid 
pRS 22 was performed using Fugene reagent. 24 hours later, the cells were induced with 10-8 M of RU 486 or were left 
uninduced. The supernatants were collected at 48 hours post induction and mIL-12 levels were determined using 
ELISA. The legend -RU 486 and +RU 486 indicates the absence or presence of RU 486.  
 
IV.2.3 mIL-12 is inducibly expressed upon cell transduction in vitro with Ad RS 
25  
 
To test for dose dependent and liver specific expression of mIL-12, Ad RS 25 was tested on the 
cell lines HepG2, PLC/PRF/5, A549, and HeLa (Chapter III.4.1). The cells were seeded at 
densities of 5x105 in six well plates and were cultured for 24 hours before infection. The cells were 
transduced with the vector Ad RS 25 at a moi of 100, and were induced with 10-8 M of RU 486 
(Chapter III.4.6) at 3 hours post infection. The first generation adenoviral vector Ad CMV mIL-12 
expressing mIL-12 under the control of the hCMV promoter at a moi of 100 served as a control. 
The amount of mIL-12 present in the supernatants was determined using ELISA. As shown in 
Figure IV.15, HepG2 cells and PLC/PRF/5 cells in the presence of RU 486 expressed mIL-12 after 
infection with 100 moi of Ad RS 25. The amount of mIL-12 secreted by HepG2 cells upon 
infection with Ad RS 25 was higher than after infection with vector Ad CMV mIL-12 expressing 
mIL-12 from the constitutive hCMV promoter. In contrast to HeLa cells, low levels of mIL-12 
were observed in A549 cells upon induction. In conclusion, vector Ad RS 25 exhibited inducible 
mIL-12 expression upon transduction of the hepatic cell lines HepG2 and PLC/PRF/5. 
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Figure IV.15: Inducible expression of mIL-12 following transduction with Ad RS 25 in vitro. 5x105 cells of 
PLC/PRF/5, A549, HeLa and HepG2 cells were seeded in 6 well plates. 24 hours later, the cells were infected with 100 
moi of Ad RS 25 or Ad CMV mIL-12. 3 hours later, Ad RS 25 infected cells were induced with 10-8 M of RU 486 or 
were left uninduced. The first generation adenoviral vector Ad CMV mIL-12 infected at a moi of 100 served as a 
control. The cell supernatants were collected at 48 hours post induction and mIL-12 levels were determined. In the 
legend -RU 486 and +RU 486 indicates the absence or presence of RU 486. In the legend CMV hIL-12 represents the 
virus Ad CMV hIL-12 expressing hIL-12 under the control of the hCMV promoter.  
 
IV.2.4 mIL-12 is inducibly expressed in vivo upon injection of Ad RS 25  
 
The vector Ad RS 25 expresses mIL-12 upon induction with RU 486 in a liver specific manner in 
vitro (Chapter IV.2.3). To characterize the kinetics of mIL-12 expression in vivo, C57BL/6 mice 
were injected with Ad RS 25 at a dose of 2x109 i.u (n=6). Two weeks post injection, mIL-12 
expression was induced by a single intra-peritoneal injection of RU 486 (n=3) at a dose of 250 
µg/kg bodyweight. Control mice (n=3) were injected with sesame oil. Serum samples were 
collected at 0, 4, 10, 24, 48, 72 and 120 hours post induction to determine the levels of mIL-12. As 
shown in Figure IV.16, in the absence of the drug RU 486 mIL-12 expression was not observed. 
Measurable expression of mIL-12 was observed at 4 hours post RU 486 induction. High levels of 
mIL-12 expression were observed 10 hours after induction. The expression of mIL-12 decreased 
sharply at 24 hours and was below the detection limit at 48 hours. Thus, the in vitro and in vivo 
properties of vector Ad RS 25 resembled the vector Ad RS 24. Vector Ad RS 25 was used in 
murine cancer models as presented below in Chapters IV.6 and IV.7. 
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Figure IV.16: Inducible expression of mIL-12 following in vivo injection of Ad RS 25. C57BL/6J mice (n=6) were 
injected with Ad RS 25 at a dose of 2x109 i.u followed by a single injection of RU 486(n=3). Serum samples were 
collected at 0, 4, 10, 24, 48, 72, and 120 hours and levels of mIL-12 were determined using ELISA. 
 65
 66
IV.3 Construction and characterization of stie2 expressing plasmids 
and vector 
 
IV.3.1 Construction of pRS 42, pRS 45 and Ad RS 45  
 
Tie2 is an endothelium specific tyrosine kinase having a crucial role during the development of the 
embryonic vasculature [127]. Tie2 knock out mice showed embryonic lethality characterized by a 
reduction in endothelial cell numbers and a defect in the morphogenesis of microvessels [59, 60]. 
Since angiogenesis is important for the development of tumors, it was plausible that blocking of 
Tie2 signalling would retard tumor growth. Recombinant soluble Tie2 receptor (stie2) expressed 
from a first generation adenoviral vector showed anti-tumor activity in murine models of cancer 
[128]. Therefore, we generated HC-Ad vector Ad RS 45 to express stie2 constitutively  
 
 
Figure IV.17: Vector Ad RS 45. The vector Ad RS 45 expresses stie2 under the control of the ubiquitously active 
MCMV promoter. Ad RS 45 was generated from plasmid pRS 45. Ad RS 45 also contains the left terminus of Ad5, the 
right terminus of Ad 5, and the packaging signal from Ad5 (Ψ). In addition Ad RS 45 also contain C346 and HPRT 
stuffer sequences. 
 
under the control of the MCMV promotor. In order to generate Ad RS 45 a series of plasmids were 
constructed and tested for integrity. pRS 31 was constructed from the plasmids pPAPCMV-
GLp65-SV40 and pPDK6 (Figure III.13). It consists of the MCMV promoter placed upstream of 
SV40pA. pRS 34 was generated from the plasmids pRS 31 and pBS II KS-Tie2 EC His. It consists 
of the stie2 cDNA placed downstream of the MCMV promoter (Figure III.15). pRS 42 was 
generated by an insertion of a Not I site into the plasmid pRS 34 (Figure III.15). pRS 45 was 
constructed from the plasmids pRS 42 and STK 129 (Figure III.17), and it was used for the rescue 
of Ad RS 45.  
 
IV.3.2 stie2 is expressed in vitro upon transfection of pRS 42  
 
The plasmid pRS 42 was tested for the expression of stie2 before being used for the generation of 
pRS 45. To investigate constitutive expression of stie2, pRS 42 was transfected into HepG2, 
PLC/PRF/5 and HeLa cell lines (Chapter III.4.1) The cells were plated at densities of 3x105 in 6 
well plates for 24 hours before transfection. The supernatants were analyzed 48 hours post 
transfection for the expression of stie2 by ELISA (Chapter III.6.4). As shown in Figure IV.18, stie2 
expression was observed in all cell lines tested, the largest amount of stie2 secreted by PLC/PRF/5 
cell line. 
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Figure IV.18: Expression of stie2 following transfection of pRS 42 in vitro. HepG2, PLC/PRF/5 and HeLa were 
plated at densities of 3x105 cells per well in 6 well plates. 24 hours later, the cells were transfected with pRS 42. The 
supernatants were collected 48 hours later and were analyzed for the expression of stie2 by ELISA. 
 
IV.3.3 stie2 is expressed in vitro upon cell transduction with RS 45  
 
Ad RS 45 was tested for expression of stie2 in vitro before being used in vivo. To test for the 
expression of stie2, cell lines HepG2, PLC/PRF/5 and HeLa cells (Chapter III.4.1) were transduced 
with Ad RS 45, rescued from the plasmid pRS 45 (Figure III.17), was transduced at a moi of 10 
and 100. 48 hours post infection the amount of stie2 secreted into the supernatant was determined 
by ELISA (Chapter III.6.4). As shown in Fig IV.19 all tested cell lines expressed stie2 at 
significant levels. The experiment demonstrated a dose dependent expression of stie2 from Ad RS 
45. The secreted stie2 protein was further tested for its activity in vitro as shown below.  
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Figure IV.19: Expression of stie2 following transduction with Ad RS 45 in vitro. 5x105 cells of HepG2, PLC/PRF/5 
and HeLa were plated in 6 well plates. 24 hours later the cells were transduced with 10 or 100 moi of Ad RS 45. The 
supernatants were collected 48 hours later and were analyzed for the expression of stie2 using ELISA. 
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IV.3.4 stie2 is detected as a 95 kD protein by Western blot analysis  
 
To confirm the molecular size of the secreted stie2 protein, Western blot analysis was performed 
(Chapter III.6.2). HeLa and PLC/PRF/5 cells were transduced with vector Ad RS 45 at a moi of 
100 and the supernatant was collected at 48 hours post infection. Controls were supernatants from 
HeLa and PLC/PRF/5 cells either left uninfected or infected with vector Ad SLS 14. To confirm  
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Figure IV.20: Western blot analysis of supernatants after cell transduction with different vectors. HeLa and 
PLC/PRF/5 cells were plated at densities of 5x105 in six well plates. 24 hours later the cells were either not infected or 
infected with 100 moi of vectors Ad RS 45 or Ad SLS 14. Supernatants were collected at 48 hours post infection. The 
stie2 protein present was visualized by Western blot analysis using murine anti-stie2 antibody. 
 
the expression of stie2, murine anti-stie2 antibody (Upstate biotechnology) was used. As expected 
a specific 95 kD band was detected (Figure IV.20). 
 
IV.3.5 stie2 inhibits tube formation of HUVECs in a matrigel assay  
 
A matrigel assay was performed to confirm the biological activity of stie2 (Chapter III.4.4). 
Supernatants were collected at 48 hours from uninfected HeLa cells or from cells infected with 
either 100 moi of vector Ad RS 45 or control vector Ad SLS 14. HUVECs incubated with the 
supernatant containing stie2 showed incomplete tube formation (Figure IV. 21B). In contrast, 
HUVECs incubated with supernatants collected from uninfected cells (not shown) or cells infected 
with Ad SLS 14 showed clear tube formation (Figure IV.21 A). Since this experiment was done in 
parallel with supernatant containing sflt1 expressed by Ad RS 23 or Ad RS 44, Figure IV.21 A is 
shown again in Figure IV.30 A. To quantify tube formation, the numbers of branch points were 
counted per field, and the results are represented as an average value of 10 fields. As shown in 
Figure IV.22, the number of branch points in HUVECs incubated with the supernatant containing 
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stie2 as found to be reduced by half, when compared with HUVECs incubated with control 
supernatant.  
BA
Figure IV.21: Inhibition of tube formation in a matrigel by stie2. HUVECs plated on a matrigel were incubated for 9 
hours with supernatant from HeLa cells, which had been infected at mois of 100 with Ad RS 45 or Ad SLS 14, 
respectively. The pattern of tube formation was visualized under a microscope. Figure A and B represent HUVECs 
incubated with 100 µl of supernatant from cells transduced with Ad RS 45 (B) or Ad SLS 14 (A) respectively. 
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Figure IV.22: Semi quantitative determination of inhibition of tube formation by stie2. HUVECs plated on a matrigel 
were incubated for 9 hours with supernatants from HeLa cells. The supernatants were obtained by transducing HeLa 
cells at a moi of 100 with Ad RS 45 or Ad SLS 14, respectively. The supernatant from uninfected HepG2 cells was 
also used as control. The pattern of tube formation was visualized under a microscope. The number of branch points 
was counted manually. The figure IV.22 represents an average value obtained by counting of 10 fields. 
 
IV.3.6 stie2 is constitutively expressed in vivo upon injection of Ad RS 45  
 
To investigate the kinetics of in vivo expression, C57BL/6J mice (n=3) were injected into the tail 
vein with Ad RS 45 at a dose of 2x109 i.u. Control mice (n=3) were injected with saline. 24 hours 
prior to injection, both groups of mice were injected with clodronate liposomes to deplete Kupffer 
cells (Chapter III.7.3). One week after the injection of the vector, the sera from the mice were 
collected at weekly intervals and were assayed for the expression of stie2 by ELISA (Chapter 
III.6.4). As shown in Figure IV.23, stable stie2 expression was observed during the observation 
period. Control mice injected with saline did not exhibit expression of stie2 (not shown). 
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Figure IV.23: Expression of stie2 in vivo following injection of Ad RS 45. Kupffer cell depleted C57BL/6J (n=3) 
mice were injected with Ad RS 45 at a dose of 2x109 i.u. Serum stie2 was determined by ELISA at weekly intervals.  
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IV.4 Construction and characterization of sflt1 expressing plasmids 
and vectors  
 
IV.4.1 Construction of pRS 20, pRS23, pRS 33, pRS 44, Ad RS 23 and Ad RS 44  
 
Growth of tumors requires angiogenesis. Angiogenesis is mediated by soluble growth factors like 
VEGF. VEGF is a potent stimulator of endothelial cell proliferation in vitro and in vivo. VEGF 
binds to endothelial cells through the high affinity receptor VEGFR1. Sequestration of VEGF is 
mediated by sflt1 in physiological conditions. Thus, the blocking of VEGF by sflt1 could be 
therapeutic for tumors that depend on VEGF function. Apart from embryonic and tumor growth, 
VEGF has been suggested to play important physiological roles [78]. Regulable expression of sflt1 
therefore could be controlling levels of sflt1 within a therapeutic window. To investigate the 
potential of blocking tumor growth by sequestration of VEGF, vectors expressing sflt1, either 
constitutively or inducibly, were constructed.  
To express sflt1 constitutively, plasmids pRS 29, pRS 33, pRS 44 and vector Ad RS 44 were 
generated and validated. For details of construction, see Chapter III.1.5. pRS 29 consists of an 
elongation factor 1-α (EF1-α) promoter placed upstream of the BGH cleavage and polyadenylating 
sequence (Figure III.12). pRS 33 was constructed by insertion of sflt1 cDNA into plasmid pRS 29 
(Figure III.14). pRS 44 was constructed by inserting the sflt1 expression cassette from pRS 33 into 
STK 129 (Figure III.16). pRS 44 was rescued as HC-Ad vector Ad RS 44(Figure IV.24 A).  
To express sflt1 upon induction in a liver specific manner pRS 20, pRS 23 and vector Ad RS 23 
were generated and validated. For details of construction see Chapter III.1.5. pRS 20 was generated 
by the insertion of the sflt1 cDNA into pRS 17 (Figure III.5). pRS 20 was used to construct pRS 23 
(Figure III.8). pRS 23 was rescued as HC-Ad vector Ad RS 23. Ad RS 23 contains as therapeutic 
principle two expression cassettes (Figure IV.24 B). The first cassette consists of the sflt1 cDNA 
placed downstream of the GAL4 E1b TATA region and upstream of BGHpA. The second cassette 
consist of GLp65 placed downstream of the liver specific promoter and enhancer TTRB, and 
upstream of the SV40 poly A sequence. In addition, Ad RS 23 contains the left and right termini of 
Ad5 and the C346 and HPRT stuffer sequences. 
 
Figure IV.24:. Vector Ad RS 44 and Ad RS 23. A) Ad RS 44 expresses sflt1 constitutively under the control of 
ubiquitous promoter EF1α. B) Ad RS 23 expresses sflt1 upon induction with RU 486 in a liver specific manner. Ad RS 
44 and Ad RS 23 also contain the left terminus of Ad5, the right terminus of Ad 5, and the packaging signal from Ad5 
(Ψ). In addition, Ad RS 44 and Ad RS 23 also contain C346 and HPRT stuffer sequences. The adenoviral termini and 
the stuffer sequence are indicated. 
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IV.4.2 sflt1 is inducibly expressed upon transfection of pRS 20 or infection with 
Ad RS 23  
  
To confirm regulable and liver specific expression of sflt1, pRS 20 was transfected into HepG2, 
PLC/PRF/5 and HeLa cells using Fugene transfection reagent (Chapter III.4.3). The cells were 
seeded at a density of 3x105 in six well plates and were cultured for 24 hours before transfection. 
24 hours later, the cells were transfected with pRS 20 followed by induction with 10-8 M of RU 
486 or were left uninduced (Chapter III.4.6). The supernatants were collected 48 hours post 
induction and were analyzed for the expression of sflt1 by ELISA (Chapter III.6.4). As shown in 
Figure IV.25, inducible expression of sflt1 was observed in hepatic cell lines HepG2 and 
PLC/PRF/5. In HeLa cells the expression of sflt1 was below the detection limit. Having confirmed 
the functional integrity, pRS 20 was further used for the construction of pRS 23. Ad RS 23 
generated from pRS 23 was tested for the expression of sflt1 in vitro, in HepG2, PLC/PRF/5, HUH 
-7, A549 and HeLa cells before being used in vivo (Chapter III.4.1). The cells were plated at 
densities of 5x105 in 6 well plates for 24 hours before infection. The cells were infected with Ad 
RS 23 at a moi of 100 and were induced with 10-8 M of RU 486 3 hours post infection. The 
supernatants were collected at 48 hours post induction and ELISA (Chapter III.6.4) was used to 
determine the amount of sflt1 present. As shown in Figure IV.26, sflt1 expression was inducible in 
the hepatic cell lines by RU 486. HepG2 cells also expressed sflt1 even in the absence of RU 486, 
but the levels were lower than observed in the presence of RU 486. In contrast, the expression of 
sflt1 upon induction was not detected in A549 and HeLa cells infected with Ad RS 23. Ad RS 23 
was further tested for expression in vivo below (Chapter IV.8). 
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Figure IV.25: Inducible expression of sflt1 upon transfection of pRS 20 in vitro. 3x105 cells of HepG2, PLC/PRF/5 
and HeLa were plated in 6 well plates. 24 hours later the cells were transfected with plasmid pRS 20 using Fugene 
transfection reagent followed by RU 486 induction. The supernatants were collected 48 hours later and amount of sflt1 
was determined using ELISA. 
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Figure IV.26: Inducible expression of sflt1 upon infection of Ad RS 23 in vitro in HepG2, PLC/PRF/5, HUH 7, A549 
and HeLa cells. 24 hours after plating the cells were infected with 100 moi of Ad RS 23 followed by RU 486 
induction. The supernatants were collected 48 hours later and were analyzed for the expression of sflt1 using ELISA. 
The symbols +RU486 or – RU 486 indicate the presence or absence of RU 486. 
  
IV.4.3 sflt1 is constitutively expressed upon pRS 33 transfection or Ad RS 44 
infection  
 
To investigate constitutive expression of sflt1, pRS 33 (Figure III.14) was transfected into HepG2, 
PLC/PRF/5 and HeLa cells using Fugene transfection reagent (Chapter III.4.3) as described above. 
sflt1 amounts in the supernatants were determined by ELISA (Chapter III.6.4). As shown in Figure 
IV.27, expression of sflt1 was observed in all transfected cell lines, the levels being highest in the 
hepatic cell line PLC/PRF/5. Having confirmed the expression pRS 33 was used for the generation 
of pRS 44. Ad RS 44 was rescued from pRS 44. To test for the expression of sflt1 cell lines 
HepG2, PLC/PRF/5 and HeLa were infected with Ad RS 23 at 10 and 100 mois. The amount of 
sflt1 secreted into the supernatant 48 hours post infection was determined using ELISA. As shown 
in Figure IV.28 all the tested cell lines expressed sflt1 at significant levels. The experiment also 
demonstrated dose dependent expression of sflt1 in the infected cells, the highest being secreted by 
HeLa cells. The experiment confirmed the expression of Ad RS 44. The secreted sflt1 protein was 
further tested for activity in vitro as shown below. 
 
Figure IV.27: Constitutive expression of sflt1 upon pRS 33 transfection in vitro in HepG2, PLC/PRF/5 and HeLa 
cells. The supernatants were collected 48 hours after transfection and were analyzed for the expression of sflt1 by 
ELISA. 
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Figure IV.28: Constitutive expression of sflt1 upon Ad RS 44 infection in vitro. HepG2, PLC/PRF/5 and HeLa cells 
were plated in 6 well plates. 24 hours later the cells were infected with 10 or 100 moi of Ad RS 44. The supernatants 
were collected 48 hours later and were analyzed for expression of sflt1 by ELISA.  
 
IV.4.4 sflt1 is detected as a 97 kD protein by Western blot analysis  
 
To confirm the molecular size of the secreted sflt1 protein, Western blot analysis was performed. 
HepG2 cells were infected with control vector Ad SLS 14 or the sflt1 expressing vectors Ad RS 44 
or Ad RS 23, at a moi of 100. Ad RS 23 infected cells were induced with 10-8 M of RU 486 at 3 
hours post infection. Supernatants were collected at 48 hours post infection and were processed as 
described earlier (Chapter III .6.2). A recombinant sflt1-Fc chimera (R&D systems) having a Mwt 
of 123 kD was used as a control. As shown in Figure IV.29, HepG2 cells infected with Ad RS 23 
or Ad RS 44 expressed sflt1 with a size of 97 kD as expected. The expressed sflt1 protein was 
further tested for biological activity. 
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Figure IV.29: Western Blot analysis of supernatants after HepG2 cell transduction with different vectors. The cells 
were infected with Ad RS 44 or Ad RS 23 at a moi of 100. 4 hours post infection, the cells infected with Ad RS 23 
were induced with 10-8 M of RU 486. Ad SLS 14 infected cells at a moi of 100 served as a control. Also a recombinant 
sflt1-Fc chimera was used to determine the specificity of the primary MAb. Supernatants were collected 48 hours post 
infection. The processed supernatants were run on a 6% SDS PAGE and were transferred to a nylon membrane for 
visualization. The sflt1 protein was visualized by western blot analysis using mice anti sflt1 antibody.  
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IV.4.5 sflt1 inhibits tube formation of HUVECs in a matrigel assay  
 
A matrigel assay was performed to confirm the biological activity of sflt1 (Chapter III.4.4). HepG2 
cells were infected with 100 moi of Ad RS 23, Ad RS 44 or Ad SLS 14 respectively. Cells infected 
with Ad RS 23 were induced with 10-8 RU 486 at 3 hours post infection and the supernatants were 
collected at 48 hours post infection. HUVECs plated on the matrigel were incubated with the 
supernatants for 9 hours. As shown in Figure IV.30.A, HUVECs incubated with the supernatant 
obtained from Ad RS 23 or Ad RS 44 infected cells containing sflt1 showed incomplete tube 
formation. In contrast, as shown in Figure IV.30 A, HUVECs incubated with supernatants from 
cells infected with Ad SLS-14 showed clear tube formation. Identical results were obtained with 
HUVECs incubated with supernatants collected from uninfected cells (data not shown). To 
quantify the pattern of tube formation, the average number of branch points per field was 
determined from an average of 10 fields (Figure IV.31).  
A B
 
 
Figure IV.30: HUVECs plated on a matrigel were incubated for 9 hours with 100 µl of supernatant of HepG2 cells, 
infected with 100 moi of Ad RS 23 (B) and Ad SLS 14 (A) and induced with 10-8 M of RU 486. The pattern of tube 
formation was visualized under a microscope. Note that A is also shown in Figure IV.21 A.  
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Figure IV.31: Semiquantitative determination of inhibition of tube formation by sflt1. HUVECs plated on a matrigel 
were incubated for 9 hours with supernatants from HepG2 cell infected with Ad RS 23, Ad RS 44 and Ad SLS 14 at a 
moi of 100. The supernatants from HepG2 cells were collected 48 hours post infection. The pattern of tube formation 
was visualized under a microscope. The number of branch points was counted visually. The figure represents an 
average value obtained from counting 10 fields. 
 75
IV.4.6 sflt1 inhibits VEGF induced proliferation of HUVECs  
 
Endothelial cells proliferate in the presence of different growth factors [26]. Proliferation of 
HUVECs can be achieved by culturing them with low serum conditions and stimulating with 
VEGF. VEGF-mediated proliferation of serum-starved HUVECs can be specifically be blocked by 
its soluble receptor sflt1. The functional activity of sflt1 was determined using a HUVEC 
proliferation assay (Chapter III.4.5). To quantitatively determine the functional activity of sflt1, 
supernatants containing sflt1 were obtained by infecting HepG2 cells with vectors Ad RS 44, Ad 
RS 23 and Ad SLS 14 at a moi of 100. The supernatants were collected 48 hours later and were 
assayed for the levels of sflt1 protein using ELISA. The sflt1 containing supernatants were diluted 
to contain sflt1 at a concentration of 100 ng/ml in 2% total serum. Control supernatants were also 
diluted to contain 2% serum. The diluted supernatants from infected HepG2 cells were incubated 
with serum-starved HUVECs, which were stimulated with VEGF to proliferate. 48 hours post 
incubation, 10 µl of WST-1 reagent was added and the OD at 550 nm was measured 4 hours later. 
As shown in Figure IV.32, serum starved HUVEC proliferated in the presence of recombinant 
VEGF at a concentration of 10 ng/ml. VEGF induced proliferation of HUVECs was blocked by 
supernatant containing sflt1 or recombinant sflt1 at a concentration of 100 ng/ml.  
The assay clearly demonstrated that VEGF induced proliferation of HUVEC was specifically 
blocked by sflt1 expressed from Ad RS 23 and Ad RS 44.  
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Figure IV.32: Inhibition of VEGF induced HUVEC proliferation by sflt1. 4x103. HUVECs were seeded in a 96 well 
plate and were incubated in endothelial cell media (ECM) containing 5% serum for 24 hours. The cells were further 
incubated in ECM containing 2% serum for 16 hours to undergo serum starvation. 16 hours later the medium was 
changed and HUVECs were incubated with supernatants from the HepG2 cells infected with Ad RS 23, Ad RS 44, Ad 
SLS 14. After the addition of supernatants, the HUVECs were stimulated with VEGF at a concentration of 10 ng/ml. 
HUVECs incubated only with 2% serum served as a negative control. HUVECs incubated only with VEGF at a 
concentration of 10 ng/ml served as a positive control. 48 hours post incubation with the supernatants the HUVECs 
were incubated for 2 hours with WST-1 reagent. The OD was read at 550 nm. 
 
IV.4.7 sflt1 is constitutively expressed in vivo upon injection of Ad RS 44  
 
The vector Ad RS 44 has been earlier shown to express active sflt1 in vitro (Figure IV.31 and 
Figure IV.32). To characterize the in vivo expression kinetics, Kupffer cell depleted C57BL/6J 
mice (n=3) were injected with 2x109 i.u of Ad RS 44 (Chapter III.7.3). Kupffer cell depleted 
control mice were injected with saline. Sera were collected at weekly intervals and serum sflt1 
levels were measured (Chapter III.6.4). As shown in Figure IV.33 there was a gradual increase in 
the expression of sflt1 from the first week of measurement. Surprisingly, at the end of the fifth 
week after the injection of the vector, all mice were observed to have ascites. Ascites was not 
observed in mice injected with clodronate liposomes alone. All mice that had received Ad RS 44 
died at the end of fifth week.  
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Figure IV.33: Constitutive sflt1 expression upon infection of Ad RS 44 in vivo. Kupffer cells depleted C57BL/6J 
(n=3) mice were injected with the vector Ad RS 44 at a dose of 2x109 i.u. Serum sflt1 levels were determined at 
weekly intervals by ELISA.  
 
IV.4.8 sflt1 is inducibly expressed in vivo upon injection of Ad RS 23 
 
Ad RS 23 has been shown to express sflt1 upon induction in a liver specific manner (Chapter 
IV.1.3). To investigate the kinetics of expression in vivo, C57BL/6J (n=3) mice were injected with 
Ad RS 23 at a dose of 5x108 i.u. Two weeks post injection the mice received a single i.p. injection 
of RU 486 (250 µg/kg body weight). The levels of sflt1 were determined at 0 hour, 4 hours, 10 
hours, 24 hours and 48 hours using ELISA. As shown in Figure IV.34 inducible expression of sflt1 
was observed at 4 hours and was highest at 10 hours post induction. The levels of sflt1 were again 
low at 24 hours and were undetectable after 48 hours. To determine the levels of sflt1 upon daily 
induction for four weeks, C57BL/6J mice (n=5) were injected with Ad RS 23 at a dose of 5x108 
i.u. Starting at one week post injection, the mice received daily i.p. injections of RU 486 (250 
µg/kg of body weight). Serum levels of sflt1 were determined at weekly intervals. As shown in 
Figure IV.35 A the levels of sflt1 were in the range of 75-300 ng/ml during the induction period. 
This experiment indicated that daily injection of RU 486 could maintain serum levels of sflt1. 
Ascites was not observed at any time in this group of mice. To investigate the expression kinetics 
of sflt1 expression in the presence of RU 486 pellets designed to release RU 486 at a dose of 250 
µg/kg of body weight of mice for 30 days, C57BL/6J mice (n=5) were injected with Ad RS 23 at a 
dose of 5x108 i.u . One week post injection the RU 486 pellets were subcutaneously implanted. 
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Figure IV.34: Inducible expression of sflt1 in vivo upon injection of Ad RS 23. C57BL/6J mice (n=3) were injected 
with 5x108 i.u. of Ad RS 23. Two weeks post injection, the mice received a single dose of RU 486. Serum was 
collected at 0 hour, 10 hours, 24 hours and 48 hours after induction and sflt1 levels were determined by ELISA. The 
legend – and + RU 486 refers to absence and presence of induction. 
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Figure IV.35: Inducible expression of Ad RS 23 in vivo. A) C57BL/6J mice (n=5) injected with the vector Ad RS 23 
at a dose of 5x108 i.u. were induced beginning one-week post injection by daily i.p. injection of RU 486. B) C57BL/6J 
mice (n=5) injected with Ad RS 23 at a dose of 5x108 i.u. were induced one week post injection by the subcutaneous 
implantation of RU 486 pellets. 
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The levels of sflt1 were determined at weekly intervals for four weeks. All mice with implanted 
RU 486 pellets showed ascites at the end of the fifth week. As shown in Figure IV.35B, sflt1 serum 
levels were in the range of 150 to 700 ng/ml. This experiment indicated that subcutaneous 
implantation of RU 486 pellets maintained relatively constant serum levels of sflt1. To summarize, 
the vector Ad RS 23 expressed sflt1 upon induction in a liver specific manner. The levels of sflt1 
were maintained by daily induction with RU 486 or by implantation of pellets releasing RU 486. 
However, ascites was observed in mice that had received RU 486 pellets but not in mice that had 
received daily i.p. injection of RU 486.  
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IV.5 Diagnostic work-up of sflt1 induced ascites  
 
Constitutive expression of sflt1 from the vectors Ad RS 23 or Ad RS 44 caused ascites in 
C57BL/6J mice. The ascites became apparent at the end of the fifth week post vector injection. All 
mice died within few days thereafter. To investigate the causative factors for the development of 
ascites, C57BL/6J mice (n=3) were injected with 1.5x109 i.u of Ad RS 44. Control mice were 
injected with saline. 24 hours prior to the injection of the vector or saline, mice were injected with 
clodronate to deplete Kupffer cells. The mice were sacrificed at the end of the fifth week to collect 
sera and organs. Since liver or kidney malfunction generally causes ascites, a diagnostic work-up 
was performed. Levels of AST, ALT, urea, albumin, bilurubin, and total protein were determined 
from the serum (Chapter III.6.3). Haemotoxylin-Eosin (H&E) staining of organ was performed.  
 
IV.5.1 Serum AST but not ALT levels are increased in RS 44 injected mice 
 
AST and ALT are transaminases, which catalyze the interconversion of amino acids and α keto 
acids by transfer of amino groups. Presence of high levels of AST and ALT enzymes in the serum 
may signal myocardial infarction, hepatic diseases, muscular dystrophy or organ damage. Serum 
elevations of ALT activities are rarely observed except in parenchymal liver disease, because ALT 
is a more liver-specific enzyme than AST. To investigate the causative factor for ascites, AST and 
ALT levels were determined in the serum. As shown in Figure IV.36 AST levels were four fold 
higher in mice injected with vector Ad RS 44 when compared to mice injected with saline. No 
significant change was observed in ALT levels between control and Ad RS 44 injected mice. The 
absence of a significant change in ALT levels signaled an absence of liver damage as causative 
factor. 
 
Figure IV.36: Determination of AST and ALT levels in serum of Ad RS 44 injected mice. Kupffer cell depleted 
C57BL/6J mice (n=3) were injected with Ad RS 44 at a dose of 1.5x109 i.u. Serum collected at the end of fifth week 
post infection was analyzed to determine the levels of AST and ALT. A and B represent the levels of AST and ALT in 
control mice and in mice injected with Ad RS 44 respectively. 
 
IV.5.2 Reduction in total protein and albumin level in Ad RS 44 injected mice 
 
Occurrence of ascites frequently reflects a decrease in the concentration of albumin and total 
protein in the serum. Albumin is synthesized by hepatocytes, and constitutes 55-65% of the total 
plasma protein. Serum albumin levels are determined as a part of diagnostic work up of liver 
diseases, nephritic syndrome, Crohn disease and neoplastic disease. Plasma proteins are 
synthesized predominantly in the liver, plasma cells, lymph nodes, spleen and bone marrow. Total 
protein measurements are used in the diagnosis and treatment of liver, kidney and metabolic 
disorders. Total protein and albumin serum levels were determined at the end of the fifth week 
after vector injection. As shown in the Figure IV.37 a 50% reduction in albumin levels and a 25% 
A
0
200
400
600
Control Ad RS 44
A
ST
 le
ve
ls
 (I
U
/d
l)
B
0
20
40
60
Control Ad RS 44
A
LT
 le
ve
ls 
(I
U
/d
l)
A
ST
 le
ve
ls
 (I
U
/d
l)
A
LT
 le
ve
ls 
(I
U
/d
l)
reduction in total protein were observed in mice injected with Ad RS 44 when compared to control 
mice. The reduction of total protein and albumin in the serum correlates with the observed ascites.  
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Figure IV.37: Total serum protein (A) and albumin (B) in mice injected with Ad RS 44 having ascites or control mice. 
Kupffer cell depleted C57BL/6J mice (n=3) were injected with Ad RS 44 at a dose of 1.5x109 i.u. Total serum protein 
and albumin was measured in serum collected at the end of fifth week after vector administration.  
 
IV.5.3 Serum bilirubin and liver histology is unchanged in Ad RS 44 injected 
mice  
 
Serum bilirubin levels are frequently elevated in certain liver disorders. Serum was collected from 
mice 5 weeks post injection to determine bilirubin levels. As shown in Figure IV.38, no significant 
differences in serum bilirubin were observed in vector injected mice when compared to control 
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Figure IV.38: Total serum bilirubin in Ad RS 44 injected mice and in controls. Kupffer cell depleted C57BL/6J mice 
(n=3) were injected with Ad RS 44 at a dose of 1.5x109. Total bilirubin was determined in serum collected at the end 
of the fifth week after vector administration. 
 
mice. To further exclude any gross liver pathology H&E staining of liver sections was performed 
from Ad RS 44 injected mice and from controls. Interestingly, as can be seen from Figure IV.39 no 
liver abnormality was detected in either control or Ad RS 44 injected mice. Taken together these 
data indicated that ascites was not caused by liver dysfunction. 
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IV.5.5 Ad RS 44 injected mice exhibit glomerular nephritis 
 
Kidney micrographs were taken from control and from Ad RS 44 administered mice. Glomerular 
sclerosis was evident in mice injected with Ad RS 44 (Figure IV.41B) but not in control mice 
(Figure IV.41A). This indicated that the ascites likely was caused by the damage of the kidney. 
 
A  B
Figure IV.41: H&E stain of kidney section from Ad RS44 injected mice with ascites (B) and control mice (A).  
Kupffer cell depleted C57BL/6J mice (n=3) were injected with Ad RS 44 at a dose of 1.5x109 i.u. H&E stains of 
kidney section were performed from mice at the end of the fifth week from each group. A shows the kidney 
micrograph of a control and B shows the kidney micrograph of an Ad RS 44 injected mouse with ascites. H&E 
staining was performed by Dr. Matilda Bustos. 
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IV.6 Anti-tumor efficacy of HC-Ad vectors in subcutaneous LLC 
model 
 
HC-Ad vectors Ad RS 23, Ad RS 44 and Ad RS 45 were tested for anti-tumor efficacy in the 
subcutaneous Lewis Lung Carcinoma (LLC) model in syngenic C57BL/6J mice. The experiment 
was performed as described in Chapter III.7.4. 
 
IV.6.1 Constitutive sflt1 expression transiently inhibits LLC tumor progression  
 
Ad RS 44 constitutively expresses sflt1 from the EF1-α promoter. To determine its anti-tumor 
effect Kupffer cell depleted C57BL/6J mice (n=5) were injected with 1.5x109 i.u of Ad RS 44 
(Chapter III.7.3). Kupffer cell depleted control mice were injected with saline (Chapter III.7.3). 
One week after vector injection (Day=0), the mice were subcutaneously injected with 1x106 LLC 
cells. The sizes of the tumors were measured at weekly intervals. 
Tumor growth in control and Ad RS 44 injected mice is shown in Figure IV.42. Initial sizes of 
tumors in vector-injected and in control mice were comparable. During the first week the 
differences in the sizes of the tumors between the controls and Ad RS 44 injected mice, were 
statistically not significant (two-tailed P value is 0.0556, Mann-Whitney test). At the third week 
after injection of the LLC cells, there was a decrease in tumor sizes in Ad RS 44 injected mice, 
when compared to the control mice. This decrease in the tumor sizes was statistically significant 
(two-tailed P value is 0.0079, Mann-Whitney test). Four weeks after the injection of the cells, 4/5 
of the control mice were dead or moribund. At week four (corresponding to week five after 
administration of the vector) mice injected with Ad RS 44 were moribund and had ascites. All 
mice with ascites died within two days. Tumor growth in individual mice of control and Ad RS 44 
injected groups is depicted in Figure IV.43. 
 
Figure IV.42: Transient suppression of LLC tumor growth in mice injected with Ad RS 44. Kupffer cell depleted 
C57BL/6J mice were injected with saline or vector Ad RS 44 at a dose of 1.5x109 i.u. One week later, subcutaneous 
tumors of LLC were established by implantation of 1x106 LLC cells. Tumor sizes were measured at weekly intervals 
after cell implantation. The figure displays the growth of tumor in Ad RS 44 (n=5) and saline (n=5) injected mice. 
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Figure IV.43: LLC tumor growth in individual mice injected with saline (A) or Ad RS 44 (B). Kupffer cell depleted 
mice were injected with Ad RS 44 at a dose of 1.5x109 i.u. One week later, subcutaneous tumors of LLC were 
established by implantation of 1x106 LLC cells. Tumor sizes were measured at weekly intervals after implantation of 
tumors.  
 
The levels of sflt1 protein were measured at weekly intervals after vector injection (Figure IV.44). 
The levels of sflt1 protein were below 200 ng/ml during the first week and between 200-700 ng/ml 
during the second and third week. sflt1 levels decreased thereafter in the third and fourth week and 
were 50-300 ng/ml. The levels of sflt1 in control mice were below the detection limit (not shown). 
This experiment demonstrated that the tumor growth in Ad RS 44 injected mice was reduced until 
the third week. Taken together, these experiments indicated that injection of Ad RS 44 resulted in 
significantly increased sflt1 levels and in an inhibition of the LLC tumor growth rate. Surprisingly, 
it was also found that all Ad RS 44 injected mice experienced ascites at four weeks after tumor 
injection (corresponding to week five after administration of the vector) and died within 2 days 
thereafter. 
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Figure IV.44: Serum levels of sflt1 in mice injected with 1.5x109 i.u of Ad RS 44, during LLC tumor growth. Kupffer 
cell depleted mice were injected with Ad RS 44. One week later, subcutaneous tumors were established by 
implantation of 1x106 LLC cells. Serum was collected at weekly intervals and levels of sflt1 were determined by 
ELISA.  
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IV.6.2 Inducible sflt1 expression transiently inhibits LLC tumor progression  
 
Ad RS 23 expresses sflt1 upon induction by RU 486 in a liver specific manner. To determine its 
anti-tumor effects, Kupffer cell depleted C57BL/6J mice (n=5) were injected with 2x109 i.u of Ad 
RS 23. Similarly, Kupffer cell depleted control mice were injected with saline. One week after 
vector injection the mice were subcutaneously injected with 1x106 LLC cells (Day=0). One-week 
later RU 486 induction was initiated by daily injections and tumor sizes were determined at weekly 
intervals (Figure IV.45). The differences in tumor sizes at 1 week between control and Ad RS 23 
injected mice were statistically not significant (two-tailed P value is 0.5206, Mann-Whitney test). 
The sizes of the tumors were measured subsequently for four weeks. At the third week, tumor 
volume was lower in Ad RS 23 injected mice compared to control mice (difference statistically 
significant, p= 0.0159, Mann-Whitney test). At the fourth week, 4/5 of the control mice were dead 
in contrast to RS 23 injected mice in which 2/5 mice had died. At the end of the fifth week, most of 
the RS 23 injected mice were moribund and were sacrificed. The tumor growth in individual mice 
in the Ad RS 23 injected and control groups is shown in Fig IV.46. 
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Figure IV.45: Transient suppression of LLC tumor growth in mice injected with Ad 23. Kupffer cells depleted mice 
were injected with saline (n=5) or Ad RS 23 (n=4) at a dose of 2x109. One-week later, subcutaneous tumors of LLC 
were established in syngenic C57BL/6 mice by implantation of LLC cells (1x106). One week after tumor implantation 
the vector Ad RS 23 injected mice were induced daily with RU 486 (250 µg/kg of mice) for four weeks to inducibly 
express sflt1. The figure displays the progress of tumor growth in saline or Ad RS 23 administered mice.  
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Figure IV.46: LLC tumor growth of individual mice injected with saline or with Ad RS 23. Kupffer cell depleted mice 
were injected with saline or 2x109 i.u. of Ad RS 23. One week later (day=0), subcutaneous tumors of LLC were 
established in syngenic C57BL/6 mice by implantation of 1x106 LLC cells. One week after tumor implantation, Ad RS 
23 injected mice were induced daily with RU 486 (250 µg/kg of mice) for four weeks to induce sflt1 expression. 
Figures A and B display tumor growth in saline (n=5) or Ad RS 23 (n=4) administered mice respectively. Note that the 
Figure IV.46 A is also shown in Figure IV.43 A. 
 
The levels of serum sflt1 protein were determined at weekly intervals after Ad RS 23 injection. As 
shown in Figure IV.47, the levels of sflt1 were between 2000-14000 ng/ml in the first three weeks. 
In the last week, the levels of sflt1 were below 2000 ng/ml. sflt1 levels in control mice were below 
the detection limit at all times (not shown). 
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Figure IV.47: Serum levels of sflt1 in mice injected with Ad RS 23 during LLC tumor growth. Kupffer cell depleted 
mice were injected with Ad RS 23 at a dose of 2x109.i.u. One-week later, subcutaneous tumors of LLC were 
established by implantation of 1x106 LLC cells. One week after tumor implantation the Ad RS 23 injected mice 
received daily injections of RU 486 (250 µg/kg of mice) for four weeks to induce expression of sflt1.  
Serum was collected from mice at weekly intervals and the levels of sflt1 were determined using ELISA. The figure 
displays levels of sflt1 expressed during LLC tumor growth in individual mice injected with Ad RS 23. 
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IV.6.3 Constitutive stie2 expression does not inhibit LLC tumor growth 
 
Ad RS 45 constitutively expresses stie2 from MCMV promoter (Chapter IV.3). To determine anti-
tumor activity of this vector, Kupffer cell depleted C57BL/6J mice (n=5) were injected with 2x109 
i.u. of Ad RS 45. Similarly, Kupffer cell depleted control mice were injected with saline. One week 
after vector injection (Day = 0), the mice were injected with 1x106 LLC cells subcutaneously. 
Tumor growth in control and in Ad RS 45 injected mice is shown in Figure IV.48. After one week, 
there were no differences in tumor sizes between controls and vector treated mice (two tailed P 
value is 0.9999, Mann-Whitney test). The sizes of the tumors were measured subsequently at 
weekly intervals. Ad RS 45 mice when compared to the controls did not exhibit any statistically 
significant difference in tumor volume during the experimental period. During the fourth week, 1/5 
of control mice in contrast to 4/5 of Ad RS 45 injected mice were alive. At the end of the fourth 
week all surviving control and vector-injected mice were moribund and were sacrificed. The 
results in the individual animals are shown in Figure IV.49. Serum levels of stie2 were determined 
by ELISA at weekly intervals and were found to be 30-450 ng/ml during the experimental period 
(Figure IV.50). This experiment demonstrated that constitutive expression of stie2 at significant 
levels did not result in a statistically significant inhibition of tumor growth in the subcutaneous 
LLC tumor model.  
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Figure IV.48: Absence of LLC tumor growth inhibition upon injection of Ad RS 45. Kupffer cell depleted mice were 
injected with saline or vector Ad RS 45 at a dose of 2x109 i.u. (n=5 for each group). One week later, subcutaneous 
tumors of LLC were established by implantation of LLC cells (1x106). Tumor sizes were measured at weekly intervals 
after implantation of tumors.  
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Figure IV.49: LLC tumor growth in individual mice injected with saline (A) or Ad RS 45 (B). Kupffer cell depleted 
mice were injected with saline or vector Ad RS 45 at a dose of 2x109 i.u. (n=5 for each group). Subcutaneous tumors of 
LLC were established by implantation of 1x106 LLC cells. Tumor sizes were determined at weekly intervals. Note that 
the Figure IV.49 A is also shown in Figure IV.43 A. 
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Figure IV.50: Serum levels of stie2 in mice injected with Ad RS 45 during LLC tumor growth. Kupffer cell depleted 
mice were injected with Ad RS 45 at a dose of 2x109 i.u. One week later, subcutaneous tumors of LLC were 
established by implantation of 1x106 LLC cells. Serum was collected at weekly intervals and the levels of stie2 were 
determined using ELISA.  
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IV.6.4 Inducible expression of mIL-12 transiently suppresses LLC tumor 
growth 
 
Ad RS 25 expresses mIL-12 upon induction with RU 486 in a liver specific manner (Chapter IV.2). 
To investigate the anti-tumor effect of mIL-12 in the LLC tumor model, Kupffer cell depleted 
C57BL/6J mice (n=5) were injected with Ad RS 25 at a dose of 5x108 i.u (Chapter III.7.3). Kupffer 
cell depleted control mice were injected with saline. One week after injection, 1x106 LLC cells 
were injected subcutaneously. One week after injection of the LLC cells, when a palpable tumor 
had developed, mice were then induced with RU 486 at a dose of 250 µg/kg every 24 hours for a 
week, during the first and the third week. The injection of RU 486 was discontinued in the second 
and fourth week to prevent morbidity due to mIL-12 mediated toxicity.  
As shown in Figure IV. 51 A, tumor sizes in control and Ad RS 25 injected mice at one week after 
injection of the cells were similar (two-tailed P value is 0.1508, considered not significant). At the 
third and fourth week after injection of the cells, the tumors in saline and Ad RS 25 injected mice 
had grown to different sizes that were statistically significant (two-tailed p value was 0.0079 and 
0.0159 for the third and fourth week respectively). At week four, 4/5 of the control mice were dead 
in contrast to Ad RS 25 injected mice in which all of the mice were still alive. However, Ad RS 25 
injected mice were moribund at the end of the fifth week and were sacrificed. LLC tumor growth 
in individual mice present in the control and the Ad RS 45 group is shown in Figure IV. 52 A. 
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Figure IV.51: Transient LLC tumor suppression upon inducible expression of mIL-12 in vivo. Kupffer cell depleted 
mice were injected with saline or vector Ad RS 25 at a dose of 5x108 i.u. One-week later, subcutaneous tumors of LLC 
were established by implantation of (1x106) LLC cells. Figure A displays LLC tumor progression in mice (n=5 for 
each group) injected with vector Ad RS 25 or saline (control mice). Figure B displays serum mIL-12 levels in Ad RS 
25 injected mice in the first and third week after tumor implantation. 
 
Serum levels of mIL-12, determined during the first and the third week after injection of the tumor 
cells, were between 100-600 ng/ml in the (first week) of induction and below 60 ng/ml (third 
week) of induction (Figure IV.51 B). This experiment indicated that reduction in tumor volume 
was observed in the presence of mIL-12. The levels of mIL-12 dropped during the third week of 
induction. 
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Figure IV.52: LLC tumor growth in individual mice (n=5 for each group) injected with saline (A) or Ad RS 25 (B). 
Kupffer cell depleted mice were injected with saline or with Ad RS 25 at a dose of 5x108 i.u. One week later, 
subcutaneous tumors of LLC were established by implantation of 1x106 LLC cells. The mice were induced with RU 
486 during the first and third week to express mIL-12. Note that the figure IV.52 A is also shown in figure IV.54 A. 
 
IV.6.5 Concomitant sflt1 and stie2 expression transiently suppress LLC tumor 
growth 
 
As shown earlier, expression of sflt1 and stie2 from the different HC-Ad vectors when injected 
individually had either no (Ad RS 45) or only a transient though statistically significant inhibitory 
effect on tumor growth and survival in the heterotopic LLC tumor model. Furthermore, ascites and 
death was observed with the use of Ad RS 44. Since sflt1 and stie2 target different vascular 
development pathways (endothelial cell proliferation and maturation of blood vessels respectively) 
we reasoned that combined expression of sflt1 and stie2 might result in a more pronounced effect. 
Therefore 1.5x109 i.u. of Ad RS 23 expressing sflt1 in a liver specific and regulable manner and 
2x109 i.u. of Ad RS 45 expressing stie2 constitutively were coinjected into Kupffer cell depleted 
C57BL/6J mice followed by subcutaneous injection of 1x106 LLC cells. One week after injection 
of the LLC cells tumors were palpable. At this time RU 486 induction was initiated. 
As shown in Figure IV.53, one week after LLC cell injection, there were no differences in the 
tumor sizes in control and vector-injected mice (two-tailed P value is 0.0952, Mann-Whitney test). 
At the third week post LLC cell injection, differences in tumor sizes in control and vector-injected 
mice were statistically significant (two-tailed P value is 0.0079, Mann-Whitney test). Tumor 
growth in individual mice of vector and control groups is shown in Figure IV.54.  
Serum levels of sflt1 were measured once per week during the experiment (Figure IV.55 B). The 
levels of sflt1 during the first week of RU 486 administration were between 200 and 1400 ng/ml 
(Figure IV.55 B). The levels dropped to below 600 ng /ml in the third week of induction. The 
levels of stie2 were between 30 and 50 ng/ml during the first week (Fig IV.55 A). The levels of 
stie2 increased to 150-350 ng /ml during the rest of the experimental period. The administration of 
RU 486 was discontinued after the third week, because the mice developed ascites. Upon 
withdrawal of RU 486, mice with ascites lost their ascites. However, due to tumor burden mice 
with both Ad RS 23 and Ad RS 45 became moribund and were sacrificed. 
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Figure IV.53: Comparison of anti-tumor efficacy in mice (n=5 for each group) injected with saline or with a 
combination of Ad RS 23 and Ad RS 45. Kupffer cell depleted mice were injected with saline or a combination of Ad 
RS 23 and Ad RS 45 at a dose of 1.5x109 i.u and 2x109 i.u. respectively. One week later, subcutaneous tumors were 
established by implantation of 1x106 LLC cells (week=0). At week 1, when tumors were palpable, mice were daily 
injected with RU 486 (250 µg/kg body weight). 
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Figure IV.54: Comparison of LLC tumor growth in individual mice (n=5 for each group) injected with saline or with a 
combination of Ad RS 23 and Ad RS 45. Kupffer cell depleted mice were injected with saline or a combination of 
vectors Ad RS 23 and Ad RS 45 at doses of 1.5x109 i.u. and 2x109 i.u. respectively. One week later, subcutaneous 
tumors were established by implantation of 1x106 LLC cells. At week 1, when tumors were palpable, mice were daily 
injected with RU 486 (250µg/kg body weight). Figure A displays LLC tumor growth in individual mice injected with 
saline. Figure B displays LLC tumor in mice injected with a combination of Ad RS 23 and Ad RS 45. Note that the 
figure IV.54 A is also shown in figure IV.52 A. 
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 igure IV.55: Levels of tie2 and sflt1 in mice injected concomitantly with Ad RS 23 and Ad RS 45. Kupffer cell 
V.6.6 Concomitant sflt1 and mIL-12 expression transiently suppress LLC 
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F
depleted mice were injected with saline (n=5) or a combination of Ad RS 23 and Ad RS 45 (n=5) at doses of 1.5x109 
i.u. and 2x109 i.u. respectively. One week later, subcutaneous tumors of LLC were established. Serum was collected at 
weekly intervals and the levels of sflt1 and stie2 were determined by ELISA.  
 
I
tumor growth  
 
s
cancer. To investigate the combined anticancer effect of sflt1 and mIL-12, Kupffer cell depleted 
C57BL/6J mice (n=5) were injected with Ad RS 25 and Ad RS 23. Kupffer cell depleted control 
mice were injected with saline. Ad RS 23 and Ad RS 25 were injected at a dose of 2x109 i.u and 
5x108 i.u. respectively. One week after vector injection, the mice received a subcutaneous 
implantation of 1x106 LLC cells. Initial tumor sizes were measured one week after the injection of 
the cells. There were no statistically significant differences in the initial sizes of the tumors 
between the controls and vector-injected mice (the two tailed P value is 0.0556, Man- Whitney 
test). The tumor growth was followed by weekly measurements. RU 486 induction was initiated at 
week one and three. Induction was discontinued during the second and the fourth week. 
Tumor growth in mice injected both Ad RS 23 and Ad RS 25 is shown in Figure IV.
third week after injection of the LLC cells, the difference in the tumor volume between control and 
vector injected mice was statistically significant (two-tailed P value is 0.0079, Mann-Whitney test). 
The mice were further observed for survival time. As shown in Figure IV.57 B, from the vector-
injected animals 3/5 survived until six weeks and 1/5 mice survived until eight weeks. In contrast, 
none of the control mice survived beyond four weeks (Figure IV.57 A). Thus the combined 
injection of vectors expressing sflt1 and mIL-12 demonstrated an increase in survival time and 
decreased tumor growth in comparison to mice injected with either of the vector alone. The 
antitumor effect could have been due either to the combined presence of sflt1 and IL-12 or due to 
the presence of high levels of mIL-12. The levels of mIL-12 were 2-6 fold higher in this 
experiment when compared to the mIL-12 levels in which Ad RS 25 was injected alone (Figure 
IV.51). The levels of mIL-12 and sflt1 expression were assayed during the first and third week of 
RU 486 induction. As shown in Figure IV.58 A, levels of mIL-12 were between 2500 and 3000 
ng/ml, during the first week of induction and between 100 and 1500 in the third week. As shown in 
Figure IV.58 B, sflt1 levels were in the range of 30 and 120 ng/ml during the first and third week 
of induction.  
 
 92
0800
1600
2400
0 1 2 3 4 5 6 7 8
weeks
Tu
m
or
 v
ol
um
e 
(m
m
3)
Saline Ad RS 23 +Ad RS 25
Tu
m
or
 v
ol
um
e 
(m
m
3)
Figure IV.56: Comparison of LLC tumor growth between mice (n=5 for each group) injected with saline or combined 
with Ad RS 23 and Ad RS 25. Kupffer cell depleted mice were injected with saline or with Ad RS 25 and Ad RS 23 at 
a dose of 5x108 and 2x109 i.u. respectively. One week later, subcutaneous tumors of LLC were established by 
implantation of 1x106 LLC cells. RU 486 induction (250 µg/kg) was performed by daily injections during the first and 
third week. 
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Figure IV.57: Comparison of LLC tumor growth in individual mice injected with saline (A) or combined with 
Ad RS 23 and Ad RS 25 (B). Kupffer cell depleted mice were injected with saline or with Ad RS 25 and Ad RS 23 at 
5x108 i.u. and 2x109 i.u respectively. One week later, subcutaneous tumors were established by implantation of 1x106 
LLC cells. Tumor sizes were measured at weekly intervals. RU 486 induction (250 µg/kg) was performed by daily 
injections during the first and third week. Note that the figure IV.57 A is also shown in figure IV.52 A. 
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Figure IV.58: Serum levels of mIL-12 (A) and sflt1 (B) in mice injected with Ad RS 23 and Ad RS 25. Kupffer cell 
depleted mice were injected with saline or combined with Ad RS 25 and Ad RS 23 at a dose of 5x108 and 2x109 i.u. 
respectively. One week later, subcutaneous tumors were established by implantation of 1x106 LLC cells. RU 486 
induction (250 µg/kg) was performed by daily injections during the first and third week. 
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IV.7 Anti-tumor effects by HC-Ad-mediated expression of sflt1 and 
mIL-12 in the orthotopic MC-38 tumor model 
 
While in the experiments described above, effects of HC-Ad vectors were tested in a subcutaneous 
tumor model, a further model was chosen that more closely mimics the clinical situation. The 
orthotopic MC-38 tumor model is based on the local inoculation of MC-38 colon carcinoma cells 
into the liver. Tumor growth is very aggressive and recipient mice become moribund within 3-4 
weeks from the date of injection. The MC-38 colon carcinoma model was performed as described 
in chapter III.7.5. 
 
IV.7.1 Inducible or constitutive sflt1 expression does not inhibit MC-38 tumor 
growth. 
 
Ad RS 23 expresses sflt1 upon induction with RU 486 in a liver specific manner. Ad RS 44 
expresses sflt1 under the control of ubiquitously active EF-1α promoter. Liver tumors were 
established by intrahepatic implantation of MC-38 cells. One week before tumor cell, inoculation, 
Kupffer cell depleted C57BL/6J mice were injected with Ad RS 23 (n=4) and Ad RS 44 (n=4) at 
doses of 2x109 i.u. and 1.5x109 i.u. respectively (Chapter III.7.3). Control mice (n=4) were injected 
with saline. Initial tumor sizes were determined by laparotomy on day 5 post implantation and 
were found to be about 8 mm3. Then in the case of Ad RS 23 injected mice, RU 486 induction was 
initiated by daily injections for 10 days. The tumor size was determined once again on day 20 post 
implantation. As shown in Figure. IV.59, 2/4 mice injected with vector Ad RS 23 had tumor size 
less than 500 mm3. In the case of mice injected with the vector Ad RS 44, 1/4 mice had tumor 
volumes less than 500 mm3. All of the control mice had tumor volumes more than 1000 mm3. In 
summary, injection of neither Ad RS 23 nor Ad RS 44 resulted in the suppression of MC-38 tumor 
growth.  
 
Figure IV.59: MC-38 tumor growth in mice injected with Ad RS 23 or Ad RS 44. Kupffer cell depleted mice were 
injected with saline, Ad RS 23 or Ad RS 44 at a dose of 2x109 or 1.5x109 i.u. respectively. One week later, liver 
tumors were established by intrahepatic implantation of 106 MC-38 cells. Initial tumor sizes were measured 5 days 
after tumor implantation. Five days after tumor implantation, in the case of Ad RS 23 injected mice, RU 486 induction 
was initiated. The mice were analyzed again for tumor growth on day 20 after tumor implantation.  
 
The levels of sflt1 observed in Ad RS 23 and Ad RS 44 injected mice on day 14 after vector 
injection is shown in Figure IV.60. Ad RS 23 injected mice had levels of 12,000-14,000 ng/ml and 
Ad RS 44 injected mice had between 900 and 2000 ng/ml. The mice were observed for long-term 
survival. As shown in Figure IV.61, none of the controls and of mice injected with Ad RS 44 
survived beyond 35 days. Although not statistically significant, 1/4 of Ad RS 23 injected mice 
survived until day 44. In summary there were no significant differences in survival time between 
the different groups. 
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Figure IV.60: Levels of sflt1 during MC-38 tumor growth in mice injected with Ad RS 44 or Ad RS 23 (with RU 486 
induction). sflt1 levels were determined on day 14 after vector injection.  
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Figure IV.61: Survival rate of mice described in Figures IV.60 and IV.61 injected with Ad RS 23 or Ad RS 44 in the 
MC-38 orthotopic cancer model. 
 
IV.7.2 Inducible mIL-12 expression inhibits MC-38 tumor growth  
 
Ad RS 25 was designed to express mIL-12 upon induction with RU 486 in a liver specific manner. 
Ad RS 25 showed anti-tumor activity in the subcutaneous LLC model, which however was not 
persistent. To investigate the effect of mIL-12 on MC-38 tumor growth, mice were injected with 
1x108 i.u. (n=4) or with 5x108 i.u. (n=11) of Ad RS 25. The control mice (n=8) were injected with 
saline. One week post vector injection, liver tumors were established by intrahepatic injection of 
MC 38 cells. Five days after implantation of the cells, tumor sizes were determined by laparotomy 
and were found to be about 8 mm3. Mice injected with the vector at a dose of 5x 108 i.u (n=7) were 
induced with RU 486 for 10 days. Control mice (n=3) injected with Ad RS 25 at a dose of 5x 108 
i.u. were not induced with RU 486. Five days after termination of induction, tumor sizes were 
determined again by laparotomy.  
As shown in Figure IV.62, control mice injected with saline showed progressive tumor growth, 
similar to mice that received 5x108 i.u. but without RU 486 induction. In contrast, mice injected 
with Ad RS 25 at a dose of 5x108, and induced with RU 486 showed complete tumor regression. 
Animals injected with Ad RS 25 at a lower dose of 1x108 i.u. followed by induction, showed a 
reduction of the tumor size, but the tumors eventually progressed and the mice finally died due to 
massive liver tumors. This experiment clearly demonstrated an inhibitory effect of inducible 
expression of mIL-12 on liver tumor growth.  
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Figure IV.62: MC-38 tumor growth in mice injected with saline or Ad RS 25. Mice were injected with Ad RS 5 at a 
dose of 108 or 5x108 i.u. Control mice were injected with saline. One week post vector injection, liver tumors were 
established by intrahepatic injection of 106 MC-38 cells. The initial tumor sizes were determined at day 5 after 
implantation. Then, the mice were induced with RU 486 for 10 days. Tumor size was determined again 20 days after 
implantation. 
The figure displays tumor size of control mice (rhombus, n = 8), mice injected with 5x108 i.u. of the vector without 
RU486 induction (triangles, n = 3), mice injected with 108 i.u. of the vector plus RU 486 induction (lines, n = 4), and 
mice treated with the vector at 5x108 i.u. plus RU 486 induction (squares, n = 7). + or – refers to presence or absence 
of induction with RU 486. 
 
Representative photographs of liver tumors before and after therapy in two mice that had been 
injected with Ad RS 25 at a dose of 5x108 i.u. are shown in Figure IV.63. Both the mice 
represented by Figure IV.63 A and Figure IV.63 B respectively, had MC-38 tumors five days after 
implantation of MC-38 cells. The animal shown in Figure IV.63 A was not induced with RU 486. 
This animal showed tumor progression and died 20 days after the end of the induction period. As 
shown in Figure IV.63 C, the uninduced mice had a tumor mass exceeding 20 mm in diameter, 
peritoneal dissemination (white asterisk) and lung metastases (black asterisk). 
In contrast, the animal shown in Figure IV.63 B had been induced with RU 486 for 10 days. The 
mouse was tumor free on day 35 and the tumor was completely eradicated as shown in Figure 
IV.63 D. 
This experiment demonstrated that inducible expression of mIL-12 resulted in complete tumor 
regression.  
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 igure IV.63: Photographs of representative tumors in mice treated with Ad RS 25. Ad RS 25 (5x10  i.u. per mice) 
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was injected intravenously. One week later, liver tumors were established by intrahepatic injection of 10  MC-38 cells. 
A and B corresponds to livers of 2 mice 5 days after cell implantation. The margins of the tumor mass are indicated 
with white arrows. From this moment, the mouse shown in A was left untreated, and the one in B received daily 
intraperitoneal injections of RU 486 (250 µg/kg) for a total of 10 days. C shows tumor progression in the untreated 
animal that died 20 days after end of induction period showing a massive tumor (indicated as T) that occupied most of 
the liver (indicated as L), peritoneal dissemination (white asterisk), and lung metastases (black asterisk). D shows 
tumor eradication in the mouse treated with the vector plus RU 486. 
 
ong-term disease free survival is a clear indicator of the effectiveness of a therapy. The survival L
rate of animals used in the above experiment is shown in Figure IV.64. Both the control and the 
uninduced mice did not survive beyond the 35th day. Mice injected with of 1x108 i.u. and induced 
with RU 486 survived longer when compared to control mice, but eventually succumbed. Mice 
injected with Ad RS 25 at a dose of 5x108 i.u. and induced with RU 486 survived longer than the 
control or uninduced mice. 90% of the mice that had received 5x108 i.u. of RS 25 and RU 486 
survived beyond day 53 and were disease free when the experiment was terminated. 
 97
025
50
75
100
Su
rv
iv
al
 r
at
e 
(%
)
5 10 15 20 25 30 35 40 45 50 55
Days
Control 5x10
8 
(-RU 486)
8 
10 (+RU 486)
8
5x10 (+RU 486)
N=8 N=3 N=4 N=7
Su
rv
iv
al
 r
at
e 
(%
)
Figure IV.64: Survival rate in the MC-38 tumor model of mice injected with Ad RS 25 with or without RU 486 
induction as indicated. 
 
The vector Ad RS 25 expresses mIL-12 upon induction with or without RU 486 induction, as 
indicated in a liver specific manner. To determine the levels of mIL-12 observed during MC-38 
tumor growth, serum was collected 10 hours post induction. As shown in Figure IV.65, control 
mice and uninduced vector injected mice did not express mIL-12. In contrast, high levels of mIL-
12 of up to 8000 ng/ml were found in sera from mouse receiving the high vector dose (5x108 i.u.) 
following induction with RU486. The lowest mIL-12 value obtained with this viral dose, that still 
showed anti-tumor efficacy, was 170 ng/ml. However, mice injected with the lower vector dose 
(108 i.u.) had serum levels of mIL-12 of around 1–2.5 ng/ml after induction. These data indicated 
that the efficacy of treatment was related to the level of mIL-12 obtained following induction with 
RU 486. This experiment showed that the levels of mIL-12 correlate with the tumor free survival 
of the mouse. The minimal amount of mIL-12 that was therapeutic was above 160 ng/ml. mIL-12 
levels in the range of 2.5 ng/ml or less were subtherapeutic. 
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Figure IV.65: Levels of mIL-12 in Ad RS 25 injected mice during tumor growth. Serum mIL-12 levels were 
determined on day 5 of induction that were subjected to vector injection in the MC-38 tumor model (Figure IV.64). 
 
IV.7.3 Inducible mIL-12 expression causes transient toxicity in the MC-38 
tumor model 
 
To test for a potential toxicity due to high local expression of mIL-12, serum ALT levels, an 
accepted marker for hepatocyte damage, were determined in MC-38 tumor bearing mice. These 
animals had received 5×108 i.u. of Ad RS 25. Part of the animals (n=5) was induced with RU 486 
(250µg/kg body weight). Control mice were left uninduced. A further group neither received 
vector nor RU 486. ALT levels were determined on days 1, 7 and 35. 
As shown in Figure IV.66 on days 1 and 7 elevated serum ALT level was only observed in 
Ad RS 25 animals that had been induced with RU 486 not in the control groups. On day 45 (35 
days following cessation of RU 486 induction) ALT levels had normalized in Ad RS 25/RU 486 
(+) mice. The control groups did not survive long enough to be tested at the 45-day time point. 
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Histological examination of liver tissue was performed to determine whether elevated ALT levels 
were reflected by alterations in liver morphology. As seen in Figure IV.67, neither RU 486 
injection alone (A) nor vector injection alone (B) were accompanied by histological abnormalities. 
However, modest infiltration of inflammatory cells was observed in Ad RS 25 injected animals 
that had received RU 486 for 4 days (C). Liver pathology had normalized in Ad RS 25/RU 486(+) 
animals 35 days after termination of RU 486 induction (D). 
Together, this data indicates that vector-mediated mIL-12 expression in hepatocytes resulted in a 
modest/mild inflammation response as evidenced by infiltration of mononuclear cells and 
increased serum ALT levels. This response was transient upon cessation of mIL-12 expression. 
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Figure IV.66: Indicators of mIL-12 mediated toxicity in the MC-38 model. Figure A shows a liver micrograph from 
an animal injected with RU 486 alone for 10 days. Figure B shows a micrograph from a mouse injected with 
Ad RS 25. Figure C shows a micrograph from an animal injected with Ad RS 25 and induced with RU 486. The 
arrows show the infiltration of inflammatory cells. Figure D shows a liver a micrograph from an animal 35 days after 
cessation of induction. Figure E shows the ALT levels on day 1 and 7of mice injected with saline or with Ad RS 25 
that either had received (+) or had not received (-) RU 486. The right column in each group corresponds to the animals 
treated with vector plus RU 486 35 days after the end of induction. H&E staining was performed by Dr. Matilda 
Bustos. 
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V Discussion  
 
Conventional tumor therapy like chemotherapy, surgery, and radiation has limitations. New 
strategies are therefore required for tumor treatment. Gene transfer is a new means to locally 
express therapeutic proteins for the treatment of tumor. In this thesis, we tested the hypothesis 
whether vector mediated expression of transgenes was able to arrest tumor growth. As transgenes 
we tested the therapeutic potential of three different molecules. As vector we chose HC-Ad vectors 
because they do not integrate into the host genome, can carry multiple transgenes up to a maximum 
capacity of 27 kb and are capable of expressing transgenes for a long period.  
 
V.1 Selection of transgenes 
 
Tumor growth is dependent on angiogenesis. We hypothesized that blocking of growth factors 
which promote angiogenesis would arrest tumor growth. Therefore, soluble receptors of VEGF and 
angiopoietins namely sflt1 and stie2 were chosen as transgenes. In addition IL-12 was chosen as an 
immunostimulatory transgene to arrest tumor growth. IL-12, despite having impressive antitumor 
activity is extremely toxic when injected as a recombinant protein or expressed using a first 
generation Ad vector. As discussed in the following chapter a new strategy was devised to 
overcome IL-12 mediated toxicity by regulating its expression. 
 
V.2 Requirement of regulation of transgene expression 
 
Cancer gene therapy in contrast to gene therapy for inherited disorders may require the expression 
of cytokines, growth factors or suicide genes, molecules, which may have severe side effects when 
expressed constitutively and at high levels for a long time. In addition, many cytokines need to be 
present only for a short interval to improve haematopoiesis following cancer chemotherapy. 
Therefore, it becomes necessary to develop systems, which would allow the regulation of transgene 
expression both at quantitative and qualitative levels. Optimally, the expression of a transgene 
would occur only upon addition of an external drug, become induced in a particular tissue and the 
expression could be turned off in its absence. Thereby adverse events related to the transgene could 
be avoided and the levels of transgenes could be fine-tuned to achieve expression wthin a 
therapeutic window. In some situations and depending upon the tumor type it would be necessary 
to constitutively express the transgenes for a required period. In the case of relapsing or recurring 
tumors it would be desirable to turn on gene expression at different time schedules. In principle, 
several systems offer the possibility to regulate transgene expression, although few have been 
tested in gene transfer experiments in vivo. Some systems are based on induction by heat, UV 
irradiation and metal, which cannot be applied in vivo. In contrast, four systems with in vivo 
potential have been developed, including regulation by the antibiotic tetracycline, the insect steroid 
ecdysone or its analogs, the antiprogestin mifepristone (RU 486), and chemical dimerizers such as 
the immunosuppressant rapamycin and its analogs. They all involve the drug-dependent 
recruitment of a transcriptional activation factor to a basal promoter that controls the expression of 
the gene of interest, but differ in the mechanism of recruitment. In the mifepristone system drug 
related control of transcription is achieved by fusing the heterologous DNA-binding domain of the 
yeast GAL4 protein and the p65 activation domain of NF-kB to a mutant human progesterone 
receptor that is unaffected by endogenous hormones but is activated by synthetic antiprogestins at 
doses sufficiently low to avoid side effects in human. The properties of the mifepristone-regulated 
system have been investigated in transgenic animals and using injection of plasmid DNA in 
muscle. Additionally an HC-Ad vector incorporating the mifepristone system was shown to 
express the human growth hormone gene in an inducible manner. Interestingly, it was 
demonstrated that background transcription was undetectable in vitro and in vivo and human 
growth hormone production could be cycled on and off 3 times for over 50 days or alternatively 
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maintained at steady state levels by delivery of the RU 486. Therefore, we used the RU 486 system 
for inducible expression of transgenes. 
 
V.3 Expression kinetics of HC-Ad vectors 
 
HC-Ad vectors expressing transgenes constitutively demonstrate linear relationship between vector 
dose and transgene expression. However, such information is unavailable for HC-Ad vectors 
expressing transgenes upon induction. Therefore, in this study a reporter vector that expresses hIL-
12 upon RU 486 induction was used to characterize the tissue distribution of the vector, the 
transgene expression, as well as the kinetics of the induction with respect to the dose of the vector, 
the dose of the inducer, and the periodicity of the induction. The vector expressing hIL-12 was 
chosen as a reporter vector because hIL-12 has minimal biological activity and no toxicity in mice 
[83].   
hIL-12 expression was first detectable at 4 hours post RU 486 induction, followed by a peak at 10 
hours. hIL-12 expression was low again at 24 hours and was undetectable at 48 hours. Similar 
results were observed with the vectors expressing sflt1 and mIL-12, upon single induction with the 
inducer RU 486. Similar kinetics of transgene expression has been earlier reported using a HC-Ad 
vector expressing hGH [10]. Interestingly, two other systems based on either tetracycline or 
rapamycin induction have been investigated for inducible transgene expression. An HC-Ad vector 
based on the tet expression system demonstrated a comparable kinetics of inducible mIFNα 
expression. Inducible gene expression based on rapamycin has been earlier studied using Ad or 
AAV vectors [129]. In this study based on the rapamycin system, it was observed that the level of 
reporter gene was high for 12 days post single rapamycin induction [130].  
The reporter vector was further analyzed for levels of hIL-12 obtained upon increasing both the 
dosage of the vector and the inducer RU 486. It was observed that the levels of transgene 
expression increased with the increase in both the dose of the vector and the drug RU 486. A 
similar result has been earlier demonstrated in another study using transgenic mice based on the 
RU 486 system. In this study, a RU 486 dose dependent increase in inhibin A levels and a supra-
physiological concentration of inhibin A was achieved when the mice were induced at a dose of 
500 µg/kg [104]. The possibility to modulate the levels of hIL-12 expression by varying the vector 
and the inducer dosage is especially important in limiting the toxicity and provides a vital 
opportunity to finetune hIL-12 expression to attain therapeutic levels during treatment.  
In some situations and depending on the nature of the disease successful application of inducible 
gene expression system for the treatment of diseases would require the maintenance of therapeutic 
levels of the transgenic protein for a longer period of time until it can be turned off. In order to 
investigate the minimum time interval required for the maintenance of stable hIL-12 levels mice 
were induced with RU 486 at different time intervals (every 12 hours, 24 hours and 48 hours for a 
week). Stable levels of IL-12 expression were observed when the mice were injected every 12 
hours or 24 hours. Mice induced with RU 486 every 48 hours with RU 486 a saw like pattern of 
hIL-12 expression was detected. Based on these data, we selected induction every 24 hours to 
analyze whether prolonged administration of the inducer could maintain its efficacy at stimulating 
hIL-12 expression. So, a different group of mice was injected with RU 486 for a period of 21 days. 
Interestingly the mice showed levels of hIL-12, which were stable during the 21-day induction 
period. In this group of mice, the serum level of hIL-12 remained constant until the ninth day of 
sustained induction and decreased moderately after this time point but still was above 50% of its 
initial value on day 21. These findings provide insight about the functioning of the mifepristone-
based regulatory system and are relevant for appropriate regulation of transgene expression in 
clinical trials. The mice which were induced every 12 hours, 24 hours or 48 hours were further 
induced again at weeks 19, 28, 33, and 48 week to determine the duration of the activity of Ad RS 
24. In all cases, hIL-12 was undetectable in serum before the injection of RU486 and was 
detectable at 10 hours after induction, indicating that the system remained operative for at least 48 
weeks. This information is of interest because of the fact that anti-adenovirus antibodies generated 
after the first dose of the vector may prevent its re-administration. However, in contrast to the 
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similar levels of hIL-12 at week 2 and 28, a 45% reduction in cytokine serum value was observed 
at week 45. This drop in the expression of hIL-12 could be explained by the normal turnover of 
hepatocytes. Thus, the long-term inducible expression of hIL-12 using RU 486 system is attributed 
to several factors. The superiority of HC-Ad vectors for long-term transgene expression has been 
demonstrated by different groups [110]. HC-Ad vectors have been shown to express transgenes 
like α-antitrypsin for more than one year demonstrating its persistence and safety [12]. In this 
study, long-term expression of transgenes using an HC-Ad vector has been demonstrated. The use 
of tissue specific promoters such as the TTRB promoter in this study has been shown to prolong 
the expression of transgenes by limiting the activation of the immune system [131]. Also the 
pSwitch molecule, which specifically transcribes the transgenes, is 85% humanized thereby 
limiting the generation of CTLs  against the protein [102].  
Interestingly, sflt1 and mIL-12 expressing vectors based on the RU 486 system demonstrated 
vector kinetics similar to the reporter vector, reconfirming that the activity of the RU 486 system  
was independent of the expressed transgenes. In addition, inducible mIL-12 expression was able to 
completely eradicate the orthotopic MC-38 tumors. In the case of the LLC tumor model, 
withdrawal of RU 486 during the second and fourth week resulted in the complete recovery of 
mice demonstrating prevention of IL-12 medaited toxicity by intermittent expression.  
Interestingly, constitutive sflt1 expression caused ascites and subsequent death of mice. Ascites 
was observed upon administration of a vector expressing sflt1 constitutively or by constitutive 
induction with RU 486 pellets of a vector expressing inducible sflt1. Interestingly, ascites was not 
observed when sflt1 was inducibly expressed upon daily injection of RU 486 thereby validating the 
inducible gene expression system. In summary, these data clearly indicated that the expression of 
toxic genes could be optimized using the RU 486 system to derive a possible therapeutic benefit. 
The reason behind the occurrence of ascites in mice expressing sflt1 constitutively is discussed in 
the following chapter. 
 
V.4 Toxicity of sflt1 
 
Endothelial cells are quiescent in the adult vasculature unless they are stimulated in conditions like 
inflammation, wound healing and during menstruation [26]. The proliferation of endothelial cells 
has been shown to be mediated by specific growth factors like VEGF, whose absence can be lethal 
during embryonic growth [66]. In the present study, vectors expressing sflt1 were generated to 
study a potential anticancer effect of VEGF blockade. It was unexpectedly observed that all mice 
injected with vector expressing sflt1 constitutively developed ascites at the end of fifth week after 
injection followed by death. To investigate the reasons pertaining to the death of mice, biochemical 
analysis and histological analysis of different tissues were performed.  
Histological analysis of Ad RS 44 (constitutive expression of sflt1) injected mice revealed that 
liver histology was normal. Serological analyses demonstrated that there was no significant change 
in liver parameters such as serum bilurubin, ALT etc. These data excluded liver damage to be 
responsible for the occurrence of ascites. Histological analysis of kidneys from animals with 
ascites demonstrated renal damage. Serological analyses revealed marked changes in the 
concentration of serum albumin, total protein, and urea. Together these data suggested kidney 
damage as the important pathogenic factor for the observed alterations and the death of the mice. 
The importance of VEGF in the maintenance of glomerular function during development and 
adulthood has been demonstrated in earlier studies [132-134]. Glomeruli in the kidneys consist of a 
barrel of glomerular basement membrane (GBM) surrounded by glomerular endothelial cells on 
the inside and glomerular epithelial cells, also called podocytes, on the outside. Capillary 
endothelial cells, the basement membrane, and podocytes constitute the filtration membrane of the 
kidney. The blood initially is filtered as it passes through the fenestrae present in the endothelial 
cells. The resulting fluid then passes through the GBM and then through the filtration slit present 
between the podocytes. The fluid is finally collected in the capsular space before it is reabsorbed 
into the blood. It has been suggested that there exists a reciprocal relationship between podocytes 
and endothelial cells, which is responsible for the mutual survival of these cell types [135]. 
Interestingly it has been demonstrated using knock out technology, that mice completely deficient 
for VEGFA expression in the podocytes die perinataly and that mice heterozygous for VEGFA 
developed end stage kidney failure by 9 weeks after birth [134]. This experiment confirmed the 
importance of VEGF signalling and the fact that appropriate amounts of VEGF are required for 
maintenance of kidney function. The significance of VEGF blocking in the development of kidney 
disease has also been demonstrated by other elegant experiments. It was shown that in mice 
neutralization of circulating VEGF by mouse anti-VEGF antibodies or murine sflt1 induced 
proteinuria and injection of VEGF was sufficient to prevent the disease [132]. It was further shown 
that injection of sflt1 resulted in endothelial cell detachment from the GBM and occasional loss of 
filtration slits indicating kidney damage and resulting in proteinuria. In another study, it was 
observed that during the use of anti VEGF antibody in phase I and phase II cancer clinical trial, 
subjects developed proteinuria indicating that VEGF is essential for normal kidney function not 
only in mice but also in men [136]. Also, it is of great interest to note that sflt1 serum levels were 
significantly increased in patients with preeclampsia [137]. Preeclampsia is a syndrome affecting 
5% of pregnancies that causes substantial maternal and fetal morbidity and mortality. The 
pathophysiology of preeclampsia had remained largely unknown and it has been hypothesized that 
placental ischemia is an early event, leading to placental production of a soluble factor or factors 
that cause maternal endothelial dysfunction, resulting in the clinical findings of hypertension, 
proteinuria, and edema. It has now been demonstrated that the elusive factor could be sflt1, which 
is found in large excess in the serum of patients and is responsible for decreased circulating levels 
of free VEGF and PIGF, resulting in endothelial dysfunction [138]. In a related study, 
administration of sflt1 to pregnant rats induced hypertension, proteinuria, and glomerular 
endotheliosis [139]. Collectively these studies suggest that high levels of sflt1 cause endothelial 
dysfunction owing to its sequestration effect on VEGF. Ascites followed by death has also been 
reported in 14 % mice injected with a first generation Ad vector expressing sflt1 [140]. In contrast, 
during the current study all mice constitutively expressing sflt1 developed ascites, which was 
followed by the death of all the animals five weeks post vector injection. Based on the observations 
of this study together with the published observations discussed above it is evident that the 
systemic use of sflt1 is accompanied by significant toxicity. It is therefore questionable whether 
systemic blockade of VEGF will become a viable option for cancer therapy.  
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V.5 Anticancer activity of sflt1, stie2 and mIL-12 expressing vectors in the LLC 
tumor model 
 
The LLC model is a simple and rapid cancer model for screening molecules with potential 
anticancer activity. In this study, constitutive sflt1 and stie2 expression or inducible expression of 
sflt1 and mIL-12 were tested. Additionally, the combination of constitutive sflt1 and stie2 
expression or combinations of inducible sflt1 and mIL-12 expression were tested. 
Inducible or constitutive sflt1 expression resulted in LLC tumor reduction until three weeks post 
tumor injection. Thus, despite the difference in the kinetics and levels of serum sflt1 the tumor 
growth rate was similar in both groups of mice. A similar study using a first generation Ad vector 
expressing murine sflt1 under the control of hCMV promoter demonstrated a delay in LLC tumor 
growth for two weeks post LLC cell injection [140]. In this study the vector had been injected after 
a tumor had become palpable. sflt1 expression was observed for two weeks post infection and it 
was suggested that the levels of sflt1 to be therapeutic should be above 2 µg/ml. It was also 
speculated that tumor re-growth after a two-week delay was due to the loss of transgene expression 
or alternatively to a change of endothelial cells in their dependance upon growth factors. In our 
study levels as high as 14 µg/ml were observed after the injection of vector Ad RS 23. In the case 
of mice injected with vector expressing sflt1 constitutively, sflt1 levels were between 200 and 700 
ng/ml. Unlike in the published study with ascites observed in only 14% of mice, all of the Ad RS 
44 injected animals developed ascites demonstrating the fact that toxic levels of sflt1 had been 
achieved. Therefore, the probable reason responsible for the absence of anti-tumor effects of sflt1 
beyond two weeks could have been the presence of alternative proangiogenic molecules such as 
aFGF, bFGF, FGF-3, FGF-4, HGF and IL-8, molecules, which have been shown to non-
specifically stimulate endothelial cells [141, 142]. It is also possible that the LLC tumor cells could 
have induced the expression of any or a combination of these growth factors, which could 
contribute to the growth of endothelial cells and tumor re-growth. In the case of breast cancer 
tumors it has been observed that 50% of newly diagnosed breast cancers produce VEGF only. 
However, during subsequent tumor progression, recurrences and metastases, other angiogenic 
factors including FGF-2, PIGF, PD-ECGF and pleiotrophin are produced [16]. Taken together it is 
evident that inhibition of tumor angiogenesis by targeting VEGF alone may not be therapeutic for 
aggressive tumors like LLC. 
Unlike sflt1, expression of stie2 did not result in LLC tumor inhibition or in an increase in survival 
time. It has been earlier reported that in BALB/c mice constitutive expression of stie2 using a first 
generation Ad viral vector resulted in a delay in tumor growth in the 4T1 and B16F10.9 tumor 
model [128]. The absence of anticancer activity upon stie2 expression may be attributed to lower 
levels of stie2 expression achieved during our study. It is also possible, similar to VEGF, that the 
role of Ang2 has been replaced by other growth factors during tumor progression.  
Since VEGF and Ang2 act by inducing endothelial proliferation and vessel remodeling, we 
hypothesized that simultaneous blocking of both growth factors might have an additive effect in 
LLC tumor treatment. Coinjection of sflt1 and stie2 expressing vectors resulted in a statistically 
significant decrease in tumor volume at three weeks post tumor cell injection. Nevertheless, an 
increase in survival time was not observed. Surprisingly, the mice were moribund at three weeks 
post tumor cell injection and had ascites, which could have been likely due to simultaneous 
inhibition of VEGF and Ang2. Interestingly, inducible expression of sflt1 or stie2 alone did not 
result in ascites. However, further experiments need to be performed to confirm this observation. In 
summary, the simultaneous blocking of both VEGF and Ang2 did not result in a significant 
therapeutic effect. As discussed earlier, the reason could be the presence of multiple angiogenic 
factors, which might replace VEGF and Ang2. 
Despite its anticancer activity a therapeutic use of IL-12 is limited by its systemic toxicity. 
Therefore, anticancer effects of IL-12 were investigated expressing IL-12 in an inducible manner. 
Similar to earlier observations, IL-12 mediated toxicity was observed after one week of mIL-12 
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expression. Consequently, IL-12 expression was induced only during the first and the third week 
post vector injection. Interestingly, the animals, showing toxicity after one week of inducion, 
recovered completely during the second week and during the fourth week when daily RU 486 
injection was discontinued. Induction beyond three weeks was averted to prevent death of mice and 
to study if the current induction schedule resulted in tumor rejection and immunological memory. 
However, the current schedule resulted only in a one-week increase in survival of the mice bearing 
LLC tumors.  
IFN γ has been shown to mediate the anticancer activity of mIL-12. It has also been shown that a 
local expression of mIL-12, which might activate the host immune system locally, is required for 
tumor growth inhibition. However, it remains to be tested, if inducible expression of mIL-12 every 
48 hours or other schedules might be able to inhibit LLC tumor growth. Nevertheless, this result is 
significant with respect to toxicity, because mIL-12 mediated toxicity was absent when RU 486 
induction was discontinued. Thus, a rapid reversal of mIL-12 induced toxicity could be 
demonstrated, an objective of this study. 
Inducible expression of mIL-12 alone showed a delay in LLC tumor growth for four weeks and a 
modest increase in survival by one week. Conversely, inducible expression of sflt1 showed a delay 
in tumor growth for three weeks post injection. The two strategies represent alternative principles 
to inhibit tumor growth. IL-12 acts predominantly by the activation of cell types like NK cells, T 
cells, macrophages, B cells and by inducing the production of IFN γ [81]. sflt1 acts by sequestering 
VEGF, an endothelial specific growth factor. Therefore sflt1 and mIL-12 were injected together in 
the LLC model to investigate if they had synergistic anticancer effects. Importantly, injection of 
RU 486 was performed only during the first and third week to prevent mIL-12 mediated toxicity 
observed earlier when mIL-12 expressing vector was injected alone. Interestingly, a delay in tumor 
growth was observed until the fifth week post LLC tumor cell injection and at least one mouse 
survived until eight weeks. In contrast, only one mouse survived until the fourth week in the 
control group. The delay in tumor growth and increased survival rate compared to control mice or 
injection of single vector may be explained in two ways. The levels of mIL-12 observed in this 
study were 2 to 5 fold higher compared to the study when the vector expressing mIL-12 was 
injected alone. The differences in the expression of mIL-12  in spite of administration of similar 
amounts of vector expressing mIL-12 can be explained by an increased transduction efficiency due 
to the presence of vector expressing sflt1, lowering the threshold for transducion. Thus, the results 
may be explained solely by the high levels of serum mIL-12. As alternative explanation, the 
presence of sflt1 could have contributed to the increase in survival. However, the levels of sflt1 
were low when compared to levels attained by injection of the vector expressing sflt1 alone. 
Nevertheless, the levels of sflt1 are still significantly high because negligible sflt1 levels are 
observed in normal mice. Thus, it is possible that sflt1 could have had an additive effect in the 
inhibition of tumor growth. Evidence exists for the presence of sflt1 receptors in numerous cells 
types apart from endothelial cells such as HSCs, monocytes, smooth muscle cells and dendritic 
cells [143-145]. It has been demonstrated that VEGF inhibits the maturation of dendritic cells and 
it was suggested that this could help the tumor cells to evade immune surveillance [65, 143, 146]. 
As described earlier DCs are the most important APCs and their loss of function is attributed to the 
development of tumors. It has been demonstrated that an antibody against VEGF was effective in 
inhibition of tumor growth by improving the function of dendritic cells [146]. Therefore, it is 
possible that the presence of both sflt1 and mIL-12 was responsible for the delayed LLC tumor 
growth and the decreased mortality rate. However, this can be confirmed only by assaying the 
function of dendritic cells, which was not performed. Nevertheless, the delay in tumor growth was 
encouraging and it is tempting to propose that combinations of both anti-angiogenic and 
immunotherapy might effectively supplement conventional cancer therapy strategies. Recently, it 
was shown in a syngenic tumor model that combinations of antibodies against VEGFR2 and IL-12 
resulted in tumor regression [147]. This strengthens the concept that the combination of anti-
angiogenic and immunotherapy could be synergistic in the treatment of cancer. 
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V.6 Anticancer activity of sflt1 and mIL-12 in the MC-38 model 
 
The MC-38 colon carcinoma model, compared to the LLC model, mimics more closely the human 
condition. Since the use of sflt1 and mIL-12 expressing vectors had resulted in modest anticancer 
activities in the LLC tumor model they were further evaluated in the MC-38 model. 
Inducible or constitutive sflt1 expression did not reduce tumor growth or prolong survival in this 
model. The lack of inhibition of tumor growth or increase in survival rate can be explained in 
several ways. It is possible that MC-38 tumors express or induce other proangiogenic growth 
factors, which overcome the VEGF requirement for angiogenesis. Incidentally it has been 
demonstrated using immunohistochemisty of human tumor specimens that aggressive hepatic 
tumors are often associated with high levels of IL-8, FGFs and PDGF [39]. It is also possible that 
there are unidentified growth factors which specifically act on hepatic endothelial cells similar to 
EG VEGF, which has been shown to specifically stimulate endothelial cells in endocrine glands 
[148]. In this regard it has been suggested that endothelial cells undergo tissue specific 
modification and therefore may respond to therapies in different ways [149]. Liver is composed of 
different cell types such as hepatocytes, fibroblasts, endothelial cells and Kupffer cells, all of which 
provide a favorable milieu for tumor cell implantation and initiation of angiogenesis. In addition, 
the analysis is further complicated by the unique anatomic nature of liver, which is richly supplied 
with vessels and has been shown to receive 30% of cardiac output. To conclude, it is evident that 
the blockade of VEGF did not result in a significant suppression of MC-38 tumor growth or in an 
increase in survival time. It would be very interesting to test in the future a combined action of 
vectors simultaneously expressing different transgenes in the MC-38 colon carcinoma model. 
In contrast to sflt1 expression, inducible mIL-12 expression resulted in a significant MC-38 tumor 
inhibition and in a tumor free survival in the post treatment period. Tumor inhibition correlated 
directly with serum mIL-12 levels. Additionally, it was observed that mice injected with the mIL-
12 expressing vector but were left uninduced also succumbed to the tumor reflecting the tightness 
of the system. The significant anti-tumor activity in the MC-38 model in contrast to that observed 
in the LLC model may have been due to the local expression of mIL-12, which has been shown to 
result in a concentration gradient with high levels peritumorally and lower amounts systemically. 
The importance of mIL-12 expression in the tumor vicinity has been demonstrated by using cell 
lines expressing increasing concentrations of mIL-12 [150]. It has been shown that the C26 colon 
carcinoma cell line expressing increasing amounts of mIL-12 exhibited decreased tumor formation 
and was associated with increased CD8+ cells and NK cells recruitment in the tumor 
microenvironment [150].   
The regression of hepatic metastases using adenovirus vectors expressing IL-12 has been 
demonstrated before. First generation Ad vectors expressing mIL-12 constitutively, when injected 
directly into the syngenic CT26 tumor implanted in the liver, resulted in tumor regression in about 
76% of mice. In addition, the tumor disappeared within 7-10 days post injection and was resistant 
to rechallenge [151]. In a similar study, hepatic metastases of MCA-26 colon carcinoma were 
treated with a tumor injection of Ad vector expressing mIL-12. Treated animals survived longer 
than untreated controls. This treatment was superior to a combined treatment with Ad vectors 
expressing herpes simplex virus type 1 thymidine kinase (HSV-tk) and mIL-2 (357). Incidentally 
in our study, mice injected with mIL-12 expressing vector succumbed to tumors in the absence of 
induction reflecting the tightness of the system. Another significant feature of our study relates to 
the reversal of mIL-12 associated toxicity upon withdrawal of RU 486 induction. This was 
confirmed by monitoring serum ALT levels and by histological analysis of liver sections. 
Although the mechanisms by which IL-12 exerts anti-tumor activity have been difficult to dissect, 
it has been shown to involve cell types such as NK cells, NKT cells, macrophages, and CD8+ cells, 
cytokines like IFNγ and chemokines like interferon-gamma-inducible protein-10 (IP-10) and Mig 
[151-153]. Among all the factors it has been clearly demonstrated that toxicity of IL-12 is mediated 
by IFNγ and the levels need to be continuously monitored in a clinical setting to avoid adverse 
events. During a phase II clinical trial with recombinant hIL-12 two deaths were reported due to 
mIL-12 mediated toxicity [126]. Therefore it is important that despite the confirmation of 
impressive anti-tumor of activity of hIL-12, serious emphasis must be laid on controlling the levels 
of mIL-12.  
The importance of regulation and safe administration of mIL-12 for anticancer activity has been 
one of the major focuses of this work. It has been demonstrated in this study that varying the dose 
of vector and the drug RU 486 can modulate the levels of IL-12. Complete remission of hepatic 
tumors was observed only by inducible and locally expressed mIL-12. Thus, vector-mediated 
expression of IL-12 and incorporating an inducible system for expression control may have 
significant potential for the treatment of hepatic tumors and metastases.  
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VI Summary 
  
This work was based on the hypothesis that vector-mediated long-term expression of 
antiangiogenic or immunomodulatory proteins may represent an attractive strategy to control the 
growth of malignant neoplasms. The experiments focused on two antiangiogenic molecules, sflt1 
and stie2, and on one molecule with well-known immunomodulatory function, IL-12.  
HC-Ad vectors were chosen for gene delivery since long-term expression in hepatocytes is 
generally achieved following intravenous vector injection. The vectors were designed to express 
the molecules either in a constitutive manner (sflt1 and stie2) or in the context of a RU 486-
inducible expression system thereby allowing for drug control of expression (sflt1, mIL-12 and 
hIL-12). 
Following in vitro characterisation of the different vectors their biological activity was analysed in 
murine cancer models, the subcutaneous LLC model and the orthotopic (liver) MC-38 model. The 
analysis of each vector started with an analysis of expression levels and kinetics following 
intravenous injection. Very significant and stable serum levels of all molecules were achieved in 
vivo. It was also found that the RU 486 system allowed for exquisite liver-specific and long-term 
expression control with practically negligible expression of the transgenes in the absence of 
RU 486. Thus, the RU 486 inducible expression system is very well suited to control expression of 
potentially toxic proteins, as also demonstrated in this study for sflt1 and IL-12. 
A significant result of this study was the observation that RU 486-induced expression of mIL-12 in 
the orthotopic MC-38 model resulted in complete tumor eradication. This was surprising since the 
MC-38 model is a very aggressive model of liver cancer. It is likely that the local expression of 
high mIL-12 levels in the tumor environment was essential for this positive result.  
In contrast, constitutive or RU 486-induced expression of sflt1 in the same model had no tumor-
inhibitory effect.  
Less promising results were observed with any of the vectors when tested in the subcutaneous LLC 
cancer model. None of the vectors, when injected alone, resulted in tumor eradication, although 
there was a tendency for tumor growth inhibition following injection of the sflt1 expressing vector. 
A similar tumor growth inhibitory effect was observed upon combined injection of the sflt1 and 
stie2 expressing vectors. When sflt1 and mIL-12 were expressed in combination, a moderate 
increase in survival time was found. However, complete tumor regression was not observed in the 
LLC tumor model with any of the vectors alone or in combination. 
Unexpected was the observation that VEGF blockade by expressing sflt1 over a longer period of 
time resulted in toxicity and death of the animals, likely due to dysfunction of renal endothelial 
cells and kidney failure. This result suggested that upon therapeutic VEGF-inhibition close 
attention has to be paid to possible side effects in particular with respect to renal function.  
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 VII Zusammenfassung 
  
Diese Arbeit beruhte auf der Hypothese, dass langzeitige Vektor-vermittelte Expression von anti-
angiogenetischen oder immunmodulatorischen Proteinen eine vielversprechende Strategie zur 
Kontrolle des Wachstums maligner Neoplasmen sein könnte. Die experimentelle Arbeit 
konzentrierte sich auf zwei anti-angiogenetische Moleküle, sflt1 und stie2, sowie das 
immunmodulatorische IL-12. 
Adenovirale Vektoren mit hoher DNA-Kapazität wurden als Vektorsystem gewählt, da sie in vivo 
nach intravenöser Injektion Langzeitexpression in Hepatozyten ermöglichen. Die Vektoren 
exprimierten die Transgene entweder konstitutiv (sflt1 und stie2) oder RU 486-induzierbar (mIL-
12 und hIL-12), so dass eine medikamentöse Steuerung der Genexpression möglich war.  
Nach der in-vitro-Charakterisierung der einzelnen Vektoren wurde ihre biologische Aktivität in 
dem subkutanen LLC-Tumormodell und dem orthotopen MC-38 Modell in der Labormaus 
untersucht. Die Analyse beinhaltete zunächst die Untersuchung von Expressionsstärke und 
Expressionskinetik nach intravenöser Injektion. Hierbei wurden stabile Serumkonzentrationen aller 
Moleküle auf hohem Niveau beobachtet. Des weiteren konnte gezeigt werden, dass die auf dem 
RU 486-System beruhenden Vektoren eine leber-spezifische und langzeitige Expressionskontrolle 
ermöglichten, und insbesondere ohne nennenswerte Expression der Transgene in Abwesenheit von 
RU 486. Diese Daten zeigen, dass das induzierbare RU 486-System gut zur Kontrolle der 
Expression potentiell toxischer Transgene geeignet ist, wie am Beispiel von sflt1 und IL-12 hier 
verdeutlicht.  
Ein wesentliches Ergebnis dieser Arbeit war die Beobachtung, dass die Expression von mIL-12 
mittels des RU 486-Systems in dem orthotopen MC-38 Tumormodell zur kompletten Tumor 
Remission führte. Die war umso überraschender, als das MC-38 Modell ein sehr aggressives 
Lebertumormodell ist. Es ist wahrscheinlich, dass die starke Expression von mIL-12 in der 
Tumorumgebung wesentlich für dieses positive Ergebnis verantwortlich war. Im Gegensatz hierzu 
hatte die Expression von sflt1 im selben Modell weder bei konstitutiver noch bei induzierbarer 
Expression einen tumor-inhibitorischen Effekt.  
Weniger vielversprechende Ergebnisse wurden mit den verwendeten Vektoren in dem subkutanen 
LLC-Tumormodell erzielt. Bei alleiniger Injektion führte keiner der Vektoren zur kompletten 
Tumor Remission, wenngleich eine Tendenz zur Inhibition des Tumorwachstums nach Injektion 
des sflt1 Expressionsvektors zu beachten war. Ein ähnlicher inhibitorischer Effekt konnte bei 
gemeinsamer Injektion der Expressionsvektoren für sflt1 und stie2 nachgewiesen werden und ein 
moderater Anstieg der Überlebenszeit wurde bei gleichzeitiger Expression der beiden Vektoren 
beobachtet. Allerdings konnte eine vollständige Tumor Remission mit keiner der 
Vektorkombinationen im LLC-Modell erzielt werden.  
Unerwartet war die Beobachtung, dass VEGF Blockade durch langzeitige Expression von sflt1 von 
starker Toxizität begleitet war und den Tod der Tiere zur Folge hatte, vermutlich verursacht durch 
eine Störung der renalen Endothelzellfunktion gefolgt von Nierenversagen. Dieses Ergebnis 
deutete darauf hin, dass bei therapeutischer VEGF-Inhibition auf Nebenwirkungen und 
insbesondere auf Störung der Nierenfunktion zu achten ist.  
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